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ABSTRACT
Ribonucleotide reductases (RNRs) catalyze the conversion of nucleotides to
deoxynucleotides supplying the dNTPs required for DNA replication and DNA repair.
Class I RNRs require two subunits (a and P) for activity. The a subunit binds the
substrates and the allosteric effectors that govern specificity and turnover. The 32 subunit
houses the diferric Y* cofactor required to initiate nucleotide reduction. Human cells
possess two type of P subunits of RNR: one (0) is involved in DNA replication and the
second (p53p') is required for mitochondrial DNA replication and likely plays some role
in DNA repair. Gemcitabine (2',2'-difluoro-2'-deoxycytidine, F2C) is used clinically in a
variety of cancer treatments and the phosphorylated F2C targets many enzymes involved
in nucleotide metabolism, including RNR. The studies presented here with [1 '-3H]- and
[5- 3H]-F 2CDP have established that F2CDP is a sub-stoichiometric mechanism based
inhibitor (0.5 equivalents F2CDP/a) of both the E. coli and the human RNRs in the
presence of a reductant. Inactivation is caused by covalent labeling of RNR by the sugar
of F2CDP (0.5 equivalents/a) and is accompanied by the release of 0.5 equivalent
cytosine/a. Studies using size exclusion chromatography reveal that in the E. coli RNR,
an u212 tight complex is generated subsequent to enzyme inactivation by F2CDP, while
in the human RNR, an a6P6 or a6p'6 tight complex is generated.
The second part of this thesis focuses on the Sml inhibition mechanism in S.
cerevisiae. Smll is a 12 kDa small protein RNR inhibitor. It regulates RNR activity by
binding directly to a to repress RNR activity. The binding of Smll to a has been
proposed to block the reduction of the active site disulfide formed concomitantly with
dNTP production, leaving a in the oxidized form. A fluorescence titration method was
employed to measure the Kd of Smll with different forms of c. Our data suggest that
Smll binds to a by a mechanism that involves its C-terminal helix (likely the
hydrophobic face) and a region of a that includes W688. The kinetics studies suggest that
Smll behaves as an uncompetitive inhibitor relative to the substrate, and binds to the
oxidized form of a in preference to the reduced form.
Thesis Supervisor: JoAnne Stubbe
Title: Novartis Professor of Chemistry
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Chapter 1
Introduction to the Human and Saccharomyces cerevisiae
Ribonucleotide Reductase
1.1 Overview
In all organisms, ribonucleotide reductases (RNRs) uniquely catalyze the
reduction of the four ribonucleotides to their corresponding 2'-deoxyribonucleotides, and
consequently are essential in DNA biosynthesis and repair (Figure 1.1) (1-3). A continuous
and balanced deoxynucleoside triphosphate (dNTP) pool, which is critical for the fidelity of
DNA replication, is maintained through controlling RNR's activity by an exquisite
regulatory network including transcriptional and translational regulation, controlled protein
degradation, subunit localization, post-translational modification, and protein-protein
interactions.
(P)PPO O N RNR (P)PPO O N
H H
OH OH r--SH r- S OH H
E E l
NDP (NTP) -- SH S dNDP (dNTP)
N = A, U, C, G
Thioredoxin (TR)
Thioredoxin Reductase (TRR)
NADPH
Figure 1.1: The ribonucleotide reduction reaction. The arrow indicates that the 3'
hydrogen is abstracted by the thiyl radical in the active site. At the end of the reaction, the
active site disulfide is re-reduced by two cysteines from the C-terminal tail of R1, which
are then reduced by thioredoxin. Thioredoxin is reduced by thioredoxin reductase, and
NADPH serves as the terminal e- donor.
RNRs have been divided into three classes based on their metallocofactors (Table
1.1). Two or more classes of RNR can coexist in one organism and can be expressed
under different growth conditions. The class Ia RNRs, which are found in aerobic
organisms, are composed of two homodimeric subunits: a large subunit R1 (a2) and a
small subunit R2 (P2). P2 contains a diferric tyrosyl radical (Y*) cofactor, essential for
catalysis, that initiates formation of a transient thiyl radical (S*) 35 A away in a2, where
nucleotide reduction occurs (4-7). a2 contains the active site and the allosteric regulation
sites that control substrate specificity and turnover rate. Five conserved cysteine residues
in a are involved in the reduction process (Table 1.2), three of which are located in the
active site and two of which are in the C-terminus (Table 1.2). The Y- in f3 generates So
on one of the active site cysteines to initiate nucleotide reduction and the two other
cysteines in the active site supply the reducing equivalents to directly reduce the substrate.
The active enzyme is regenerated by re-reducing the resulting disulfide bond with the
pair of C-terminal cysteines on a (4).
Class I RNRs are divided into class Ia, Ib, Ic. Class Ib is distinct from class Ia,
lacking the N-terminal allosteric regulation domain in a (8). In most prokaryotic cells, the
class Ib RNR is the enzyme involved in aerobic conditions. Recently, a class Ic RNR that
utilizes a manganese(IV)/iron(III) cofactor in place of the Y* was discovered in
Chlamydia trachomatis, a human intracellular parasite (9-12). Class II RNRs (a or a2)
are found in organisms living under aerobic or anaerobic conditions. Unlike the Y-
cofactor in class I RNRs, the adenosylcobalamin cofactor in class II RNRs can directly
interact with the active site cysteine and initiate transient thiyl radical formation (13-18).
Class III RNRs are found in bacteria growing under strict anaerobic conditions and in
bacteriophages. A smaller subunit (32), which is also called the activase, carries a 4Fe-4S
cluster coupled to S-adenosylmethionine (SAM) and generates a glycyl radical (G*) in a2
(19-24).
Table 1.1: Overview of the different classes of RNRs (adapted from Ref.(3))
Class la Class Ib Class Ic Class II Class III
Metallocofactor Fe(III)-O- Mn(III)-O- Mn(IV)-O- Adenosyl Fe4S4, SAM
Fe(III) Mn(III)? Fe(III) Cobalamin
Fe(III)-O-
Fe(III)?
Radical Y* YO Mn(IV)-O- deoxyadenosyl G*
initiator Fe(III) radical
Catalytic S. S. S* S. S.
radical
Complex a2p2, a6p6 (x2P2 a2p2 ? a2, a (2 or a222
structure a4p4? ca6p2? (32 for
initiation)
Oxygen aerobic aerobic aerobic aerobic or anaerobic
dependence anaerobic
Substrate NDP NDP NDP NDP, NTP NTP
Allosteric sites A-, S- and H- S-site S-site S-site S- and A-site
sitesa (purine site)
Reductants Thioredoxin, NrdH Thioredoxin? Thioredoxin Formate
Glutaredoxin Glutaredoxin
Occurrence Eukaryotes Eubacteria Archebacteria Archebacteria Archebacteria
Eubacteria Eubacteria Eukaryotes Eubacteria
bacteriophages algae bacteriophages
viruses
Prototype for E. coli nrdA, S. typhimurium Chlamydia L. leichmannii E. coli
class, gene nrdB nrdE, nrdF trachomatis, nrdJ nrdD,nrdG
names nrdA, nrdB
a: S-site, specificity site; A-site, activity site, H-site, a proposed third allosteric site, called
hexamerization site,
Table 1.2: Important catalytic residues on RNR in E. coli, human and S. cerevisiae
E. coli RNR Human RNR S. cerevisiae RNR
C439 C429 C428
C225 C218 C218
a C462 C444 C443
C754 C787 C883
C759 C790 C886
E441 E431 E430
Y122 (Y*) Y176 (P), Y183(3)
f3 Y138 (13')
Despite the differences in sequences, structures, metallocofactors, and reductants
among the three classes of RNRs, their active site structures are similar and the chemistry
of nucleotide reduction is believed to be largely conserved (4, 25). Only class Ia RNRs
are found in nearly all eukaryotic organisms. The following sections will focus on studies
of the class Ia RNRs, especially the mammalian and S. cerevisiae enzymes.
1.2 Structure and Mechanism of Class la RNR
1.2.1 Structure of class I RNR
The E. coli class Ia enzyme is a prototype for class I RNRs. The active form of E.
coli RNR is a 1:1 complex of a2 and 32. Although structures of a2 (26-28) and 32 (29-31)
have been solved, only recently has a structure of the S. typhimurium class Ib enzyme
with both a and P present been solved at 4.5 A resolution (32). As discussed later, it is not
likely to be the active complex, but may be indicative of interactions leading to an active
complex. The docking model of the E. coli a202 class Ia holoenzyme, generated based on
shape complementarities between a2 and 32, and on the co-crystal structure of a2 with a
f32 C-terminal peptide, is shown in figure 1.2 (26).
The interactions between E. coli a2 and 132 are weak (Kd - 0.4 gM in the absence
of nucleotide), and are largely governed by the C-terminal tail of 32 (33, 34). A peptide
of the C-terminal tail of p behaves as a competitive inhibitor of a:p interactions (33-38).
The 32 C-terminal tail is structurally flexible and cannot be resolved in any of the
reported X-ray crystal structures (26, 29-31, 39). In the E. coli 32 structures, the last 35
residues (from 341 to 375) are not visible. In the structure of a2 with a 20 residue peptide
(355-375) corresponding to the 32 C-terminal tail, only residues 360-375 are visible.
Thus the locations of residues 341 to 359 in 3, including Y356, a key residue in the
electron transfer pathway between a and 3, cannot be defined in the a202 docking model.
The 35 A distance between the Y* site of P (Y122) and the S. site of a (C439) is
too long for transient tunneling of the radical, given the turnover of E. coli RNR (2-10 s-1).
As a result, radical propagation from Y122 to C439 has been proposed to occur by long
range proton-coupled electron transfer (PCET) via a network of aromatic amino acid
radical intermediates (40-44). As shown in Figure 1.3, the radical is proposed to be
propagated in P from Y122 to W48, and to Y356 on the C-terminal tail, and then across
the 3/a interface to Y731 and Y730, which oxidizes C439. The radical transfer is
reversible, and the reverse reaction occurs on each turnover (45, 46).
- R2 Peptide
(375)
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4-)-q90O
Figure 1.2: Docking model of E. coli a2p2 complex (26).
a2 (blue and green) and j2 (red and yellow) are shown. The iron atoms are in blue. The
32 C-terminal peptide is shown in magenta. GDP (substrate) and TTP (allosteric effector)
are rendered as space filling models. The key residues in PCET (cyan) are shown using a
stick model.
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Figure 1.3: Proposed PCET pathway between p and a.
The amino acids proposed to be involved in the PCET pathway between 32 (left) and a2
(right) are shown. The distances between each residue are shown and Y356 is disordered
in the structure.
Although the docking model predicts a symmetric RNR subunit organization,
increasing experimental data now suggest an asymmetry in the structure of the RNR
complex. Recent pulsed electron-electron double resonance (PELDOR) studies suggest that
firing of the radical occurs on one side first and second firing may occur subsequent to
formation of the first dNDP (47, 48). In studies carried out using wt P2 (1.2 Y*/p2) and
Y731NH2Y-a2 (unnatural amino acid acting as radical trap), the Y122. in one 0 gave rise
to a NH2 Y* at Y731 in a, while the Y122* in the second P subunit remain unchanged (48).
In another set of experiments using wt a2, 32 (Figure 1.4), inactivation of RNR with the
mechanism based inhibitor, N3UDP (2'-azido-2'-deoxyuridine-5'-diphosphate), which labels
the active site with a nitrogen-centered radical (N.), did not result in N*-N* species in both
active sites (Figure 1.4, c), but instead led to Y--N. interaction in only one of the two active
sites (Figure 1.4, b) (47, 48). This and other PELDOR data has shown a distance across the
32 and a2 pair between Y122* and Y356 in 0 as 30.6 A, 38 A between Y731 and Y122*,
and 48 A between Y122* and C225 in the symmetry-related a active site. All those
distances agree well with the docking model and indicate that the distance between Y122
and C439 is long (48). The docking model indicates a distance of 25 A between the W48
on 32 and Y731 on a2.
R1 N3UDP N3UDP No N3UDP N
R2 YY e
(a) (b) (c)
Figure 1.4: Model showing the asymmetry of the radical propagation pathway (47).
(a) N3UDP binds to both active sites of a2. (b) The Y 122* in one 0 transfers the radical to
N. on the different side of a. (c) Y*s on both ps transfer the radical to both active sites of
a2. The experimental data support model (b) instead of (c).
The unnatural tyrosine analogue 3,4-dihydroxyphenylalanine (DOPA)
incorporated into position 356 of 32, has been employed as a probe to detect the
conformational gating between a2 and 32 (49). As DOPA behaves as a radical trap during
radical propagation, loss of Y122- is kinetically correlated with the appearance of DOPA-.
Only in the presence of substrate and/or effector and a2, the conditions that generate active
RNR complex, is DOPA. generated, with only 50% of total Y122 * being converted to
DOPA*. This indicates asymmetry in the active RNR complex (41). In addition, incubation
of a2, effector, and substrate with a heterodimer DOPA-PP' in which 0' is missing the C-
terminal 22 residues, only -25% of Y- was converted into DOPA* (45). This study
emphasizes the essential role of the P C-terminal tail in the PCET pathway, as well as the
asymmetry of the a-n or ap interaction.
The first structure of a class I a202 complex was solved recently for the class Ib
enzyme from Salmonella typhimurium (32). The structure suggests an asymmetry of a2 and
f2 interaction: or one 0 interacts with a, whereas the other 0 only contacts its partner in the
dimer (Figure 1.5 (a)). The crystallization was successfully induced at pH 7.5 in the
presence of both the substrate ADP and the effector dGTP. Strong electron density, likely
associated with a substrate, was seen in the active site of one a of the dimer. No extra
density was identified in the other a, although the effector dGTP was bound to both a
subunits, suggesting an asymmetry of substrate binding to RNR. The structure may report
on an intermediate step in catalysis, i.e., binding of substrate triggers a conformational
change that puts one P in an optimal position for radical transfer, while the second P moves
away, perhaps to allow re-reduction of the active site cysteines [Figure 1.5 (a)], and then
moves back into contact with a to resume the reaction [Figure 1.5 (b)].
This X-ray structure, agrees well with the half-site reactivity consistently
observed in the studies using mechanism-based inhibitors. Further discussion on this
subject will be presented in Chapters 3 and 4.
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Figure 1.5: Structure of class Ib nrdEF complex from Salmonella typhimurium (32).
The dGTP effectors (grey sticks) are located at the a2 dimer interface. The irons are in
orange spheres. The 0 binding site in a is a hydrophobic cleft. The tail of 0 is shown as a
peptide in blue sticks. (a) nrdEF complex, as crystallized (b) Proposed movement of j2 to
form a symmetric complex.
1.2.2 Mechanism of nucleotide reduction class I RNR
The nucleotide reduction mechanism in E. coli RNR has been well established by
the Stubbe group (1, 4, 50-54). As shown in Figure 1.6, the initiation step of the reaction is
the abstraction of an H atom from the C3' position of the substrate by a thiyl radical
generated via long-range oxidation from the Y122. on P2 (Figure 1.6 a). The cleavage of
the 2' carbon-hydroxyl bond is facilitated by deprotonation of the 3'-hydroxyl by a
carboxylate (E441 in E. coli RNR) in the active site (b). Loss of H2 0 generates an a-keto
radical (c) which is then reduced by oxidation of two cysteines in the active site to generate
a disulfide radical anion and the 3'-keto deoxynucleotide (d). This intermediate is reduced
by PCET to generate the 3'-deoxynucleotide radical (e) (55-57). Finally the H atom which
was originally removed by thiyl radical is used to reduce the 3' radical, regenerating the
thiyl radical and yielding the 2'-deoxynucleotide (f).
SH
CO2- HO OH
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CONH 2 HS X
D OH
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Figure 1.6: The proposed mechanism of class la RNR.
To complete the turnover, the active site disulfide is re-reduced by two cysteines
located on the C-terminal tail of a2, and the resulting disulfide is then reduced by
thioredoxin/thioredoxin reductase or by glutaredoxin/glutaredoxin reductase in vivo (55,
57, 58). In E. coli, pre-steady-state and steady-state kinetic experiments have revealed
that the rate-limiting step in RNR is a physical step prior to rapid nucleotide reduction
(46). This physical step is likely a conformational change triggered by ternary or
quaternary complex formation, prior to long-range PCET.
1.2.3 Mechanism of 2'-monohalo-2'-deoxynucleotide inhibition
The class of 2'-monohalo-2'-deoxynucleotide inhibitors (2'-XNDP, X=F, Cl) has been
studied since 1976 (59). The targets of these compounds are the a and f subunits of E. coli or
mammalian RNRs (60, 61), with multiple turnovers occurring before RNR is completely
inactivated. The inactivation occurs with release of C- or F, pyrophosphate, and elimination
(b) (c)
of the base, concomitant with the formation of a new chromophore, with maximum
absorption at 320 nm. A furanone (Figure 1.7g) is found to be covalently attached to the
inactivated a.
The proposed mechanism of RNR inhibition by 2'-monohalo-2'-deoxynucleotides is
shown in Figure 1.7. The reaction is initiated as in the normal RNR mechanism by
abstraction of a hydrogen atom from the C3' position (a). The next step (b) is different from
the mechanism involving normal substrate, since the 2'-halides can leave without protonation
from C225 (bottom face cysteine) because they are better leaving groups with lower pKa
values. An a-keto radical is formed and the reaction proceeds by abstraction of a hydrogen
atom from either the top face cysteine (C439, E. coli) to regenerate the thiyl radical (c) or
from the bottom face cysteine (C225, E. coli) (d). In the latter scenario (d), the thiyl radical
cannot be reformed and inactivation results in loss of Y* on 13. In both pathways (c, d), no
disulfide radical anion is formed and the 3'-ketonucleotide is released into solution (e, f). The
3'-ketonucleotide decomposes into an electrophilic furanone upon elimination of
pyrophosphate and base (g). This is the furanone derivative is alkylated by cysteines of a (h)
or by the thiols of DTT in vitro. Alkylation of the furanone by the C-terminal tail cysteines of
a, followed by reaction with K760 is thought to produce the chromophore that absorbs at
320-330 nm.
Addition of DTT protects RNR against inactivation by quenching the reactive
furanone. A substantially different number of turnovers per inactivation is observed with
different bases and/or effectors, reflecting a change in the partitioning of the intermediate
between inactivation and normal reduction (62). Compared to the 2'-chloro-2'-deoxy analogs,
2'-fluoro-2'-deoxy analogs behave more similarly to the normal substrate, resulting in
production of more dNDPs or dNTPs relative to inactivation (63, 64). The reduction with
normal substrate requires protonation of the leaving group and the difference in partitions
between C1- and F is likely due to differences in acidity with Cl- > F- > OH.
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Figure 1.7: The mechanism of inactivation of RNR by 2'-monohalo-2'-deoxy-
nucleotides (X = F, CI).
1.2.4 Regulation of E. coli RNR
RNR is tightly regulated in cells to keep balanced dNTP pools for DNA
replication and repair. Insufficient RNR activity causes mis-incorporation of dNTPs into
DNA, growth defects and increased sensitivity to DNA damaging agents, whereas excess
RNR activity decreases fidelity of DNA replication and affects RNA synthesis.
One method of regulation of RNR's nucleotide reduction utilizes ATP and dNTPs
as allosteric effectors. In class Ia RNRs, the a subunit contains at least two allosteric sites.
The specificity site (S site) binds ATP, dATP, dGTP, or TTP and regulates substrate
specificity. The activity site (A site) binds ATP or dATP and controls the overall enzyme
activity (65). As shown in the E. coli a2 structure in Figure 1.8, the S site (red) is a four
helix bundle generated from two helices from each a (28). Binding of effectors to the S
site controls which substrate is reduced. Binding of ATP or dATP prepares RNR for the
reduction of UDP or CDP; TTP is the effector for GDP reduction and dGTP for ADP
reduction.
The A site (magenta) binds either ATP, to stimulate activity, or dATP, to inhibit
reaction. The A site is located at the N-terminus of a, adjacent to the a/13 interface (Figure
1.2, 1.8) (28). Moreover, it has been observed that the type of effector (ATP, dGTP, TTP,
dATP) bound to the S site affects the affinity of dATP for the A site, suggesting the
existence of communication between the S site and A site (65, 66).
Above all is the general mechanism of class Ia RNR. The S. cerevisiae RNR and
human RNR will be the focus of this thesis.
Figure 1.8: Structure of E. coli a2 highlighting the allosteric effector binding sites
(67).
Allosteric activity sites are at the N-terminus of a, with ATP analog AMPNP (magenta)
bound. Specificity sites are at the a2 dimer interface, shown with TTP (red) bound. GDP
(yellow) is bound in catalytic sites at a distance of 15 A from the specificity site.
1.3 Yeast RNR
1.3.1 Structure of yeast RNR
In Saccharomyces cerevisiae, four genes encode RNR subunits. RNR1 and RNR3
encode the large subunits Y1 (a) and Y3 (a'), which share 80% and -60% identity with
the mammalian a respectively (68, 69). The physiological role of RNR3 is not clear.
Although overproducing RNR3 can complement the deletion of RNR1, deletion of RNR3
exhibits no obvious phenotype, and does not change the cells' sensitivity to DNA
damaging agents. RNR2 and RNR4 encode the small subunits Y2 (0) and Y4 (0'), which
are essential for mitotic viability in S. cerevisiae. P and P' share 56% sequence identity.
Besides lacking 50 residues at the N-terminus of , ' lacks three of the six residues
involved in iron binding, and exhibits a Y to F substitution at the position of the essential
Yo (70-72). A large body of data suggests that the active form of the small subunit is the
Y2Y4 (P ') heterodimer, in which P' facilitates iron delivery to 3 (73, 74).
Structures of S. cerevisiae a with different effector/substrate pairs have been
solved (75). These structures are the first of a a subunit to show ordering of certain loops
upon substrate and effector binding. The overall structure of the S. cerevisiae a is very
similar to that of the E. coli protein. The primary difference is a C-terminal insert and
three helixs insert (Figure 1.9 blue and red). In the active site of the structure, the pair of
cysteines that provide the reducing equivalent for NDP reduction (C218, C443) is
reduced and the 2' and 3' OH of the ribose are close to the catalytic residues C428, C218,
C443, E430. Two loops are important for the allosteric regulation. Loop 1 only interacts
with the effector region (S site), and loop 2 contacts both the specificity and active sites.
Binding of different effectors and substrates twists the position of loop 2 into a specific
conformation for each effector/substrate pair (Figure 1.10). The structure presented here
shows a as a dimer. However, the oligomerization state of the S. cerevisiae a in solution
is more complicated than it appears from the structure. In Chapter 5, we present our
studies on the oligomerization state of S. cerevisiae a with different substrate/effector
pairs.
Figure 1.9: Structure of S. cerevisiae a at 2.2 A (75).
The structure is very similar to that of E. coli a with dGTP (violet) and ADP (blue)
binding at the catalytic site and S site. A major difference between the S. cerevisiae and E.
coli a structures is that the former contains a three-helix insert (red) and C-terminal insert
(blue).
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Figure 1.10: Specificity cross-talk of
pairs (75).
S. cerevisiae a for different effector/substrate
Loop 1 (yellow) folds on the effector, and loop 2 (cyan) spans over both the effector
(green) site and catalytic site. (B) with dGTP/ADP, (C) with TTP-GDP, (D) with
AMPPNP/CDP, and (E) AMPPNP/UDP. The position of loop 2 adapt to a specific
conformation for each effector/substrate pair
In vivo, close to 1 Y*/P3p' is observed with whole cell EPR method (76). However,
generation of stoichiometric amounts of diferric-Y* cofactor (l1Y/ P3') in vitro has been
difficult with the S. cerevisiae PP'. Stoichiometries of only 0.2-0.4 Y*/Pp' are routinely
obtained using in vitro reconstitution methods developed by the Stubbe lab. Co-
expression of His-33' in E. coli, followed by purification and in vitro reconstitution, was
carried out in an attempt to achieve higher Y* content without success. Rapid isolation of
Flag-PP' directly from yeast strains yielded a maximum of 0.5 Y*.
1.3.2 Mechanism of yeast RNR
The mechanism of nucleotide reduction by yeast RNR is very similar to that of
the E. coli RNR. On each turnover in E. coli, the pair of bottom-face cysteines in the
active site is oxidized and is re-reduced by the pair cysteines (CX 2C motif) on the C-
terminal tail of a for subsequent reactions (55, 77, 78). Recent work on RNR in S.
cerevisiae has supported this model in vivo (79). A RNR3 strains carrying an RNR1 gene
in which the C-terminal tail has been mutated (CX 2C to SX2S) are not viable. Mutation of
C428, the essential S*-forming cysteine (equivalent to C439 in E. coli) is also lethal.
However, a yeast strain harboring both a C428S RNR1 with a wt CX2C at the tail and an
RNR1 gene with no C428 mutation but a SX2S C-terminal tail is viable albeit with
severely retarded growth (79). This suggests that via interallelic complementation, the C-
terminal tail of one a is able to regenerate the active site of its neighboring a (Figure
1.11), although this may not be true of wt RNR1.
a -lxl
Figure 1.11: Model depicting the C-terminal tail of one a regenerating the active site
of its neighbor a (79).
(a) a is oxidized at the end of each turnover cycle with a disulfide bond formed between
the redox active cysteine pair in the active site. (b-c) The C-terminal tail of one a
accesses to the active site of the neighbor a and reduces its active site cysteines via
disulfide exchange.
1.3.3 Regulation of yeast RNR
In yeast cells, RNR is controlled at the level of substrate specificity (80),
transcription (81, 82), subunit localization (83-86), and Smll (small protein RNR
inhibitor) regulation during S-phase of the cell cycle or in DNA repair. The overall
regulation of S. cerevisiae is shown in Fig 1.12. As with the E. coli RNR, the activity and
substrate specificity of S. cerevisiae RNR are regulated by ATP and dNTPs. The cell-
cycle dependent expression of RNR1, RNR2, and RNR4 are regulated at the transcription
level through the Mbpl/Swi6 (transcription factors) binding to MCB (Mlul cell cycle
box) (Fig 1.12A). In resting cells, pp' is localized in nucleus by an anchor protein Wtml,
while a stays in cytosol. The RNR activity is also regulated by a 12 kDa protein inhibitor,
Smll, in S phase and in DNA damage. As suggested by yeast two hybrid assays,
immunoprecipitation, and biochemical studies (87-90), Smll inhibits RNR activity by
directly binding to a. In response to DNA damage or replication blocks, the Mecl (signal
transducers) and Rad53/Dunl (effector S/T kinases) checkpoint pathway is triggered (91-
93), resulting in release of Sml inhibition, translocation of pp' from the nucleus to the
cytoplasm, and stimulation of RNR transcription via removal of Crtl, which binds a
conserved cis element (X-box) of RNR2, RNR3, and RNR4 to repress their transcription
(Fig 1.12B).
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Figure 1.12: RNR regulation in S. cerevisiae during (A) DNA replication and (B) in
response to DNA damage.
1.3.3.1 Allosteric regulation
In contrast to the E. coli and mammalian RNRs, the S. cerevisiae RNR shows a
relaxed dATP feedback inhibition (80). While 50% of the activity of the mammalian
RNR is inhibited at 5-10 CgM dATP, the inhibition of the S. cerevisiae RNR requires at
least 50 lgM dATP (66, 94, 95). In addition, the activity of the S. cerevisiae RNR is
regulated by Smll, the expression levels of which correlate inversely with the amount of
dATP. Smll will be described in more detail in section 1.3.3.5 and Chapter 5. The
interplay between levels of dATP and Sml 1 in the cell is important in controlling RNR
activity and balancing the dNTP pools in S. cerevisiae (80). Moreover, dNTP levels in
yeast cells are about four fold higher after DNA damage than in undamaged cells in S
phase. Therefore, it appears that yeast cells require more dNTPs for DNA repair than for
3, Rnr4 ge
3, Rnr4 gene
DNA replication, a different scenario from what is observed in mammalian cells. One of
the explanations for the high dNTP requirement in yeast cells is that the yeast translesion
DNA synthesis (TLS) protein used in DNA repair has Km for dNTPs at least 10-fold
higher than the polymerase used in normal DNA synthesis (80, 96). Therefore, the
concentration of dNTPs has to be at least above the Km for efficient DNA repair even at
the expense of higher mutation rates.
1.3.3.2 Cell cycle-dependent regulation
Transcription of RNR1, RNR2 and RNR4 in yeast is cell cycle-dependent, and is
regulated through Mbpl/Swi6 binding to Mlul cell cycle box (MCB). Swi6 is a
regulatory protein, and Mbpl is a DNA binding protein that recognizes the MCB
promoter elements (97-99). RNR1, which is essential for mitotic viability, is tightly cell-
cycle regulated. The mRNA level of RNR1 reaches a maximal level in the late G1/S
phases and a minimal level in G1 phase. The half life of RNR1 mRNA is short relative to
RNR2 and seems to be rate-limiting. RNR3, which is not an essential gene, expresses at
very low levels under normal conditions, but is induced over a hundred-fold in response
to cell cycle arrest, or in response to DNA damage, compared to 3 to 5 fold induction
level of RNR1 under same conditions (69, 100, 101). The expression of both RNR2 and
RNR4 remain constant throughout the cell cycle but increase 2-20 fold after DNA
damage (71, 72).
1.3.3.3 Transcriptional regulation during DNA damage and at replication
checkpoints
RNR is transcriptionally induced through Mecl/Rad53/Dunl kinase pathway in
budding yeast, or through rad3/cdsl/chkl checkpoint pathways in fission yeast, in
response to both transcription and cell cycle arrest. MECIA and RAD53A mutants show
failure to activate RNR, decreased dNTP pools, incomplete chromosome replication, and
eventually cell death (102).
Three genes, CRTI, TIP], and SSN6, are downstream targets of DUN] (DNA
damage responsive kinase). Crtl binds a 13-bp cis-regulatory element (X-box) in the 5'-
untranslated region (5'-UTR) of the RNR2, RNR3, and RNR4 genes and represses their
transcription by recruitment of the co-repressor complex Tup6-Ssn6 (81, 103). Upon
activation of the Mecl-Rad53-Dunl kinase cascade, Crtl is inactivated by
phosphorylation and loses its ability to bind X-box elements present on RNR promoters.
After DNA damage is repaired, CRT] is induced and the increased amount of Crtl
rapidly restores RNR repression. Furthermore, it has been found that RNR2 and RNR4 are
partially induced in response to DNA damage in a DUN] deletion strain, indicating the
existence of a DUN]-independent pathway for the transcription of RNR in response to
DNA damage.
1.3.3.4 Regulation by subcellular localization
In contrast to human and mouse RNRs, the small RNR subunits in S. cerevisiae
are anchored in the nucleus and the large RNR subunits remain in the cytoplasm when
dNTPs are not needed (86). In S. cerevisiae, Wtm (WD40-containing transcriptional
modulator) proteins and the importin 0 homolog Kap122 are regulators of j3p' localization
(83, 104). Wtml and Wtm2, which are nuclear proteins, have been observed to be
physically interacting with P3'. Deletion of Wtml or Kap122 causes 3p' to lose its nuclear
localization, but increases the viability of MECA cells in hydroxyurea (HU), an anti-
cancer drug which inhibits RNR by scavenging Y*. The role of Wtm2 is unclear,
although high levels of Wtm2 can suppress the sensitivity of MECA SMLIA mutant cells
to HU, suggesting that it may play a supportive role to Wtml. The Mecl/Rad53/Dunl
checkpoint kinase pathway has been proposed to control the redistribution of 3p' through
regulating Wtml in response to cell replication or DNA damage.
In addition, Difl (Damage regulated import facilitator 1) was discovered recently
to mediate the localization of P3' in S. cerevisiae (105). It is a sequence homolog of Smll
and Hugl in S. cerevisiae, and Spdl(S phase delayed protein) in S. pombe (Fig 1.13A).
Three conserved domains have been identified. HUG] is located directly upstream of
SML1 in the genome (Fig 1.13B). Difl, Hugl and Smll are paralogs from an ancestral
gene duplication. Hugl is highly induced after DNA repair via the Mecl pathway, but its
function still remains unclear. The details of the function of Spdl and Smll will be
described in the next section.
Although deletion of Difl does not affect the in vivo RNR levels, its phenotype is
the same as that of AWTM1, i.e., loss of P3' nuclear localization. However, Difl functions
through a pathway distinct from Wtml. Blocking nuclear export in AWtml causes
accumulation of nuclear P3', whereas this is prevented in the AWtmlADif mutant. Based
on this and other data, Difl has been proposed to facilitate the nuclear import of 3p'
rather than serving as an anchor in the nucleus (figure 1.14). In addition, the level of Difl
expression is regulated in a cell-cycle dependent fashion by Duni phosporylation,
reaching a maximum at the end of S phase for transport of pp' back to the nucleus.
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Figure 1.13: Sequence alignment of Difl, Smll, Hugl, Spdl and Aer122c.
(A) Difl, Smll, and Hugl are S. cerevisiae proteins, Spdl is in S. pombe, and Aerl22c is
a Difl/Smll ortholog in Ashbya gossypii. Three conserved domains have been identified.
(B) Synteny in the proximity of the HUG1/SML 1 loci on chromosome XIII and the DIF1
locus in S. cerevisiae.
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Figure 1.14: Model of the nuclear import facilitator and anchor of pp' in response to
DNA damage (106).
Difl facilitates the nuclear import of 3p' (R2R4), while Wtml aids in retention of P3'. At
left, the cell in the absence of DNA damage. At right, Difl is phosphorylated, and
degraded, resulting in the release of P1' in response to DNA damage (DDR). The affinity
between Wtml and pp' is also decreased. Kap is Kap122, which facilitates pp' import.
Crml is an exportin that mediates pp' nuclear export. E3 stands for E3 ubiquitin ligase.
Dashed arrows indicate pathways that are blocked during DNA damage.
1.3.3.5 Regulation of RNR by protein-protein interaction
In S. cerevisiae, DNA damage or S-phase activates the Mecl/Rad53 kinases,
which subsequently activate Dun1 and regulate RNR activity by controlling the
phosphorylation state of Smll (Figure 1.15) (107). Smll was originally identified as an
RNR inhibitor as Smll deletion suppresses the lethality of AMEC1 or ARAD53 (108).
The expression level of Smll depends on both the cell cycle and DNA damage; it is
lowest during S phase, and is almost undetectable after DNA damage. However, the
dNTP levels in ASML1 cells do not differ significantly from those in wild-type cells after
DNA damage, indicating rapid degradation of Smll after DNA damage (96). This rapid
change in RNR activity indicates post-translational regulation rather than transcriptional
regulation. Cells lacking Smll showed 2.5 times higher dNTP levels than in the wild-type
cells in normal growth and increased resistance to DNA-damaging agents.
Relief of Smll inhibition is proposed to be associated with its phosphorylation,
which targets it for degradation. The current model proposed by Rothstein's group is that
the Mecl/Rad53 kinases activate Dunl to control the induction of RNR genes by
relieving Crtl repression and targeting the degradation of Smll by phosphorylation in
response to DNA damage or in S phase (Figure 1.15) (107, 108).
DNA damage S phase
Rad 17, Rad24, Mec3 y Rad9
MeeI Mbpl/Swi6
Rad53
Dun I
Transcriptional induction
Sml1
(inactive) (active)
NTPs dNTPs
DNA synthesis
Figure 1.15: The current model for Smll regulation in S. cerevisiae (96, 107, 109).
Mecl/Rad53 pathway causes phosphorylation and degradation of the unbound form of
Smll, which drives the equilibrium from Smll-bound RNR to the free RNR at S phase
and after DNA damage. RNR is also controlled at a transcriptional level by Mbpl-Swi6
at S phase and Mecl/Rad53/Dun after DNA damage.
Studies from the yeast two-hybrid assay and co-immunoprecipitation experiments
have revealed that Smll regulates RNR by binding directly to a rather than by controlling
the RNR transcription (90, 108). Further support for this proposal is the observation that
the mRNA levels of RNR1 in wild type and Asmll cells remain unchanged during normal
growth and after DNA damage (108). A 2D NMR structure of Smll suggests it is loosely
folded with two a helices, one at the N-terminus and the other at C-terminus oriented in
an anti-parallel fashion. The residues (8-20) at the N-terminus have been proposed to be
important for Smll dimerization, whereas the last 33 amino acid residues on the C-
terminal alpha helix have been mapped as the site of interaction with a (89). A Kd of 0.4
tM for Smll-a binding in the absence of effectors was measured by surface plasmon
resonance (SPR) spectrometry (90). Finally, recent two-hybrid assays have shown that
deletion of the C-terminal tail of a (778-880) increases interaction between Smll and a,
suggesting that Smll inhibits a by competing with the C-terminal tail's accessing the
active site to re-reduce the disulfide formed by turnover (110). The assays also suggested
that W688 of a plays a key role in Smll-a interaction.
Spdl in S. pombe is a homolog of Difl and Smll. It is a 14 kDa protein and was
initially found as a cell cycle-regulated protein, with the lowest level in S phase (111).
Over-expression of Spdl blocks S-phase and mitosis progression (112). It was initially
proposed that Spdl served to anchor P inside the nucleus on the bases of indirect
immunofluorescence microscopy showing the nuclear co-localization of Spdl and P (84).
Although no direct interaction between P and Spdl has been observed, deletion of SPD1
causes p mis-localizaton (83, 104, 113). However, biochemical studies from Thelander's
group have suggested that Spdl plays a similar role to Smll as an inhibitor of a and does
not interact with p (113). A Kd value of 2.4 jM was obtained for Spdl and S. pombe a
using a biosensor method. Recent studies from Borgne et al (114) have suggested, in
contrast to earlier reports, that Spdl localized in the cytosol, where it can bind a. Above
all, more and more data supports that Spd 1 functions as a RNR inhibitor rather than a
anchor.
1.4 Human RNR
1.4.1 Introduction to human RNR
Most studies to date on mammalian RNRs have been carried out on calf thymus
and mouse RNRs, with few reports on human RNR. The calf thymus RNR was the first
mammalian RNR to be purified in 1979 (115). The mouse RNR was first purified in 1985
and has since been studied extensively. The most striking difference between the mouse,
calf thymus, and E. coli 3s is the stabilities of their Y* and diferric clusters. In the case of
E. coli P, the Y* is stable for four days at 4 'C. In the case of the calf thymus enzyme,
however, both the Y* and iron cluster are labile, with a half life of 10 min for Y- at 37 'C
(116). Assays on calf thymus P were carried out at 37 'C requiring the presence of FeC13,
DTT and a continuous supply of oxygen for in vitro regeneration of Y* to maintain
activity (115). In the mouse 0, 50% of the iron is lost after 30 min at 37 'C (117). EPR
spectroscopy showed stronger interactions between the diferric cluster and the Y- in
mouse P than in E. coli 0 (118). Despite these differences, the interaction between the
subunits in mammalian RNRs is similar to that in E. coli RNR with a Kd of 0.5 tM for
mouse RNR in the absence of effectors (119). Unlike E. coli RNR, however, the presence
of effector is required for enzyme activity (95).
Human cells contain three RNR subunits: H1 (a), H2 (0), and p53R2 (P'). The
quaternary structure of human RNR has not been studied extensively. However,
Cooperman's lab has provided convincing evidence that mouse a which exhibits 80%
sequence identity with human a, can be a monomer, dimer, tetramer or hexamer,
depending on the presence and concentration of dNTPs and ATP (120). f3 and P' are
always homodimers.
Both human P and P' contain tyrosyl radical, iron ligands, key residues in the
PCET pathway, and C-terminal tail that binds a. The p53R2 (P') gene was first isolated
from a colon cancer cell line by Tanaka and co-workers in 2000 (121). The gene contains
a p53 binding motif in intron 1 and its expression is inducible by p53, a transcription
factor which is regulated by ATM/ATR and CHK2 kinase signal transduction pathway
and has a tumor-suppressing function through regulation of cell-cycle arrest or induction
of apoptosis (122). P' is essential for mammalian cell survival and two models have been
proposed for its role. p's induction by p53 suggests that it might be involved in DNA
repair (123), but recent data suggests the role of P' is likely much more complex. Studies
by three independent methods have demonstrated that the localization of ribonucleotide
reduction in human cells is in the cytosol instead of the nucleus (124). The data also
suggest that P' is localized to the cytosol (124) and is not shuttled to the nucleus as
previously suggested (121, 125). In addition, low constitutive levels of 13' are expressed in
all stages of the cell cycle, regardless of p53 status (126), allowing the cell to provide
basal levels of dNTPs for mitochondrial DNA synthesis in Go/G 1 phases (126). Mutations
of 0' cause severe depletion of mitochondrial DNA in both mouse, and human cells,
leading to the proposal that 1' plays a primary role in mitochondrial DNA replication
(127). However, most recent data has shown that 3' interacts with ATM kinase (ataxia
telangiectasia mutated) and is found in the MRE 11 complex involved in DNA double
strand break repair, suggesting a role for P' in DNA repair, and a possible translocation to
nucleus (128, 129).
1.4.2 Regulation of human RNR
In eukaryotic cells, nuclear DNA synthesis, requiring large dNTPs pools, occurs
in S phase, whereas the replication of mitochondrial DNA, needs a much lower supply of
dNTPs and occurs in all stages of the cell cycle. In S phase, the majority of dNTP/dNDPs
are produced by an /P3 RNR complex, the formation of which is mediated by allosteric
regulation, S-phase transcription and Go/G 1 phase degradation of P (Figure 1.16). P' is
regulated by p53 at both transcriptional and protein levels. In resting cells devoid of 3, 3'
is at a level of 30 fold lower than 0 in cycling cells (126). The rate of DNA synthesis is
only 2-3% of that in cycling cell (130). Recent data suggest that P' is also regulated by
the p53 family members p21 in a p53-mediated way (131) and p73 in a p53-independent
way (123). Unlike in yeast, all the RNR subunits in human cells stay in cytosol (124).
a' transcription factor, transcription factor,
S~e ' YY1, TFII-F NF-Y
Figure 1.16: Overview of the regulation of human RNR in S-phase and in response
to DNA damage.
YY-1, TFII-F and NF-Y are transcription factors which bind the promoter of a and f
respectively. The transcription of P' is controlled in a p53 dependent pathway or p53 non-
dependent way when p53 is absent. a, P and P' locate in the cytosol and provide DNA
precursors for DNA replication and mitochondria DNA synthesis. 0' is also regulated at
protein level by p53 or p21.
1.4.2.1 Allosteric regulation
Unlike E. coli RNR, the mammalian RNR has a stringent requirement for bound
effector binding to be active. Binding of the effectors to a at the dimer interface
facilitates dimerization and is key for a binding to P2. Compared to the Kd (0.52 pM) for
mouse a and 0 in the absence of effectors, the affinity of them was increased in the
presence of TTP (Kd = 0.46 M), dGTP (Kd = 0.4 riM), dATP (Kd = 0.05 rM), and ATP
(Kd = 0.12 tiM) (119).
For mouse RNR, Cooperman's group has proposed a third allosteric binding site,
the hexamerization site (H site), which binds ATP and drives formation of the a hexamer,
a6 (132, 133). Based on glycerol gradients analytic centrifugation and dynamic light
scattering studies, a model was proposed in which effector binding to the S site drives
formation of the active form a2, and ATP or dATP binding to the A site drives formation
of a4, in which the inactive form (a4)b predominates over an active (a4 )a form (Figure
1.17). It was proposed that the interaction of a4 and 32 might distort the electron transfer
distance and pathway and result in a decrease in the electron transfer rate. Higher
concentrations of ATP leads to ATP binding at the H site, driving the formation of the a6
form (133, 134). The required ATP concentration for a6 formation is about the same as
the in vivo ATP concentration in mouse cells. Therefore, the a6(02)j (j = 1, 2, 3) is
proposed to be the major active form of RNR in mammalian cells.
Recent studies on mouse RNR using gas-phase electrophoretic-mobility
macromolecule analysis (GEMMA) and mass spectrometry methods have demonstrated
that in the presence of ATP/dATP, a stays in a6 form, which can interact with 02 and
form an a6 2 complex (135), whereas other allosteric effectors can only induce a to
dimerize. In contrast to Cooperman's model, this study did not observe the tetramer and
did not support the existence of H-site.
R1 R12
Figure 1.17: The modulation of mouse a oligomerization state and the activity by
ATP and dATP effectors (132).
The equilibrium between different forms is regulated by three allosteric sites, S-site, A-
site and H-site. The three forms in green are active forms, and the two forms in red are
inactive.
1.4.2.2 Cell cycle-dependent regulation
The transcription of genes encoding a and P is exclusively cell cycle-dependent,
reaching a maximum level during S-phase (66, 136). The half-life of a is about 15 h, long
enough that the concentration of a is virtually constant throughout the cell cycle (136). P
has a short half life (3 h) and is degraded in the Go/G 1 phases. The maximal level of 0' is
reached at GI/S transition. Therefore, S phase RNR activity is limited by the expression
and degradation of P. Although the transcription of the genes encoding a and P reaches
the maximum levels during S-phase, the genes' promoters do not show sequence
homologies to explain the coordination of transcription. On the promoter of the
mammalian a gene, a TATA-less region that contains four protein-binding DNA
elements have been found to regulate the promoter activity (137, 138). Of the four
elements, two are essential for cell cycle-regulated transcription of a; and the other two
E] = S-site, no (d)NTP O = a-site, no (d)ATP
1 = S-site bound to dGTP,
TTP, dATP, or ATP = a-site bound to
ATP or dATP
A = h-site no ATP 0 = a-site bound toATP
A = h-site bound
to ATP
R13monomer
control the a promoter strength. Transcription factor YY-1 and TFII-F bind to the a
promoter. In contrast to the a promoter, the mammalian p promoter contains a TATA-box.
The S-phase specific transcription of P is mainly regulated by an upstream activating
region and an element repressing the promoter activity in G1 phase by binding to E2F4
element (139). At the beginning of S phase, repression of the P promoter is released by
the recruitment of the NF-Y transcription factor to disrupt E2F4 binding; meanwhile, the
upstream activating region is allowed to activate the promoter region.
The major sequence difference between P and P' is that P' lacks 33 amino acids at
its N-terminus, which includes the KEN box in P. In Go/G 1 phase, Cdhl-APC binds the
KEN box of P to facilitate its polyubiquitination and subsequent degradation by the
proteasome. Thus P is completely absent in postmitotic cells. The lack of KEN box in the
p53R2 gene prevents the degradation of P' during the cell cycle. In the absence of DNA
damage in quiescent cells, the expression level of P' is about 30-fold lower than P in S
phase (126), and the nucleotide reduction rate is about 2 to 3% that in proliferating cells
based on isotope incorporation experiments (130).
1.4.2.3 Transcriptional regulation through DNA damage and replication
checkpoints
In human and mouse cells, 1' is transcriptionally induced by p53 through ATM-
ATR/CHK2 signal transduction pathway in response to DNA damage. It has been shown
that homeodomain-interacting protein kinase 2 (HIPK2), which phosphorylates Ser46 of
p53, is involved in p53 binding to the 0' promoter in activating the transcription of P'
(140). The level of activated 0' and the efficiency of DNA repair were significantly
reduced as a result of HIPK2 deletion. It has been found that in the absence of p53, p73,
another member of the p53 family that regulates factors involved in mitochondrial DNA
synthesis, can induce 3' in a p53-independent pathway (Figure 1.16) (123).
In contrast to yeast cells, no significant increase in the size of dNTP pools has
been observed in mouse cells in Go/G 1 and S phase after DNA damage (126), even
though the basal level of 3' is increased. One explanation might be that the activation of
p' only increases the local concentration of dNTPs close to the DNA damage site. Since
DNA repair requires much smaller amounts of dNTPs than DNA replication, mammalian
cells might have evolved mechanisms to produce an optimal level of dNTPs in response
to DNA damage while maintaining high fidelity in DNA replication. By contrast, it has
been reported that the expression of P during S phase is not affected by DNA damage or
cell cycle arrest (141).
1.4.2.4 Regulation of RNR subcellular localization
In human cells, a, 0, 3' are normally located in cytosol. However, the localization
of the ribonucleotide reduction has become a debatable question. Tanaka et al reported
that p' could undergo relocation from the cytosol to the nucleus in response to DNA
damage (121, 125). During S phase, P and a are transported to the nucleus to produce
dNTPs (142). Thus controlling the subcellular localization of a, P and 3 was proposed as
another RNR regulation mechanism. Nevertheless, the current model proposed by
Pontarin et al (124) suggests that the ribonucleotide reduction occurs only in the
cytoplasm and the produced dNTPs are imported into the nucleus or mitochondria for
DNA replication or repair. Their data has demonstrated that even in S-phase and after
DNA damage, all three RNR subunits only locate to the cytoplasm (124). The
translocation of 0' was not observed. These results agree with earlier studies that
suggested the RNR subunits exclusively localize to the cytoplasm (143).
1.4.2.6 Regulation by protein-protein interaction
Besides regulation at the transcriptional level, p53 also binds P', but this binding
is inhibited upon DNA damage. Moreover, it has been reported that the N-terminus
(residues 1-113) of p' interacts with the N-terminus (residues 1-93) of p21 and the p2l1/3'
complex stays in the cytosol. p21, which is a downstream target of p53, is a cyclin-
dependent kinase (Cdk) inhibitor that causes G1 arrest (131, 144). After DNA damage,
p21 dissociates from P' and inhibits Cdk2 in the nucleus to arrest cells in G1 phase (131).
More recently, data has shown that ATM kinase can directly phosphorylates S72
of 0' and forms a complex with 0' (145). This modification has been found to be
important for maintaining the stability of 0' by inhibiting its polyubiquitination and
degradation.
1.5 RNR as target for anti-cancer therapy
The discovery of P' has provided a connection between RNR activity and the p53
checkpoint pathways for DNA repair in an effort to maintain genome stability.
Inactivation of p53 directly interferes with the transcription of P', causing insufficient
RNR activity to provide dNTPs required for DNA repair, thereby increasing cell
sensitivity to DNA-damaging agents (121). In addition, the expression level of P' has
been found to be significantly correlated to the degree of tumor invasion (146). P' has
been shown to interact with ERK1/ERK2 (extracellular signal-regulated kinase) and to
inhibit MEK-ERK kinase signaling and prevent cancer invasion (128, 129).
The key role of RNR in DNA replication and repair has made it an important
target for anti-tumor agents. Increased RNR mRNA levels and activity have been found
to be associated with tumor cell growth, and thus inactivation of RNR could inhibit
cancer cell proliferation. Tumor cells are more sensitive to RNR inhibition than the
normal cells due to their increased demands for dNTPs for their replication. In recent
years, RNR inhibitors such as Gemzar®, Hydroxyurea, and Triapine® have been used for
cancer treatment or have advanced to various phases of clinical trials. Inhibitors can
target either the regulation of RNR gene expression or the RNR protein. The inhibitors
targeting RNR proteins can attack either RNR subunit, or disrupt subunit interactions.
The a inhibitors are usually nucleoside analogs that are either substrate analogs, such as
Gemcitabine (2', 2'-difluorodeoxycytidine, F2C) (147-149), Tezacitabine (2'-
fluoromethylene cytidine, FMC)(150-152), or allosteric effector analogs, such as
clofarabine, or those that inactivate a by alkylation. The 0 inhibitors are either iron
chelators, such as thiosemicarbazones (153, 154), or radical scavengers, such as
hydroxyurea (155-158). Drugs that are designed to prevent a, P complex formation are
small peptides corresponding to the C-terminal tail of 13.
1.5.1 Gemcitabine
Gemcitabine (F2 C) is taken up into cells via CNT type or ENT type nucleoside
transporters, and is phosphorylated by deoxycytidine kinase (dC kinase) to F2CMP and
subsequently to the corresponding 5'-diphosphate (F2CDP) and triphosphate (F2CTP) forms.
Gemcitabine has multiple targets in the cell including RNR, dC kinase, and DNA polymerase
(Figure 1.18). F2CDP inhibits RNR, reducing the dNDP and consequently dNTP pools. The
decrease in the dCTP pools activates dC kinase. The activated dC kinase produces more
F2CMP and consequently more F2CDP which further inhibits RNR activity. The reduced dNTP
pools allow F2CTP to be more efficiently incorporated into DNA, resulting in chain
termination and leads to cell death (159). Gemcitabine resistance has been observed to be
associated with overexpression of a in some cell lines and f3 in other cell lines (160, 161).
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Figure 1.18: Gemcitabine metabolism.
Only unphosphorylated nucleosides can be taken into the cell. Once inside the cell, they must
be phosphorylated to the di- and triphosphate states to be active. The diphosphate state targets
RNR and reduces dNDP and consequently dNTP pools. The decrease in the dCTP pools
activates dC kinase. The activated dC kinase produces more F2CMP and consequently more
F2CDP which further inhibits RNR activity. The reduced dNTP pools allow F2CTP to be more
efficiently incorporated into DNA, which results in chain termination.
Gemcitabine has been widely used in anti-cancer treatment and has shown significant
clinical activity. It is the first line treatment for non-small cell lung cancer and pancreatic
cancer (162-166). It has also been used in combination with other chemotherapies for the
treatment of various carcinomas: bladder cancer, breast cancer, ovarian cancer and
lymphomas (167-170). Patients with pancreatic cancer treated show significantly reduced
rate of recurrence and improved longer disease-free survival with F2C treatment after tumor
resections (171, 172).
Gemcitabine has multiple intracellular targets including RNR, DNA and RNA chains,
deoxycytidine kinase (dCK), CTP synthase, nucleoside transporters hENTI, hENT2. Over-
production or decrease of any of those targets may cause resistance to the drug (75). Patients
with higher levels of hENT1 transporters have shown longer survival and sensitivity after
gemcitabine treatment, suggesting the amount and the type of nucleoside transporters on cells
are related to the efficacy and toxicity of gemcitabine (173). Deoxycytidine kinase (dCK)
which catalyzes the rate-limiting step in F2C phosphorylation, has been found to be a pivotal
factor for the cytotoxicity of F2C. A lack of dCK causes resistance to F2C in several leukemic
cell lines (174-176). The efficacy of F2C is significantly reduced with addition of 2'-
deoxycytidine, which down-regulates dCK activity. In addition, over-expression of RNR a
subunit or f3 subunit has been observed in several F2C resistant cell lines, suggesting that both
subunits are the targets of F2 C (177-180). The expression ratio of RNR and dCK closely
correlates with efficacy of F2 C.
The deamination product F2U is the major inactive metabolite of F2C at low F2CTP
concentration, whereas most F2C is secreted at high injection concentration (181). Cytidine
deaminase (CDA) and cytosolic 5'-nucleotidase (cN-II) play major roles in inactivation of
active metabolites. Over expression of CDA or cN-II has resulted in drug resistance and is
associated with shorter survival (182).
Previous studies in our lab on the inactivation of E. coli RNR by gemcitabine
have established that F2CDP is a potent irreversible mechanism-based inhibitor of RNR
(149, 183, 184). The inhibition mechanism of F2CDP is unique. While the 2'-monohalo-
2'-deoxy-nucleotides lead to partitioning between turnover and inactivation, 0.5 eq.
F2CDP can completely eliminate RNR activity accompanied with 1 cytosine and 2 F
released, and 1 ribose ring covalently attached to the inactivated enzyme.
Based on our past and current studies on E. coli and L. leichmannii RNRs, a model to
account for the pathway of inactivation has been proposed (Figure 1.19) (185). The first step
is 3'-hydrogen atom abstraction followed by loss of F- (1 to 3, Figure 5), as in the mechanism
of 2'-fluoro-2'-deoxynucleoside 5'-diphosphate (Figure 1.7). The partitioning of the next step
depended on the presence of reductant (4, 61). In the presence of reductant, one of the bottom
phase cysteine attacks the 2' carbon to generate 5 with forming covalent linked product. In
the absence of reductant, water attacks the 2' carbon to generate 4 concomitant with loss of
the second F-. Intermediates 4, 6 are proposed to be the new nucleotide radical detected by
EPR spectroscopy. The conversion of 3 to 4 has no chemical precedent. This step is the
reverse of water loss in the normal reduction process and requires that there is a water in the
active site in the vicinity of the C2' carbon.
A computational method has also been used recently in an attempt to unravel the
F2CDP inhibition mechanism (186, 187), leading to the proposal of a similar mechanism. In
their work, C225, one of the redox cysteines in the active site has been proposed as the
conjugation site. However, the charges on the intermediate proposed in their model appear to
be incorrect, which require the kinetics to be reexamined.
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Figure 1.19: Proposed mechanism of inactivation of RNR by F2CDP in the absence (4)
and the presence (5) of reductant.
The recently solved crystal structures of yeast RNR with F2CDP/AMPPNP
(effector analogue) bound, and CDP/AMPPNP bound display different binding modes
(Figure 1.20) (75, 188). The crystals were grown under following conditions: 0.1 M
sodium acetate, pH 6.5, 20-25% PEG 3350, and 0.2 M ammonium sulfate, followed by
soaking with 20 mM AMPNP-F2CDP pair or AMPNP-CDP in a mother liquor containing
20 mM DTT and 10 mM MgC12. As shown in the AMPPNP-CDP structure in figure 1.20
(right), the 2' and 3' OH of the ribose are close to the catalytically relevant residues, N426
and E430, the thiyl radical residue C428, and the active site cysteine C218. In the
AMPPNP- F2CDP structure (Figure 1.20 left), however, the cytosine and ribose ring bind
higher and away from N426 and E430. C218 remains close to the 2' carbon of F2CDP. In
addition, two additional water molecules close to the ribose of F2CDP have been
identified. Overall, these structures provide support for our proposed mechanism (Figure
1.19).
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Figure 1.20: Yeast RNR
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active site structures with F2CTP (left) or CDP (right) bound.
1.5.2 Hydroxyurea
Hydroxyurea is another important anti-tumour drug used in combination with other
chemotherapies targeting RNR. It causes decreased dNTP pools to inhibit DNA synthesis by
starving the DNA polymerase at the replication fork (189). Hydroxyurea inactivates RNR by
reducing the Y- in 0 via a one-electron transfer mechanism (190). The Y* in mammalian
RNR is more sensitive to hydroxyurea inhibition than the E. coli analog, perhaps because the
iron center is more solvent exposed in mammalian P (191). However, the activation energies
of the reactions are quite similar for both the E. coli (67 kJ mol1 ) and mouse RNRs (66 kJ
mol 1), suggesting a common reaction pathway (192). The presence of a reduces RNR
!
susceptibility to hydroxyurea, whereas the addition of positive effector and substrate makes
the radical in RNR complex more susceptible to hydroxyurea inactivation and accelerates the
inhibition significantly. The control experiment with addition of substrate to P alone did not
change the radical susceptibility to hydroxyurea by a large extent (192). It might be that
addition of a to P blocks the radical site, but addition of positive allosteric effectors changes
the RNR complex conformation drastically from apo to holo form and opens up the active
site. The data thus far suggest that there is no particular binding site for hydroxyurea
inhibition.
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Chapter 2
Characterization of Human Ribonucleotide Reductase
2.1 Introduction
Ribonucleotide reductases (RNRs) catalyze the reduction of all four
ribonucleotides to the corresponding deoxyribonucleotides and consequently are essential
in DNA biosynthesis and repair. Human RNR (hRNR), a class Ia enzyme, is composed of
one large subunit H1 (a) and two small subunits, H2 (P) and p53R2 (3'), which
share 80% sequence identity (1). As with other class Ia enzymes, 0 contains a diferric-
tyrosyl radical (Ye) cluster, which is essential for catalysis. Current evidence suggests
that there is one Y* and 2 diferric clusters/P2 (2, 3). a contains the active site and effector
binding sites that control substrate specificity and turnover rate (4-7). The quaternary
structure of human a has yet to be investigated, but based on analogy with mouse RNR
(90% homolog), it can be a monomer, dimer, tetramer or hexamer depending on the type
of nucleotide present (8, 9).
In mammalian cells, RNR is regulated at the level of allosteric regulation(10),
transcription during S-phase or DNA repair (11), proteolysis of P in late mitosis (12), and
subunit localization. Transcription of a and P genes are exclusively cell cycle dependent,
reaching their maximum levels during S-phase (13, 14). However, the half-life of a is
about 15 h, so its levels remain constant throughout the cell cycle (14). f has a short half
life of only 3 h, and is degraded during Go/G 1 phases, thus RNR activity in the S phase is
controlled by the expression and degradation of P. In the Go/G 1 phase active RNR is
required for mitochondrial DNA replication and DNA repair. Because 0 is degraded
during these phases, P' must be capable of forming a complex with a to generate active
RNR.
Both human P (hp) and P' (hp') contain the essential Y* and the diferrric cluster,
as well as the conserved PCET pathway residues D265/D227, W102/W64, Y369/Y332
(E. coli D237, W48, Y356 equivalents) (Table 2.1). The major sequence differences
between p and p' are in their N-termini. 3' lacks 33 N-terminal amino acids which
correspond to a KEN box in 3, the site for polyubiquitination when P is targeted for
degradation during the Go/G 1 phase. Because P' lacks this domain, its levels remain
constant throughout the cell cycle (15, 16).
The function of 13' is not well understood. Recent studies (17) suggest that 3' is
localized to the cytosol and is not transported to the nucleus as previously thought (1, 18).
The authors proposed that P' plays a primary role in mitochondrial DNA replication.
Another report has suggested that 3' can be phosphorylated directly by the kinase ATM,
and that phosphorylated 3' has been detected in the MRE 11 complex involved in DNA
double strand break repair (19). 3' has also been proposed to have catalase activity to
protect the mitochondrial membrane from oxidative stress, an activity that has not been
attributed to P (20). 0' shows less susceptibility to hydroxyurea and more susceptibility
the iron chelator deferoxamine mesylate compared to 3, but both of the P' and P are
inhibited with similar potency by Triapine (20, 21).
Table 2.1: Conserved key residues in PCET pathway of E. coli, mouse and human
small subunits.
E. coli p Mouse p Mouse 3' Human p Human 3'
In PCET Y122 Y177 Y138 Y176 Y138
pathway W48 W103 W64 W102 W64
D237 D266 D227 D265 D227
Y356 Y370 Y332 Y369 Y332
Iron D84 D139 D100 D138 D100
ligands Ell15 E170 E131 E169 E131
H118 H173 H134 H172 H134
E204 E233 E194 E232 E194
E238 E267 E228 E266 E228
H241 H270 H231 H269 H231
The prototype for the class Ia RNR is the E. coli enzyme. The human small
subunit 0 is 90% identical to mouse 3, but only 27% homologous to E. coli P. Despite the
low sequence homology, the overall structure of mouse and human P are very similar to
that of E. coli 1, with a root mean squared deviation of only 1.6 A for 262 Ca atoms (22).
All of the key residues in the PCET pathway and the iron ligands are conserved (Table
2.1), and the major differences is that the mammalian P and P' lack the P-hairpins on the
tip of the heart shape structure of E. coli P. In both the mouse and E. coli 1, the essential
Y* is closely coupled with the iron cluster, with the former displaying a stronger magnetic
interaction (23). In addition, the X-ray structures reveal that a 15 A wide, 10 A long
hydrophobic channel connects the surface of the protein to a proposed oxygen binding
site near Y177- in the mouse P, making the radical diiron center more accessible to the
solvent (22). Furthermore, the mouse P and E. coli P have different reduction properties:
the Y* and iron center of mouse 1 can be reduced simultaneously, whereas in the E. coli
3, the Y* is reduced before the iron center (24, 25).
The cloning, expression and purification of human a, 1, and P' have been reported
by the Thelander and Yen groups (16, 21). Yen's group reported 1.2 Y/32 and 0.8 Y*/
P'2 based on EPR experiments at 20 K for the His-tagged proteins. However, their
constructs of 1 and 1' contain long (24 amino acid) linker regions between the His-tag
and the start of the protein. In these studies, the protein concentration was determined by
Bradford assay, which might account for the difference in the quantitation of Y* content,
compared to the method using extinction coefficients. In addition, Yen's lab reported
activities of 75 nmol/min/mg and 52 nmol/min/mg for hp and hp3' respectively
(21). Thelander's lab reported values of 158 and 95 nmol/min/mg for the activities of
non-tagged hp and hp', and 140, and 60 nmol/min/mg for mouse 1 and 13' respectively
(16). Mouse 0 isolated by Thelander's lab contains 0.8 Y* per 12 (26). The radical
content of mouse and human 0' has not been reported by Thelander's lab.
Furthermore, from site-directed mutagenesis and EPR studies, Yen's group
proposed that an additional tyrosine residue, Y162 in hp and Y124 in hp', is essential for
radical formation and enzymatic activity. The evidence for their dityrosyl-diiron cluster
model in 1' was that both the Y124F-P' and Y138F-P' (Y122 equivalent) were EPR silent,
suggesting that both Y124 and Y138 are essential to P'. The evidence for a dityrosyl
center in 0 is contradictory to that of p'. Both the Y162F- and Y176F-0 (Y122
equivalent) still contains radicals and were active, only the double mutants Y176F
Y162F- lost all activity (27). Therefore, they proposed that human P and P' contain a
unique dityrosyl-diiron center.
Here we report that using the in vitro reconstitution methods developed in the
Stubbe group, 1.2 Y*/2 and 0.63 Y*/P'2 have been be obtained with the his-tagged P and
non-tagged P'. The highest activities obtained for these constructs are 1089 nmol/mg/min
for p and 420 nmol/mg/min for P'. The stability of the Y* in P and P' have been measured,
revealing similar half-lives in the two subunits. The mutants Y176F-, Y162F-0, Y138F-
f' and Y124F-3' have been constructed to examine Yen's proposal that, in contrast to E.
coli RNR, human 0 and P' contain a dityrosyl-diiron cofactor, essential in catalysis. Our
results do not support their findings, rather we have found that the essential tyrosine
mutant Y176F- and Y138F-P' are EPR silent, while the second tyrosine mutants Y162-0
and Y124-P' contain 0.1 Y* and 0.2-0.3 Y* per dimer respectively. However, our stability
test revealed that the Y- in those mutants are very unstable compared to wt. Overall, our
data are inconsistent with Yen's dityrosyl-diiron model, and instead we believe that hp
and hp' contain a single essential Y* as with the other class Ia RNR.
2.2 Materials and Methods
2.2.1 Materials
Luria Bertani (LB) broth powder and agar were purchased from Difco (Sparks,
MD). Competent E. coli BL21 (DE3) cells were purchased from Stratagene. The pET28a
vector was obtained from Novagen (part of EMD Biosciences, Inc, San Diego, CA).
Complete EDTA-free protease inhibitor tablets, DNaseI, and calf alkaline phosphatase
(20 U/ tL) were purchased from Roche Biochemicals (Indianapolis, IN). Restriction
enzymes were obtained from New England Biolabs (Beverly, MA). [3 H]-CDP (17 Ci
/ptmol) was obtained from Moravek Biochemicals, Inc (Brea, CA). Ni-NTA resin was
purchased from Qiagen (Valencia, CA). Isopropyl P-D-thiogalactoside (IPTG) and 1,4-
dithiothreitol (DTT) were obtained from Mallinckrodt Chemicals (Paris, KY). DEAE
Sepharose Fast Flow, Q Sepharose Fast Flow and Sephadex G-25 column were obtained
from Amersham Biosciences (part of GE Healthcare, Piscataway, NJ). Ultrafiltration
membranes (YM30), Centricons, and Amicon Ultra centrifugal devices were obtained
from Millipore (Bedford, MA). All other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO).
2.2.2 General Procedures
E. coli thioredoxin (TR, specific activity of 40 U/mg) and thioredoxin reductase
(TRR, specific activity of 1320 U/mg) were isolated as previously described (28, 29).
Plasmids containing the genes for a (formerly called H1) and P (formerly called H2),
phRRM1 and phRRM2, were generous gifts from Yun Yen (City of Hope National
Medical Center). p53R2 containing the gene for 1' was a gift from Prof. Lars Thelander
(Department of Medical Biosciences, Medical Biochemistry, Umeai University, SE-901
87 Umed, Sweden). Protein concentrations were determined using the extinction
coefficients (6280 nm) of the monomer [45,900 M' cm' 1 for (His)6-P, 119,160 M' cm for
a, 62,000 M "1cm "1for P'].
2.2.3 Construction of plasmids for expression of His-a, His-P and His-p' in E. coli.
Sequencing of the a and P genes in phRRM1 and phRRM2, respectively,
obtained from Yen's lab, revealed a number of mutations relative to the sequences
reported in the NCBI data base (30, 31). In the a gene, nucleotide C521 was mutated to a
T resulting in a Val to Ala substitution. At nucleotide 1763, C was changed to T
resulting in an Ile to Thr substitution. In the gene for 3, A650 was changed to G resulting
in the conversion of a Lys to Arg. These mutations were corrected by site directed
mutagenesis using the Quick Change Kit by Stratagene with primers shown in table 2.2.
In addition the N-terminal tags of each protein were re-engineered to minimize the
number of additional residues. The NdeI digestion site in a was silenced. All a, P and 3'
genes were PCR amplified with primers listed in table 2.2, digested with NdeI and NotI
and ligated into the NdeI - NotI sites of pET28a (Novagen) to produce (His) 6-a, (His) 6-
3, (His) 6-' containing a "MGSSHHHHHHS-SGLVPRGSH"- N-terminus. We name
them as pHis-H1, pHis-H2 and pHis-p53R2 plasmid. The construct of Yen's (His)6-a
(phRRM1) contains the N-terminal sequence
"MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRDPNSSSVDKLAAA" and
(His) 6-3 (phRRM2) and (His)6-P' (php53R2) contains the N-terminal sequence
"MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGT".
The non-tagged p53R2 in pET3a construct from Thelander's lab is not modified.
The plasmid maps are attached in the appendix. All constructs were verified by
sequencing at the MIT biopolymers laboratory.
Table 2.2 Primers for making the new constructs His-H1, His-H2, His-p53R2 and
correcting sequence errors.
Primer name Sequence of the primer (from 5'-3')
H1-5' primer CTTGCGGCCCATATGCATGTGATCAAGCGAGATGG
(NdeI site)
H1-3' primer CGAGTGCGGCCGCTCAGGATCCACACATCAGACATTC
(NotI site)
H2-5' primer CGCGGATCCCATATGCTCTCCCTCCGTGTCCCGC
(NdeI site)
H2-3' primer GCTTGCGGCCGCTTAGAAGTCAGCATCCAAGGTAAAAG
(NotI site)
His-p53R2 GGGTCGCGGACATATGGGCGACCCGGAAAGGCCGG
5'primer
(NdeI site)
His-p53R2 CGAGT GCGGCCGCTTAAAAATCTGCATCCAAGGTGAAGAC
3' primer
(NotI site)
H1-521 CC ACAACATATG TTGATGAGAG TATCTGTTGG GATCCAC
forward
H1-521 GTGGATC CCAACAGATA CTCTCATCAA CATATGTTGT GG
reverse
H1-1763 GGGAC TGGAAGGTTC TCAAGGAGAA GATTGCAAAG TGTGG
forward
H1-1763 CCATA CTTTGCAATC TTCTCCTTGA GAACCTTCCA GTCCC
reverse
H2-650 GCGCTGGA TTGGGGACAA AGAGGCTACC TATGG
forward
H2-650 CCATA GGTAGCCTCT TTGTCCCCAA TCCAGCGC
reverse
The restriction sites and mutation sites are highlighted.
2.2.4 Expression and purification of a
The expression and purification procedures of human a and P were based on the
reported procedures described by Yen's group (21). Additional steps were included to
remove DNA to increase the purity of the isolated protein.
pHis-H1 was transformed into E. coli BL21 Codon Plus (DE3) (Stratagene),
plated on LB agar plates with 50Vtg /mL kanamycin (kan) and a single colony chosen for
growth. For growth of a, an overnight culture (40 mL) was grown from a single colony at
37 'C and transferred to 2L of LB and grown at 37 'C. IPTG (1 mM) was added at an
OD 600nm 0.7- 0.9 and the cells were grown overnight (16 h) at 25 'C. The cells were
harvested and growths typically yielded 4 g/L.
The isolation of a was carried out at 4 OC by the following general procedure. The
cell pellets (15 g) were suspended (5 vol/g) in 50 mM NaH2PO4, pH 7.0, 0.1% Trition X-
100 and 10 mM 2-mercaptoethanol with the complete protease inhibitor (Roche). The
suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 20,000 x g for 30 min. The supematant was treated with streptomycin
sulfate to a final concentration of 1% (w/v) (determined by streptomycin titration) and the
pellet was removed by centrifugation. The supernatant was incubated with Ni-NTA
agarose resin (1 mL/g of cells, Qiagen) at 4 oC for 1 h and then loaded into a column (2.5
x 10 cm). The column was subsequently washed with 40 column volumes of 50 mM
NaH2PO 4, 800 mM NaC1, 50 mM imidazole, pH 7.0, 0.1% Trition X-100 and 10 mM 2-
mercaptoethanol. The protein was eluted with 50 mM NaH2PO 4, 300 mM NaC1, 125 mM
imidazole, pH 7.0. Fractions containing protein were identified using the Bradford assay.
The fractions were pooled and concentrated to < 10 mL, and then the imidazole was
removed by Sephadex G-25 chromatography (200 mL, 2.5 x 50 cm). a was stored in 50
mM Tris, 100 mM KC1, 15 mM MgCl2, 5 mM DTT, pH 7.6, 5% glycerol. Protein yields
of a were typically about 1-2 mg per g of cell pellet.
a purified using the method above (15 mg) in buffer of 50 mM Tris, pH 7.6, 5%
glycerol, 1 mM DTT was added to a dATP resin (30 mL, 2.5 x 10 cm, pre-equilibrated
with 50 mM Tris, pH 7.6, 5% glycerol, 1 mM DTT) and stirred gently for 2 h at 4 OC.
The resin was then placed in a column (2.5 x 10 cm), and the column was washed with
300 mL 50 mM Tris, pH 7.6, 5% glycerol, 300 mM KC1, 1mM DTT. The protein was
eluted with 50 mM Tris, pH 7.6, 5% glycerol, 100 mM KC1, 5mM DTT, 10 mM ATP.
Fractions containing protein were identified using the Bradford assay. The fractions were
pooled and concentrated to < 0.5 mL, and the ATP was removed by Sephadex G-25
chromatography (40 mL, 2.5 x 30 cm). a was stored in 50 mM Tris, 100 mM KC1, 15
mM MgCl2, 5 mM DTT, pH 7.6, 5% glycerol. The typical yield of a was about 0.2 mg
per g of cell pellet after the dATP column.
2.2.5 Expression and purification of 3
pHis-H2 was transformed into E. coli BL21 Codon Plus (DE3) (Stratagene),
plated on LB agar plates with 50[g /mL kanamycin (kan) and a single colony chosen for
growth. For isolation of 0, an overnight culture (40 mL) in 250 mL flask grown to
saturation was diluted into 2 L of LB in 6 L flask containing 50 pg/mL kan and grown at
37 °C to OD 600nm 0.7- 0.9. Isopropyl-l-thio-p-D-galactopyranoside (IPTG, 1mM) was
then added and the cells were grown for an additional 6 h at 30 OC.
The isolation of P2 was carried out by the following general procedure. The cell
pellets (15 g) were suspended (5 mL/g) in 50 mM NaH2PO4 , pH 7.0, 0.1% Trition X-100
and 10 mM 2-mercaptoethanol with the complete protease inhibitor (Roche). The
suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 20,000 x g for 30 min. The supernatant was treated with streptomycin
sulfate to a final concentration of 1% (w/v) (determined by streptomycin titration) and the
pellet was removed by centrifugation. The supernatant was incubated with Ni-NTA
agarose resin (1 mL/g of cells, Qiagen) at 4 'C for 1 h and then loaded into a column (2.5
x 10 cm). The column was subsequently washed with 40 column volumes of 50 mM
NaH2PO4, 800 mM NaCl, 50 mM imidazole, pH 7.0, 0.1% Trition X-100 and 10 mM 2-
mercaptoethanol. The protein was eluted with 50 mM NaH2PO4, 300 mM NaCl, 125 mM
imidazole, pH 7.0. Fractions containing protein were identified using the Bradford assay.
The fractions were pooled and concentrated to < 10 mL, and the imidazole was removed
by Sephadex G-25 chromatography (200 mL, 2.5 x 50 cm). P was stored in 50 mM Tris,
100 mM KC1, pH 7.6, 5% glycerol. Protein yields of P were about 5 mg per g of culture.
2.2.6 Expression and purification of 3'
The expression and purification procedures of P' were based on the reported
procedures described by Thelander's groups (16).
The plasmid of p53R2 (non-tagged, from the Thelander lab) was transformed to
BL21 Codon Plus (DE3)-RIL cells (Stratagene), plated on LB agar plates with 100
pg/mL Amp and 34 ig/mL Chloramphenicol (CM). For the expression of P', an
overnight culture (20 mL LB in 150 mL flask) was grown to saturation, diluted into 2 L
of LB in 6L flask containing 100 [tg/mL Amp, 34 [tg/mL CM and grown at 37 'C to
OD 600nm 0.7. 1,10-Phenanthroline (100 pM) was added and the cells were grown for an
additional 15 min. IPTG (400 [M) was added and the cells were induced and grown at 37
'C for 5 h. The cells were harvested and typically yielded 2 g/L.
For the isolation of the apo p', around 16 g of cell pellet were suspended (4 mL/g)
in extraction buffer (50mM Tris-HC1, pH7.6, 1mM PMSF, 1mM EDTA at 4 oC). The
suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 27, 000 x g for 30 min at 4 oC. A 10% (w/v) solution of streptomycin
sulfate, in extraction buffer, was added to the supernatant over 10 min while stirring at 4
0C, to a final concentration of 2.5 % (w/v, from Thelander's protocol). After an additional
10 min of stirring, the pellet was removed by centrifugation (27, 000 x g for 30 min, 4
°C). Solid ammonium sulfate (0.243 g/mL, 40% saturation) was added to the supernatant
over 10 min at 4 oC. After an additional 30 min of stirring, the protein pellet was
recovered by centrifugation (27, 000 x g for 30 min, 4 'C).
The pellet was dissolved into 4 mL of extraction buffer and loaded directly onto a
Phenyl Sepharose 6 Fast flow column (20 mL, 2.5 x 10 cm) which was pre-equilibrated
with buffer A (200 mL, 25 mM Tris pH 7.6, 10% glycerol, 30% w/v (NH4)2SO 4). The
column was washed with buffer A (100 mL) followed by buffer B (300 mL, 25 mM Tris
pH 7.6, 10% glycerol, 5% w/v (NH4)2SO 4). Finally P' was eluted with 50 mM Tris pH7.6,
5% glycerol, 1 mM EDTA, 1 mM PMSF. Fractions (2 mL) containing p53R2 (based on
Bradford assay) were collected.
The pooled protein elution fractions were loaded onto a Q-sepharose column (20
mL, 2.5 x 10 cm), which was pre-equilibrated with 100 mL 50 mM Tris, 5% glycerol, 1
mM EDTA, 1 mM PMSF, pH 7.6 at 4 'C. The column was washed with 200 mL of 50
mM Tris, 150 mM KC1, 5% glycerol, pH 7.6 at 4 oC. The protein was eluted with a 70
mL x 70 mL linear gradient from 150 - 400 mM KCl in 50 mM Tris, 5% glycerol, pH 7.6.
Fractions (2 mL) containing 0' (based on Bradford assay and 10% SDS-PAGE) were
collected. Apo P' eluted around 220 mM KC1. The impurities around 50 kDa eluted
around 280 mM KC1. At typical yield of 0.4 mg of apo P' was obtained per g of cells.
2.2.7 Conversion of human apo 32 to holo 12.
Stock solutions of (His) 6-32 (2 mL, 2.5 mg/mL) were deoxygenated by 6 cycles
of evacuation (for 3x 5 s) followed by argon flushing (2 min) on a Schlenk line. The
deoxygenated 32 solution was brought into the glove box (M. Braun, Stratham, NH) and
5 eq of Fe(II) per 32 was added from a degassed Fe(NH4 )2(SO 4) solution in buffer A (50
mM Tris, 100 mM KC1, pH 7.6, 5% glycerol). The resulting mixture was incubated at 4
'C for 15 min. The protein was then removed from the glove box and 1 mL of 02
saturated buffer A (50 mM Tris, 100 mM KC1, pH 7.6, 5% glycerol) was added. Excess
iron was removed by Sephadex G-25 chromatography (40 mL, 2.5 x 20 cm). The typical
recovery of 32 is about 65%. With this method, 0.8-1.2 Y* is routinely generated with a
specific activity of about 800-1100 nmol/min/mg.
2.2.8 Conversion of human apo P'2 to holo P'2
A solution of 3'2 (60 pM) in 500 [pL in 50 mM Hepes, 100 mM KC1, 10%
glycerol, pH 7.6, ascorbic acid (2.5 mM) was deoxygenated by 6 cycles of evacuation (3x
5 s) followed by argon flushing (2 min) on a Schlenk line. The deoxygenated P'2 solution
was brought into the glove box (M. Braun, Stratham, NH) and 6 eq. of Fe (II) (ferrous
ammonium sulfate solution in 50 mM Hepes, 100 mM KC1, pH 7.6) per P'2 was added.
The resulting mixture was incubated at 4 OC for 30 min. The protein was then removed
from the glove box and 100 tL of 02 saturated buffer of 50 mM Tris, 100 mM KC1, pH
7.6 was added. 02 (g) was blown over the surface of the protein solution for 1 min.
Excess iron was removed by Sephadex G-25 chromatography (40 mL, 2.5 x 30 cm). The
activity assay was carried out immediately and 250 L protein solution was packed and
frozen into EPR tube for Y* measurement. With this method, 0.5-0.6 Y* is routinely
generated with a specific activity of about 300-400 nmol/min/mg.
2.2.9 Construction of the genes for Y124F-p', Y138F-p', and Y162F-p, Y176-p,
expression and isolation of the mutant proteins.
The Y124F-3', Y138F-', and Y162F-3, Y176F-J were generated by site directed
mutagenesis using the Quick Change Kit (Stratagene). The 0 gene in pET28a (pHis-H2
plasmid) or P' gene in pET3a (non-tagged p53R2 plasmid) was amplified by PCR using
PfuUltra II polymerase (Stratagene) with primers for Y176F, Y162F, or Y138F, Y124F
(Table 1). Success obtain mutagenesis reaction was confirmed by sequencing at the MIT
biopolymers laboratory. Y124F-P', Y138F-P', and Y162F-P, Y176F-3 were expressed,
purified, and reconstituted as described for P' or P with similar yields.
Table 2.3: Primers for generation of Y124F- p', Y138F-p', and Y162F-p, Y176-p
Name of Sequence of the primer (from 5'-3')
the
mutant
Y138F-P' GAATGTTCACTCAGAGATGTTCAGTTTGCTGATAGACAC
forward
Y138-3' GTGTCTATCAGCAAACTGAACATCTCTGAGTGAACATTC
reverse
Y124F-P' CCAGAGGCTCGCTGTTTCTTTGGCTTTCAAATTCTCATCG
forward
Y124F-P' CGATGAGAATTTGAAAGCCAAAGAAACAGCGAGCCTCTGG
reverse
Y176F-0 CAGAAGCCCGCTGTTTCTTTGGCTTCCAAATTGCCATGG
forward
Y176-3 CCATGGCAATTTGGAAGCCAAAGAA ACAGCGGGCTTCTG
reverse
Y162F-0 CATGGAAAACATACATTCTGAAATGTTTAGTCTTCTTATTGACAC
forward
Y162- GTGTCAATAAGAAGACTAAACATTTCAGAATGTATGTTTTCCATG
reverse
The mutation sites are highlighted.
2.2.10 Human RNR Activity assays
The reaction mixture contained in a final volume of 350 tL: 50 mM Hepes (pH
7.6), 15 mM MgC12, 1 mM EDTA, 0.3 tM (or 2.1 tiM) c, 2.1 jiM (or 0.3 jiM) P or P3', 3
mM ATP, 1 mM [3H]-CDP (specific activity 3400 cpm /nmol), 100 M E.coli TR, 1.0
tM TRR, 2 mM NADPH. The assay mixture was pre-incubated at 37 'C for 2 min and
the reaction was initiated by the addition of CDP. Aliquots of 50 jIL were removed over a
15 min time period and quenched in a boiling water bath. dCDP production was analyzed
by the method of Steeper and Steuart (32) subsequently to dephosphorylation with
alkaline phosphatase. The activities of Y124F-P' and Y162F-0 were measured at 1 jiM in
the presence of 7 pM a.
2.2.11 Stability test of the wt p and p'and Y124F-p' mutant
Stock solutions (15 tL, 30 [pM) of wt 3, P' or Y124F-P' were incubated at 37 'C.
Aliquots of 0.5 tL from each of them was removed at several time points from 30 s to 30
min and diluted into 50 iL of assay mixture with a finial concentration 0.3 pM. The
assay mixture contained the following: 3 M a, 3 mM ATP, ImM [3H]-CDP (specific
activity 4800 cpm /nmol), 100 [M E. coli TR, 1.0 gM TRR, 2 mM NADPH, and assay
buffer. The reaction mixture was incubated for 3 min at 37C and quenched in a boiling
water bath. dCDP production was measured as described above.
2.3 Results and Discussion
2.3.1 Purification of the His-a of human RNR
We obtained the plasmid phRRM1 from the Yen group. However, sequencing of
the clone revealed a number of mutations relative to the sequences reported in the NCBI
database. In addition the N-terminal His-tag region of a was re-engineered to minimize
the number of additional residues in the linker region between the His-tag and a.
Mutations in the genes were corrected and the N-terminus of a was re-engineered to
maintain the (His) 6 tag and to reduce the length of the intervening linker prior to the start
of the gene to 10 amino acids. The detailed changes are described in the method section.
Based on Yen's growth protocol in which overexpression of a is induced at 30°C
for 3 h, we tested various conditions of induction time, and temperature and found that
higher amounts of soluble a can be obtained when IPTG is added after the cell culture
was cooled to 25 "C or 20 'C for overnight induction. The final optimized condition is
described in the method section. The purification protocol for His-a was based on the
protocol reported by Yen and uses only Ni-NTA affinity chromatography (16, 21). In our
hands, the resulting proteins were contaminated with a large amount of DNA. Therefore,
a streptomycin sulfate precipitation step was added to the protocol. The final
streptomycin sulfate concentration used was chosen based on streptomycin titration and
activity assays. The proteins were then chromotographed on a Ni affinity column yielding
about 90% homogeneity based on SDS-PAGE (Figure 2.1), which co-purified with a
protein of 74 kDa. Initially we though that this 74 kDa protein was proteolytically clipped
a. However, N-terminal sequencing revealed that it was Ama (bifunctional polymyxin
resistance protein), a hexameric E. coli protein.
a purified using the Ni affinity column always contains - 10% contamination of
Ama, which is a hexamer and has a huge extinction monomer coefficient of 89895 M'
cm- 1 at 280 nm, with monomer MW of 74 kDa and hexamer MW of 444 kDa. Because
Ama interferes with SEC analysis to determine the MW of a6 (540 kDa), a606 (872 kDa)
and a6p'6 (794 kDa), dATP-affinity chromatography was explored as a method to
remove the Ama impurity and to obtain highly pure a. However, the binding affinity of a
to dATP resin is relatively weak, leading to only 25% recovery of the total loaded a. The
purification gel (Figure 2.2, lane 3) with 8 [L of wash through buffer (from 300 mL total
volume without concentration) shows the loss of a during the wash (50 mM Tris, pH 7.6,
5% glycerol, 300 mM KC1, ImM DTT). Highly pure and active a (specific activity of
232 nmol/min/mg) could be obtained at the end but with low recovery (Figure 2.2).
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Figure 2.1: Purification of human RNR subunits.
10% SDS-PAGE gel. Lane 1, molecular mass markers. Lane 2, His-a (5 ug); Lane 3, His-0
(5 ug); Lane 4, His-' (5 ug).
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Figure 2.2: Purification of a subunit by dATP-affinity chromatography.
1. a purified from Ni column, 2, dATP column flow through, 3, wash, 4, 5, a elution
from dATP column. 10% SDS-PAGE was used.
2.3.2 Purification of the His-p
The plasmid phRRM2 from the Yen group revealed one mutation relative to the
sequences reported in NCBI data base. It was corrected by Quick Change site directed
mutagenesis, and the N-terminal His tag was re-engineered to minimize the number of
additional residues in the linker region.
Based on Yen's growth protocol in which f3 expression is induced at 30'C for 3 h,
we optimized the induction temperature and time. To obtain a higher amount of soluble 3,
induction at 30'C for 6 h was selected. The purification protocol for His-0 uses only Ni-
NTA affinity chromatography, which is similar as that for His-a optimized as described
above.
2.3.3 Purification of P' subunit of human RNR
p53R2 obtained from Thelander's lab does not contain an affinity tag or any extra
amino acids in its sequence. The purification protocol ofholo 0' developed by Thelander
lab includes precipitation of nucleic acids with streptomycin, ammonium sulfate
fractionation, and DEAE chromatography (16). We applied the same procedure for apo 3'
purification but did not obtain protein of the same purity. Therefore, additional
purification steps including Phenyl Sepharose 6 Fast and Q-sepharose Fast Flow anion
exchange chromatography (Figure 2.3) were investigated. Although the purity of apo 03'
could be improved by each additional chromatography step, purifying apo 0' with Phenyl
Sepharose 6 Fast and Q-sepharose chromatography omitting the DEAE chromatography
gave about the same purity (80%). Elution from the Q-Sepharose column with a 150-400
mM KCl gradient resulted in separation of two distinct peaks. The first peak centered at
220 mM KCl is apo P' as judged by SDS-PAGE (Figure 2.3). The second peak eluting at
280 mM KCl is a 50 kDa impurity.
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Figure 2.3: Analysis of fractions from Q-Sepharose column for p'.
10% SDS/PAGE shows the eluted apo 3' fractions after Q-sepharose chromatography.
The numbers above each lane are the fraction #.
2.3.4 Characterization of p subunit of human RNR
The growth of apo f3 in the presence of 1, 10-phenanthroline resulted in failure of
expression, thus 3 has to be induced under conditions without phenanthroline. 0 as
isolated is in the apo form and was reconstituted based on the protocol we have
developed for reconstitution of the E. coli 02 (33). Unfortunately, apo P is very unstable,
and addition of ferrous solution to the protein caused 13 precipitation. pH measurement
revealed that the ferrous water solution was acidic. Thus the reconstitution condition was
improved by dissolving ferrous into Tris buffer (pH 7.6) in the glove box and gentle
addition to apo P protein in the presence of glycerol. Various amounts of ferrous (1 eq. to
8 eq./P2) were titrated and demonstrated that titration in 6 eq. of ferrous which results in
maximum p activity. With our optimized protocol, the resulting protein yielded 0.8- 1.2
Y./P2 (Figure 2.4) and a specific activity of 800-1089 nmol/min/mg in the presence of a
seven fold excess of a (Figure 2.5). These results contrast with previous reports in the
literature of 75 nmol/min/mg and 158 nmol/min/mg for P3 (Table 2.4) (16, 21). The
difference in the activities might be related to the method of protein purification,
reconstitution and assaying. Both of these two groups use DTT as reductants while we
use E. coli TR, TRR and NADPH. Thelander's lab also has large excess of Fe(II) in the
assay. Unlike the assay method of Yen's group in which P or P' (0.625-10 pg) is
incubated with 30 [pg a in the presence of 0.05 mM CDP (21), we assayed with 1 mM
CDP to saturate the enzyme active site. Given the low affinity between a2 and 32, the
activity of an individual RNR subunit is generally assayed in the presence of a large
excess the other subunit. We titrated the activity of one subunit with increasing amount of
the other subunit to obtain optimum activity. We have established that in the presence of
seven fold excess of c, the highest activity is achieved.
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Figure 2.4: EPR spectra at 9 GHz of tyrosyl radical in human 0 and 0' at 77 K.
Power is at 1.006 mW; modulation amplitude is 1.00 G, and the frequency is 9.386 GHz. [3]
= 76 iM in 50 mM Tris, 100 mM KC1, pH 7.6, 5% glycerol, and [P'] = 25 LM in 50 mM
Hepes, 100 mM KC1, 10% glycerol. 0.8-1.2 Y./P2 and 0.5-0.63 Y./P'2 are routinely
obtained.
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Figure 2.5: Activity assays of a (top left), 0 (top right) and P' (bottom)
The specific activity of ca is 462 nmol/min/mg when assayed with 7 fold excess of P. The
activity of 3 is 1089 nmol/min/mg, and that of P' is 420 nmol/min/mg, when assayed with
7 fold excess of a.
Table 2.4 Comparison of the human RNR activities obtained from different groups
(16, 21, 26)
(nmol/min/mg) (nmol/min/mg) (nmol/min/mg)
Stubbe 462 1089 420
Yen 6.8 75 52
Thelander ND 158 95
Thelander ND 140 (mouse) 63 (mouse)
Cooperman 201 (mouse) ND ND
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2.3.5 Reconstitution and characterization of human 3'
Expression of 3' was carried out in the presence of 1,1 0-phenanthroline, which
results in apo protein, as this procedure gave higher recovery of Y- and activity than
growth in the absence of phenanthroline. A variety of methods to assemble the essential
diferric-tyrosyl radical (Y-) cluster of 13'2 including anaerobic, or aerobic reconstitution
on the purified apo-3', addition of Fe(II) to crude cell extracts, or addition during
purification, were examined. Both the His-tagged and non-tagged 1' constructs and
various ratios of Fe(II)/ 3' have been titrated. The procedure described in Methods section
gave 0.63 Y- per 3'2 with an activity of 420 nmol/min/mg in the presence of 7 fold
excess of a (Figure 2.5, Table 2.4). The His-P' construct gave 0.5 Y-/P'2 as the best when
reconstituted by the same method. The P' isolated by Thelander group gave activity of 95
nmol/min/mg (16), but the radical amount was not reported. Yen's group reported that
their His tagged-P'2 contain 0.8 Y./'2 and a specific activity of 50 nmol/min/mg (21).
The low activity and high Y* content reported by these groups are at odds with activity
being directly proportional to Y- (34, 35). In our hands we have been unable, after many
attempts with identical constructs to those used by Thelander, to obtain higher levels of
Y*/'2, although our reconstitution of 13 did obtain higher amount of radical (1.2 Y-/02).
An aerobic reconstitution method was also carried out. An Fe(II) solution was
prepared by dissolving ferrous ammonium sulfate in water and the pH was adjusted to 2.3
by addition of concentrated nitric acid. The protein solution was not degassed or put into
the glove box. Seven equivalents of Fe(II) (2-10 gL) per P'2 were added aerobically to
the protein solution very slowly with mixing. A few sec after the final addition of Fe (II),
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02 (g) was blown over the surface of the protein solution for 5 min. An activity of 356
nmol/min/mg and 0.6 Y*/j'2 was obtained with this method.
A third assembly method we used was described by Anderson and Solomon (36),
which involved reducing P' with methyl viologen and dithionite, adding 7 eq./13'2 of
ferrous solution anaerobically, and incubating for 15 min at 4 OC. The protein solution
was removed from the glove box and an 02 saturated solution was added immediately.
Only 0.4 Y*/P'2 with activity of 163 nmol/min/mg was obtained from this method.
An additional method of cofactor assembly used was to add ferrous ammonium
sulfate to the partially purified apo-P'. After purification by streptomycin sulfate
precipitation, ammonium sulfate fractionation, and Phenyl sepharose chromatography
steps, ferrous ammonium sulfate (5 mg/g of cell) and sodium ascorbate (5 mg/g of cell)
were dissolved in 50 mM Tris, pH 7.6, 5% glycerol and added over 10 min to the
partially purified apo-p' at 4 OC with stirring. After stirring for an additional 15 min at 4
'C, the protein solution was loaded onto a Q-Sepharose column and purification
continued as described in methods section. The rest of the procedure is the same as it
described in the purification method. P' with a specific activity of 396 nmol/min/mg was
obtained (the Y* content was not measured). An alternative method with addition of
ferrous to the crude cell extracts before purification gave a specific activity of 272
nmol/min/mg. The last two reconstitution methods were repeated only once.
Overall, both the anaerobic and aerobic methods on the reconstitution of purified
apo-P' can give the highest amount of Y* (0.6 Ye) and activity. It remains unknown why
we can not achieve 1 Y*/P'2 remains unclear.
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2.3.6 Characterization of human a
With titration of amount of P in the activity assay, we have obtained a specific
activity of a as high as 462 nmol/min/mg (Figure 2.5) in the presence of a 7 fold excess
of p. This result contrasts with the previous report in the literature of 6.8
nmol/min/mg (Table 2.4) (21). However, a was difficult to work with because of its low
solubility. The highest concentration that can be obtained for His-tagged a is 3 mg/mL.
The non-tagged a purified from Dealwis group can be concentrated to more than 10
mg/mL. We have measured the activity of their a, which gave a specific activity of 484
nmol/min/mg, a value similar to ours. Whether the His-tag makes a difference on the
solubility of a is not clear. The difference might be related to the methods of purification
used. Whereas we use Ni and dATP chromatography, a peptide affinity chromatography
was employed by Dealwis lab (37).
2.3.7 Investigation of the proposed role for a second tyrosine required for RNR
activity (38)
Recently Yen's group proposed that human P and P' contain a unique dityrosyl-
diiron cofactor center. In addition to the essential tyrosines, Y176 of h3 and Y138 of h3'
(Y122 equivalent in E. coli), Yen's group suggest that Y162 of hp and Y124 of hp',
which correspond to V108 in E. coli P by structure alignment, are also essential for the
RNR activities. The evidence for the di-tyrosine cofactor model in hp' proposed by Yen
was that isolated Y138F-P3' and Y124F-P3' were both EPR silent and contained no activity.
The evidence for the di-tyrosine cofactor model in hp was that both Y176F-0 and Y162F-
13 contained 3% activity, 0.012 Y* per dimer, and only the double mutant Y176F/Y162F-
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13 were completely inactive (38). Yen's group also made additional tryptophan mutants,
which gave the contradictory results that Y124W-3' contained 0.28 Y* per dimer, and
Y138W-P' were EPR silent. For 0 mutants, neither Y176W-3, Y162W-P showed any
activity. Unfortunately, Yen's group did not address those problems properly, and they
interpreted these inconsistencies as a result from the radical harboring ability of
phenylalanine and tryptophan, and structural differences between 0 and P'.
In order to investigate Yen's model, we did site directed mutagenesis on the His-
p and non-tag 13' plasmids, cloned and isolated Y176F-3, Y162F-3, Y138F-P', and
Y124F-P' following the protocol for wt 13 and 13'. The Y- amounts in these mutants were
quantified immediately after cluster assembly, compared to quantification after overnight
dialysis performed by Yen's lab. In our studies, Y176F-0 and Y138F-3' are EPR silent
(Figure 2.6) and showed no activity, which agree well with their essential role in RNR
activities. However, in contrast to results from Yen's lab, our EPR studies have
demonstrated that Y124F-P' and Y162F-3 contain 0.2-0.3 Y* and 0.1 Y* per dimer
respectively (Figure 2.6). Both of the mutants have activity (Figure 2.7), although the
linear range is short and shows time dependent loss of activity, likely associated with loss
of Y* as a function of assay conditions. The activity of Y 162F-3 has been measured at 1
tM and 1.5 jM 0 concentration, which resulted in a proportional increase of the rate. The
stability test of Y124F-' has been carried out, which revealed that the Y- in the Y124F
decays fast with a half life of about 5 min at 37 'C, compared to the half life of wt 0' of
30 min. This might explain why Yen's group has observed these mutants to be EPR silent
(Figure 2.8).
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Figure 2.6: EPR Spectra at 9 GHz of human p' and p mutants.
(a) Y124F-P' (b) Y138F-3' (c) Y162F-0 (d) Y176F-3 are shown. Instrument settings for
all spectra were as follows: frequency, 9.341 GHz, power 1.003 mW, modulation
amplitude 1.00 G, number of scans (a) 5, (b) 5, (c) 20, (d) 5, and temperature 77 K.
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Figure 2.7: Activity assays of Y162F-p and Y124F-p'.
(a) Y162F-3 (1.5 pM) was assayed in the presence of 7 fold a (10.5 1M); (b) Y124F-3'
(0.3 p~M) was assayed in the presence of 10 fold a (2.1 1 M).
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Figure 2.8: Stability test of Y124F-p', wt-P', wt-p at 37 OC.
Stock solutions of (a) Y124F-P', (b) wt-P', (c) wt-3 (15 jiL each) were incubated at 37 'C.
Aliquots were removed at various times and diluted into 0.3 LM in assay mixture to
measure the 0' or P activity in the presence of 10 fold excess a.
2.4 Discussion
In our studies, the three human RNR subunits, oc, P and P', have been purified,
characterized and found to have significantly higher activities than have been obtained in
previous reports. The reason why we have achieved such high activities might be due to
the way in which we assay for activity as discussed in section 2.3.4.
Using our in vitro reconstitution method, we have obtained P2 containing 1.2 Y*
and P'2 containing 0.63 Y* as the highest radical content, compared to 1.2 Ye and 0.8 Y*
for P2 and 1'2 obtained by Yen's group. Multiple methods have been explored to attempt
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to increase the Y* content in P'2, however, no significant improvement has been achieved.
The problem of sub-stochiometric amount of Y* is not unique to the human P'2. We have
seen this with S. cerevisiae RNR and other proteins as well, indicting that another factor
might be required for cluster assembly (39).
In addition, we have investigated whether human P2 and P'2 contain the unique
diiron-dityrosyl radical cofactor as proposed by Yen. Mutagenesis studies have been
carried out by making the essential tyrosine mutants, Y176F- and Y138F-P', and
mutants of proposed second essential tyrosines, Y162F-0 and Y124F-P'. Our results from
EPR quantitation and activity measurements have demonstrated that Y176 and Y138 are
the only essential tyrosines in P and 3'. p and P' mutants with Y162 and Y124 substituted
with phenylalanine still have activity, although their Y* decay faster than in the wt
proteins.
The structure of hP (PDB ID 2UW2) and hp' (PDB ID 2VUX) have recently been
solved. Compared to the E. coli 0 structure (PDB ID 1AV8), the positions of Y176/Y138
relative to Y162/Y124 in human 0 and 0' are very similar to that of Y122 relative to
V108 in E. coli P (Figure 2.9). V108/Y162/Y124 are more deeply buried than Y122/
Y176/Y138. Moreover, the distance between Y176/Y138 and the essential tryptophan
radical in the PCET pathway, W102/W64 (W48 in E. coli P), is 7.8 A compared to 15.9
A from Y162/Y124 to W102/W64 in the human proteins. Y176/Y138 is 5.8 A away from
H172/H134 (HI 18 of E. coli P), whereas Y162/Y124 is 16.8 A away from this residue.
The second proposed tyrosine is clearly too far away from the current suggested PCET
pathway to be directly involved in it. Thus far, no alternative route of PCET has been
identified, suggesting that Y162 is unlikely involved in radical initiation and propagation.
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Figure 2.9: Comparison of the positions of Y176, Y162 of human P, Y138, Y124 of
human p' to Y122, V108 of E. coli p in the active site structures.
The overlay structures of key residues in PCET pathway Y122, W48, D237, Hi 18 of E.
coli 3 (cyan), Y176, W102, D265, H172 of human 13 (red), Y138, W64, D227, H134 of
human 3' (magenta), and iron ligands, D84, E115, E204, E238, H241 of E. coli 13 (cyan),
D138, E169, E232, E266, H269 of human P (red), D100, E131, E194, E228, H231 of
human 3' (magenta) are shown in stick. Irons are shown in spheres. The second proposed
essential tyrosine Y162 of human 3 (red), Y124 of human 13' (magenta) and the
equivalent residue V 108 of E. coli 1 (cyan) are shown.
Above all, the Y124 in 1'2 and Y162 in 32 may play important roles in
maintaining the activity and stability of the human RNR diiron cluster, but our data does
not support the proposal that these residues are essential tyrosine radicals or that the
cluster in human RNR is a diiron-dityrosyl radical cofactor. We believe that human RNR
shares the same mechanism as other class Ia RNRs, which contains only one essential
tyrosyl radical.
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Chapter 3
Inactivation studies of Human Ribonucleotide Reductase by Gemcitabine
Adapted from Wang J, Lohman GJ, Stubbe J. (2006) Enhanced subunit interactions with
gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci U S A.
104(36):14324-9
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3.1 Introduction
2',2'-Difluoro-2'-deoxycytidine (gemcitabine, F2C) is a drug that is used clinically
in the first line treatment for advanced pancreatic cancer and non small cell lung
carcinomas (1-3). As it is described in Chapter 1, the diphosphorylated F2C is a potent
mechanism based inhibitor of class I RNR. Studies on the inactivation of E. coli RNR by
F2CDP were carried out and reported by our group several years ago (4, 5). It was shown
that one equivalent (eq.) of F2CDP per E. coli RNR (a232), in the presence of reductants,
thioredoxin (TR) and TR reductase or dithiothreitol (DTT), is sufficient for enzyme
inactivation. The inactivation was accompanied by release of 2 fluoride ions and one
cytosine (Figure 3.1) (4).
The inhibition in the absence of reductants was also studied. A new and stable
radical was formed concomitant with the loss of Y*. Carrying out the inhibition by
F2CDP in D20 or with uniformly deuterated a did not change the EPR spectrum of the
new radical, suggesting that the hyperfine interactions are not associated with solvent or
a. Recently, Artin in the Stubbe lab showed that inactivation with I'-[2H]-F 2CDP caused
collapse of the triplet signal to a doublet, indicating that one of the couplings is associated
with the nucleotide (6). The source of the 2 nd hyperfine interaction has not been
established, but is postulated to be associated with the 4'-H of F2CDP. This postulation is
based on the similarity of its EPR spectrum with that resulting from interaction of E441Q
RNR with CDP. The proposed structure is shown in Figure 3.1.
Studies with several mutants of RNR have defined further the requirements for its
formation. F2CDP with C754S, C759S generate the same radical as did oxidized a, that
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C225 and C462 in a disulfide form. Thus 4 of the 5 essential cysteines are not required
for radical formation.
NH2
E. coli RNR
ATP
reductant
F release
Cytosine release
50% Y* reduction
Complete inactivation of a
1 equivalent
E. coli RNR
ATP
No reductant
F release
Cytosine release
Complete reduction of Y*
Formation of new nucleotide based radical
1 equivalent
Figure 3.1: Products accompanying E. coli RNR inactivation (4).
While many parallels lie between inactivation by F2CDP and 2'-substituted CDP
analogs, subtle differences exist that are mechanistically important. The F2CDP mechanism
involves inactivation of both a and 13 subunits as do all 2'-substituted nucleotide inhibitors.
However, unlike other 2'-substituted nucleotide inhibitors where DTT protects a from
inactivation, DTT is required for a inhibition by F2CDP. With 2'-deoxy-2'-halonucleotides,
an electrophilic furanone derivative is generated resulting in RNR inactivation. This reactive
sugar is alkylated by cysteines of a or by the thiols of DTT. Alkylation of furanone by the
C-terminal tail cysteines of a followed by reaction with K760 produces a chromophore that
absorbs between 320-330 nm. This chromophore has not been detected after RNR
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inactivation by F2CDP, indicating that the reaction might happen here in the active site
where structure analysis reveals the absence of a lysine.
In addition, the inactivation of the L. leichmannii RTPR by F2CTP has also been
studied (7, 8). One eq. of F2CTP can rapidly inactivate 90% of the activity in 15 s. The
inactivation can happen in the presence and absence of external reductants. The synthesis
of [1'-3H] and [5- 3H]-F 2CTP has made it possible to quantitate the end products of the
inactivation process. After inactivation, 0.47 eq. ribose ring from F2CTP covalently
labeled RTPR and 0.16 eq. of cytosine remained attached to the enzyme, while 0.7 eq.
cytosine is released. Moreover, about 0.8 eq. of 5'-dA per RTPR was released and on a
very slow time scale the protein was alkylated by an AdoCbl-derived species. Glu-C
digestion of the covalent modified RTPR at pH 5.8 followed by HPLC separation
identified a peptide containing a cobalamin chromophore. Further characterization of the
peptide by N-terminal sequencing revealed that it contained residues 411-420 and an
adduct attached to the active site residue C419, one of the bottom face reducing
equivalents. A Co-S linkage was detected suggesting that the chemistry happened within
the active site.
Rapid freeze quench EPR and stopped flow UV-vis spectroscopy were used to
study the kinetics of the inactivation. A thiyl radical exchange coupled to cob(II)abamin
species was first detected at 22 ms, followed by the formation of a new nucleotide-based
radical, concomitant with disappearance of the initial thiyl radical over the subsequent
255 ms.
The details of the inhibition by F2CDP have remained largely unexplored due to
the unavailability of radiolabeled sugar and base F2CDP. Dr. Greg Lohman in our group
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has recently developed methods to synthesize [1'- 3H] and [5- 3H]-F 2CDP (7, 8), which has
allowed us to re-investigate the mechanism of inhibition of the E. coli RNR and to study
for the first time the details of the inhibition of the human RNR. Incubation of human and
E. coli RNRs with [1'- 3H] or [5- 3H] F2CDP in the presence of reductant results in one eq.
of sugar covalently bound per a2, and one cytosine released per a2, agreeing well with
our previous studies on E. coli RNRs.
To investigate how sub-stoichiometric labeling can prevent nucleotide reduction,
size exclusion chromatography has been employed to study the effect of F2CDP on the
RNR subunits interaction. In prokaryotic systems a and 3 are both homodimers. The
active E. coli RNR is thought to be an a202 complex (9, 10). The a of eukaryotic RNR
can be a monomer, dimer, tetramer or hexamer based on the presence of allosteric
effectors (dATP, TTP, dGTP, ATP) (11, 12). In the absence of nucleotides a is a
monomer. The millimolar levels of ATP found intracellularly cause a to oligomerize to a
hexamer (a6). p is a homodimer (02).The complex responsible for RNR activity has been
proposed by Cooperman and coworkers to be a232, a6P2 or a6P6 based on a variety of
physical biochemical and kinetic studies (12). Recent Gas-Phase Electrophoretic-
Mobility Macromolecule Analysis studies have suggested that the mouse quaternary
structure is a6P2 (13).
Studies using size exclusion chromatography of the inactivated RNRs reveal that
sub-stoichiometric labeling of a dramatically alters an/pn subunit interactions, forming a
tight complex, which is ultimately responsible for complete RNR inhibition. In the E. coli
RNR, a a2P2 tight complex is generated subsequent to enzyme inactivation by F2CDP,
while in the human RNR, a a636 tight complex is generated. This information, and the
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proposed asymmetry between the interactions of anpn, provides an explanation for
complete inactivation of RNR with sub-stoichiometric amounts of F2CDP.
Furthermore, mutagenesis studies have been carried out replacing all the key
residues in the active site and C-terminal tail of a to identify the site of labeling.
3.2 Materials and Methods
3.2.1 Materials
[5-3H] F2C and 2-deoxy-3,5-di-O-benzoyl-3,3-difluororibonolactone were kind
gifts of Eli Lilly. Competent E. coli BL 21 (DE3) cells were purchased from Stratagene.
Complete EDTA-free protease inhibitor tablets and calf alkaline phosphatase (20 U/tL)
were purchased from Roche Biochemicals. Plasmids containing the genes for a (formerly
called H1) and P (formerly called H2), phRRM1 and phRRM2, were generous gifts from
Yun Yen (City of Hope National Medical Center). Protein concentrations were
determined by using extinction coefficients (6280 nm) per monomer [45,900 M-1 cm -1 for
(His) 6-P, 119,160 M 1 cm 1 for u]. E. coli TR (specific activity of 40 U/mg) (14) and TR
reductase (specific activity of 1320 U/mg) (15) were isolated as previously described.
3.2.2 Expression and purification of human a, a mutants and P
phRRM1 and phRRM2 were transformed into E. coli BL21 (DE3) (Stratagene),
plated on LB agar plates with 50ptg /mL kanamycin (kan) and a single colony chosen for
growth. For isolation of P, an overnight culture (40 mL) grown to saturation was diluted
into 2 L of LB containing 50 pg/mL kan and grown at 370 C to OD 600nm 0.7- 0.9.
Isopropyl-l-thio-p-D-galactopyranoside (IPTG, lmM) was then added and the cells were
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grown for an additional 6 h at 300 C. For growth of a, an overnight culture (40 mL) was
grown from a single colony at 370C and transferred to a 2L of LB and grown at 370 C.
IPTG (1 mM) was added at an OD 600nm 0.7- 0.9 and the cells were grown overnight (16 h)
at 250 C. The cells were harvested and typically yielded 4 g/L.
The isolation of 32 and a were carried out by the following general procedure.
The cell pellets were suspended (5 vol/g) in 50 mM NaH2PO4, pH 7.0, 0.1% Trition X-
100, 10 mM 2-mercaptoethanol, and cocktail protease inhibitor (1 tablet / 10 mL, Roche).
The suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 20, 000 x g for 30 min. The supernatant was treated with streptomycin
sulfate to a final concentration of 1% (w/v) and the pellet was removed by centrifugation.
The supernatant was incubated with Ni-NTA agarose resin (1 mL/g of cells, Qiagen) at
4°C for 1 h and then loaded into a column (2.5 x 10 cm). The column was subsequently
washed with 40 column volumes of 50 mM NaH2PO 4, 800 mM NaCl, 50 mM imidazole,
pH 7.0, 0.1% Trition X-100 and 10 mM 2-mercaptoethanol. The protein was eluted with
50 mM NaH2PO4, 300 mM NaC1, 125 mM imidazole, pH 7.0. Fractions containing
protein were identified using the Bradford assay. The fractions were pooled and
concentrated to < 10 mL, and then the imidazole was removed by Sephadex G-25
chromatography (200 mL, 2.5 x 50 cm). P2 was stored in 50 mM Tris, 100 mM KC1, pH
7.6, 5% glycerol. a was stored in 50 mM Tris, 100 mM KC1, 15 mM MgC12, 5 mM DTT,
pH 7.6, 5% glycerol. Protein yields of a and P were about 2 mg and 15 mg per L of
culture, respectively. The mutants of a were purified following the same protocol as
described for wt a with similar yields.
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3.2.3 Activity assays
A reaction mixture contained in a final volume of 350 piL: 50 mM Hepes (pH 7.6),
15 mM MgCl 2, 1 mM EDTA, 0.3 [M (or 2.1 [M) a, 2.1 pM (or 0.3 M) 13, 3 mM ATP,
1mM [3H]-CDP (specific activity 3400 cpm /nmol), 100 gM E.coli TR, 1.0 gM TR
reductase, 2 mM NADPH. The assay mixture was preincubated at 37 'C for 3 min and
the reaction was initiated by the addition of CDP. Aliquots of 50 [tL were removed over a
15 min time period and quenched in a boiling water bath. dCDP production was analyzed
by the method of Steeper and Steuart (16).
3.2.4 Time dependent inactivation studies.
The inactivation mixture contained in a final volume of 100 jiL: 1.2 gM a, 1.2
pM 3, 3 mM ATP, 1 mM [3H]-CDP (specific activity 3400 cpm /nmol), in the presence
or absence of 5 mM DTT, 50 mM Hepes (pH 7.6), 15 mM MgC12, and ImM EDTA. The
reaction was initiated by addition of F2CDP (0.6 pM, 1.2 M and 6 jM, final
concentrations) and incubated at 370C. Aliquots (12.5 pL) were removed from 30 s to 17
min, and assayed for dCDP production as described above. Control experiments were
carried out in which the F2CDP was omitted.
3.2.5 Quantitation of covalent labeling of E.coli RNR and human RNR with [1'- 3H]-
F2CDP and [5- 3H]-F 2CDP
A typical reaction mixture (5.5 pM c, 3 in 300 jL) was identical to that described
above except that F2CDP was replaced by either [1'- 3H]-F 2CDP (5889 cpm /nmol) or [5-
3H]-F 2CDP (6643 cpm/nmol). After 10 min at 370 C, an aliquot of 270 jL was loaded
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onto a Sephadex G-50 column (1 cm x 20 cm, 20 mL) that was pre-equilibrated with the
assay buffer (50 mM Hepes, 15mM MgCl 2, 1mM EDTA, pH7.6) or made 6 M in
guanidine-HCI and loaded onto a Sephadex G-50 column with assay buffer containing 2
M guanidine-HC1. Fractions (1 mL) were collected and assayed for A280nm and A260nm
and 500 L of each fraction was analyzed by scintillation counting.
3.2.6 Quantification of cytosine released during the inactivation of E. coli and
human RNR by [5- 3H]-F 2CDP
The reaction mixture was as described above (1.2 pM human RNR c, 3 in 500
iL). The reaction was initiated by addition of 1.2 jiM [5- 3H]-F 2CDP (6643 cpm/nmol).
After 20 min, the inactivation mixture was filtered through an YM-30 Centricon device
(Millipore) at 40C. F2C (120 nmol) and cytosine (120 nmol) were added as carriers
before filtration. The flow-through was treated with 30 U of alkaline phosphatase (Roche)
for 3 h at 37 'C and filtered through a second YM-30 Centricon device. The flow through
was analyzed using a Waters 2480 HPLC with an Altech Adsorbosphere Nucleotide
Nucleoside C-18 column (250 mm x 4.6 mm) at a flow rate of 1mL/min. The elution
buffer contained: Buffer A, 10 mM NH40Ac, pH 6.8; Buffer B: 100% methanol. A 10
min isocratic elution was followed by a linear gradient to 40% B over 30 min. A linear
gradient was then run to 100% B over 5 min. Fractions (1 mL) were collected and 200 jtL
of each were analyzed by scintillation counting. Standards: retention times are: cytosine,
5.7 min; cytidine, 12.6 min; ara-C, 17.4 min; dC, 19.0 min and F2C, 23.2 min. The
recovery of cytosine and F2C was calculated based on the UV spectrum (cytosine, X267nm,
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= 6100 M-lcm "', F2C, X268 nm, s = 9360 M'lcm-l). The radioactivity recovered with
cytosine and F2C was analyzed by scintillation counting.
3.2.7 SEC to examine the quaternary structure of RNRs subsequent to inactivation
by F2CDP
SEC was performed using a Superose 12 column (10 x 300 mm, GE healthcare)
for E. coli RNR or a Superdex 200 column (10 x 300 mm, GE healthcare) for human
RNR attached to a Waters 2480 HPLC. Gel filtration molecular weight standards (GE
healthcare) were ovalbumin, 43 kDa; conalbumin, 75 kDa; aldolase, 158 kDa; pyruvate
kinase, 232 KDa or catalase 232 KDa; ferritin, 440 kDa; thyroglobulin, 669 kDa; and
blue dextran, 2000 kDa. The elution buffer was 50 mM Hepes (pH 7.6), 15 mM MgCl2
and 0.5 mM ATP. KC1 (150 mM) was added in the running buffer to separate E. coli
RNR ± F2CDP in the presence of ATP on the Superose 12 column. Molecular weight
standards were run at the beginning of each experiment. The reaction mixture was
prepared as described above (15 pM a, P in 300pL or 30 [tM a, P in 150pL). After 10
min incubation, 150 [tL or 300[L was injected onto the column. The elution rate was 0.5
mL/min and 0.5 mL fractions were collected. If [1'- 3H]-F 2CDP was used in the
inactivation, 100 jiL aliquots of each fraction was analyzed by scintillation counting.
3.2.8 Quantitative analysis of the subunits of E. coli and human RNRs by SDS
PAGE.
The fractions collected from the SEC analysis were analyzed by 10% SDS- PAGE
and compared with concentrations of c and 0 from E. coli RNR (0.4 [tM to 3.2 jM) or
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human RNR (0.2 pM to 1.6 gM) as standards. The proteins were visualized with
Coomassie blue staining. The band intensities were quantified using Bio-Rads Quantity
One software. The concentrations of at and 13 in the complex were determined from the
standard curves.
3.2.9 Trypsin digestion of human RNR inactivated with [1'- 3H]-F 2CDP
The reaction contained a final volume of 500 gL: 7.7 pM a, 3, 3 mM ATP, 5 mM
DTT, in 50mM Hepes, pH 7.6, 15mM MgSO 4, 5% glycerol, 1mM EDTA. 19.5 pM [1'-
3H]-F 2CDP (2.5 fold, SA 7584 cpm / nmol,) was used to initiate the reaction, and
incubated at 37 'C for 8 min. The reaction was quenched with 1500 pL 8M guanidine, 40
mM DTT, 5.33 mM EDTA, 400 mM Tris (pH 8) and the reaction was incubated at 370 C
for 30min. Iodoacetamide was added to a final concentration of 250 mM and the reaction
was incubated at 37C for additional 1 h. The small molecules were removed by a
Sephadex G-50 column (1 cm x 40 cm, 40 mL) to equilibrate in 100 mM NH4HCO 3, 2M
urea, pH 8.0. Fractions containing protein were identified using the Bradford assay. A
typical recovery is 70%. Trypsin (Worthington, lot # 35J8187, - 20 [pL) was added from
a freshly prepared stock to a final concentration 4:1 (w/w) RNR: trypsin and incubated
for 5 h at 37°C. The reaction was quenched by addition of 60 [pL TFA to pH< 2. The
peptides were loaded immediately on a Phenomenex Jupiter C18 peptide column (150 x
4.6 mm, 5 micron, 300 A pore size) by a 5 mL loop, and separated on a Waters 2487
HPLC at a flow rate of 1 mL/min. The solvent system was: Buffer A, 0.1% TFA in H20,
Buffer B, 0.1% TFA in acetonitrile. A linear gradient of 0-45% B over 90 min was used.
Fractions (1 mL) were collected and analyzed for radioactivity by scintillation counter.
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The recovery of injected radioactivity was 85%, and 20% of the radioactivity eluted in
the void volume of the column. The recovery of each region of radioactivity is reported in
the results section below.
3.2.10 In gel Trypsin digestion and Mass spectrometry
In gel trypsin digestion on the F2CDP inactivated human RNR and mass
spectrometry analysis was performed by Brad Evans in Prof. Neil Kelleher's lab in
University of Illinois, Urbana-Champaign for mass spectrometry. The reaction contained
a final volume of 250 ptL: 7.7 ptM a, 0, 3 mM ATP, 5 mM DTT, in 50mM Hepes, pH 7.6,
15mM MgSO 4, 5% glycerol, ImM EDTA, 19.5 jiM (2.5 fold) of 1:1 mixed [1'- 3H]-
F2CDP and [1'- D]-F 2CDP was used to initiate the reaction, and incubated at 37 OC for 8
min. The reaction was quenched with 750 [tL 8M guanidine, 40 mM DTT, 5.33 mM
EDTA, 400 mM Tris (pH 8) and the reaction was incubated at 370 C for 30min.
Iodoacetamide was added to a final concentration of 250 mM and the reaction was
incubated at 370 C for additional 1 h. 300 tL reaction mixture was loaded onto a 10%
SDS-PAGE. After stain and destain the gel, gel slices containing a and 0 were cut out
individually and dried in a speed vacuum without heating. To the dried gel slices, a
solution of 12.5 ng/mL trypsin in 100 mM ammonium carbonate pH 8 was added to
enough cover the slices. Digestion was carried out overnight at 25 'C. To extract the
digested peptides, a solution with 50 mM ammonium carbonate pH 8 was added and
mixed for 5 min. After removing the supernatant, 50% ammounium carbonate and 50%
acetonitrile were added, mixed for 5 min and the supernatant was removed again. This
aqueous/organic wash was repeated 3 times. For each time, the volume of the solution
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added was just enough to cover the slices. Then washes with 100% acetonitrile followed
by 100% ammounium carbonate were repeated twice. At the end, the peptide containing
solution was concentrated by a speed vacuum to near dryness and the brought up to 35
jiL in 0.1% acetic acid before injection onto C 18 reverser phase nano LC column (10 cm
x 75 jtm) and analyzed. The flow rate is 300 nL/min. The mass spectrometry method
was 5th order double play using 12T-FT-ICR-MS detection for MS and MS/MS with CID
fragmentation. Data was analyzed manually as well as with Prosight PC.
3.3 Results
3.3.1 Time Dependent Inactivation of Human RNRs
Time dependent inactivation studies on the human RNR was carried out in the
presence of reductants. The inactivation mixture contained 0.5 or 5.0 eq. of F2CDP/a and
revealed that 0.5 eq. of F2CDP/a results in complete loss of RNR activity (Figure 3.2).
The instability of the 32 radical requires that a control in the absence of F2CDP be carried
out and used to correct the data observed in its presence. The weak interaction between a
and p of RNR allow assays of the subunit activity individually (17, 18). Thus, the
inactivation mixture was assayed as a 1:1 mixture of subunits (Figure 3.3) for activity of
a (3) in the presence of a seven-fold excess of P (ca). Under the latter conditions, a is
100% inactivated. p, on the other hand retained 60% of its activity (Figure 3.3)
suggesting that the excess a is capable of facilitating subunit dissociation. The results of
these experiments have interesting implications in recovering RNR activity in vivo
subsequent to its inactivation by F2CDP.
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Figure 3.2. Time-dependent inactivation of human RNR by F2CDP.
The inactivation mixture contained final concentrations of a, 3, 1.2 rM; F2CDP, 0.6 pM
(m) and 6 iM (A); ATP, 3mM; DTT, 5mM. Aliquots were removed at various times and
diluted 4 fold for determination of RNR activity. Control experiment (*) is identical to
the experiment except that F2CDP was omitted.
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Figure 3.3. Time-dependent inactivation of human RNR by F2CDP.
The inactivation mixture contained final concentrations of a, 3, 1.2 iM; F2CDP, 0.6 jiM;
ATP, 3mM; DTT, 5mM. Aliquots were removed at various times and diluted 4 fold for
determination of a (A) and p (l) activity in the presence of 7 fold excess of 0 or a. The
activity of p (0) was adjusted using results from the control experiment (*) for 3
activity , which is identical to the experiment except that F2CDP was omitted.
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3.3.2 Quantitation of covalent labeling of human and E. coli RNR inactivated by [1'-
3HI and [5- 3H]-F 2CDP
The previous studies of F2CDP inactivation of E. coli RNR were carried out using
unlabeled inhibitor. The results were provocative in that one mole of F2CDP inactivated 1
mole of 213P2 which has two active sites. The synthesis of [1'- 3H]-F 2CDP and [5- 3H]-
F2CDP allowed us to re-investigate the mechanism of RNR from E. coli and track the fate
of the sugar ring and the base. Incubation of 15 p~M x2 and 15 p~M 32 with 15 or 30 .M
of [1 '-3H]-F 2CDP in the presence of 5 mM DTT resulted in recovery of 0.9 (1.1) moles of
radiolabel/RNR (ca212) from analysis of the reaction mixture that was passed through a
Sephadex G50 column in the absence or presence of denaturant after 20 min incubation at
25 'C (Table 3.1). With the [5- 3H]-F 2CDP, 0.19 and 0.08 eq. were detected in the
absence or presence of denaturant, respectively. These results establish that there is one
eq. of the sugar from F2CDP covalently bound to the enzyme and that most of the
cytosine has been released. In addition, under these conditions 40% of the tyrosyl radical
is lost similar to our previous studies (4).
Incubation of [1'- 3H] or [5- 3H]-F 2CDP with human RNR followed by Sephadex
G50 chromatography under native and denaturing conditions gave the results summarized
in Table 3.1. With the [1'- 3H] F2CDP 0.8-0.85 labels were bound per c2, while with the
[5- 3H] only 0.1 labels were retained with the protein. The results are very similar to those
observed with the E. coli RNR, with the unusual stoichiometry of 1 F2CDP per x2
observed. These results in conjunction with the time-dependent inactivation studies,
establish that sub-stoichiometric amounts of F2CDP completely inactivate the human and
E. coli RNR.
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Table 3.1. Covalent labeling of E. coli and human RNR with [1'- 3H]-F 2CDP and
[5- 3H]-F 2CDP analyzed by SEC.
Protein [3 H]-F 2CDP Conditions Reductants [3H]/a2
1' native Y 0.9
E. coli 1' denaturing Y 1.11
RNR 5 native Y 0.19
5 denaturing Y 0.08
human 1' native Y 0.85
RNR 1' denaturing Y 0.8
1' native N 0.1
5 native Y 0.1
5 native N 0.1
3.3.3 Cytosine release by human RNR
The inactivation studies suggested that covalent modification is accompanied by
cytosine release. To test this hypothesis, two eq. of [5- 3H] F2CDPs were incubated with
cc232. Subsequent to inactivation the nucleotides were recovered by ultrafiltration and
analyzed by HPLC. The analysis revealed one eq. of cytosine and one eq. of F2CDP
(Figure 3.4). These results parallel those previously reported for inactivation of E. coli
RNR (4) and support the model that inactivation can be achieved with sub-stoichiometric
amounts of F2CDP.
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Figure 3.4. Analysis by HPLC of products generated during inactivation of human
RNR and E. coli RNR by [5-3H]-F2CDP.
The inactivation mixture contained final concentrations of a, P', 1.2 riM; [5- 3H]-F 2CDP,
1.2 pM, 3mM ATP, 5mM DTT subsequent to removal of the protein from the small
molecules by YM3 centricon, the filtrate was injected into Altech Adsorbosphere
Nucleotide Nucleoside C-18 column at a flow rate of 1mL/min. The elution buffer
contained: Buffer A, 10 mM NH40Ac, pH 6.8; Buffer B: 100% methanol. A 10 min
isocratic elution was followed by a linear gradient to 40% B over 30 min. The elution
profile monitored by A 280nm (-) and scintillation counting (0). 1 cytosine / a2f2 was
released, 0.83 F2C/a212 was recovered.
3.3.4 Subunit interactions of E. coli RNR in the presence of F2CDP
The active form of E. coli RNR is thought to be a 1:1 mixture of a2 and 32,
although there is only one Ye per 32 providing one piece of evidence that the active RNR
complex is asymmetric. One way to achieve complete inactivation of a2P2 with 1
F2CDP is that once chemistry has occurred in the active site of the first a, it precludes
chemistry from occurring in the active site of the second c. This chemistry further leads
to a tight complex between the two subunits preventing recycling of the unmodified a.
To test this model the inactivation mixture and a number of controls (including one with
a mixture of a, 3, and ATP) were examined using SEC on a Superose 12 FPLC column.
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All elution buffers contained either 0.5 mM ATP or 100 pM TTP previously shown to
enhance a2 formation (10, 19, 20) and more recently to enhance ca22 interactions (20).
The results of SEC analysis of RNR inactivated with F2CDP/ATP, with ATP in
the elution buffer, are summarized in Figure 3.5 (A-C) and Table 3.2. Figure 3.5A reveals
a single protein peak. Fractions collected through the protein peak were analyzed by
scintillation counting and by SDS PAGE. The former revealed 0.9 labels per a232
(Figure 3.5 A). The SDS PAGE analysis (Figure 3.5 B) revealed the presence of a and
p. Their relative ratios were determined in each fraction by comparison with standard
curves made with known concentrations of a and p (Figure 3.5 B) and found to be
approximately 1:1 (Figure 3.5 C).
A control SEC analysis in the absence of F2CDP, with ATP in the elution buffer
reveals separation of a2 and 32 (Figure 3.5 D and 3.5 E). Analysis of the ratio of ca:
supports this conclusion (Figure 3.5 F). The analysis in Figure 3.5 suggests that a tight
complex between subunits is unique to the presence of F2CDP.
Since the sub-stoichiometry inactivation is similar to another mechanism based
inhibitor, 2'-azido-2'-deoxynucleotides (N3NDP) (21-23). With [5'- 3H] N3NDPs
inactivation, >90% of RNR activity was lost in 2 min, 50% of Y* was reduced and 0.7 eq
radiolabel are associated with RNR. Inactivation was carried out with equal molar a, 03
incubated with N3UDP, ATP, TR, TRR. A similar SEC experiment provides no evidence
for an a2P2 complex (Figure 3.6). It suggests that the chemistry associated with N3NDP
is different that of F2CDP.
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Figure 3.5. SEC on a Superose 12 column to detect complex formation (a2p2) in E.
coli RNR incubated with ATP in the presence or absence of [1'- 3H] F2CDP.
Elution buffer contains 0.5 mM ATP. A-C presence of F2CDP: A, the elution profile
monitored by A2 80nm and scintillation counting (.). B, fractions through the protein peak
in A monitored by SDS PAGE. Note the slower migrating band (5% of the protein) is an
altered conformation of a. C, analysis of the ratio of a:p (-), using standard curves
generated from known amounts of a and P. D-F absence of F2CDP: D, the elution profile;
E, fractions through the protein peak in D monitored by SDS PAGE. F, analysis of the
ratio of a:f, using standard curves generated from known amounts of a and P3.
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Figure 3.6. Control experiment, a and P inactivated with N3UDP.
(A) Equal molar E. coli [a] = [3] = 10iM, N3UDP=5 pM, [ATP] = 1.6mM, [TR]=20M,
[TRR]=0.5[M. The mixture was loaded onto superose 12 column after 2 min inactivation
at 25°C. The mobile phase contained 0.5mM ATP in the 50mM Hepes, 150mM KC1,
15mM MgCl 2, pH7.6 running buffer. (-) ratio of a: P. (B) Fractions collected from
21.5min to 24.5min, show that a peak eluted first then overlap with P peak at the fraction
eluted at 23min.
Table 3.2. Molecular Weight Determination of E. coli and human RNR and their
subunits by SEC.
Protein Apparent Expected Retention Oligomeric
(effector) mass (kDa) mass (kDa) Time (min) state
p 96 87 25.4 02
aa 143, 105 172, 86 24.9 a2, a
a (100tM TTP) 174 172 24 a2
E. coli a (0.5mM ATP) 174 172 24 a2
RNR a, pa 156, 108 172, 87 23 a2, 32
a, 0 (ATP) b 167, 109 172, 87 22.5, 23.6 a2, 32
a, 3 inactivated 277 259 22 a232
by F2CDPb complex
p 108 94 26.3 02
a 88 92 25.6a
human a (100tM TTP) 189 184 24d a2
RNR a, P (ATP) 589, 94 553, 94 21, 25.8 a6, 32
a, p inactivated 872 834 19.1 a66
by F2CDP b,c complex
a: The HPLC trace indicates multiple species. Gaussian fits to the peak shape using
Origin 6.1 gave the peak retention times. b: Elution buffer contains 0.5 mM ATP.
Fractions were collected through the protein peak and were analyzed by 10% SDS-PAGE
as summarized in Figure 3.5 (A-F) or Figure 3.9. c: apparent mass 872 kDa (a66, 834
kDa) based on standard curve (Figure 3.7). d: Superose 12 column was used
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Further experiments were carried out to assess the resolution of the SEC method
and to obtain information about the relative molecular weights of the observed protein
peaks. The behavior of the individual subunits and complex were examined. In the
absence of nucleotides, a migrates as a mixture of monomer and dimer with apparent
molecular weights of 105 and 143 KDa (Table 3.2), respectively. The apparent molecular
weights are obtained by comparison of the retention times of the eluting proteins with
retention times of known molecular weight standards. With ATP or TTP in the running
buffer, a now migrates as a dimer (a2) of 174 KDa (Table 3.2 and Figure 3.7). When
RNR is inactivated by [l'- 3H] F2CDP/ATP and chromatographed with ATP in the
running buffer, the protein has an apparent molecular weight of 277 KDa (Figure 3.4 A
and Figure 3.7). The SEC analysis presented in Figure 3.5 A-C, the stability of the
complex during the inactivation reaction and the subsequent 25 min chromatogratography,
and the apparent molecular weight suggests that the active form of RNR is a2P2 and that
the interaction between the subunits has dramatically increased relative to the non-
nucleotide bound forms (Table 3.2).
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Figure 3.7. SEC on Superose 12 column to determine the molecular weight of the a,
a2, P2 and a2P2 in E. coli RNR.
The mobile phase contained 0.5mM ATP in the 50 mM Hepes, 15 mM MgCl 2, pH7.6
running buffer. a was eluted with buffer containing 100 tM TTP. a and 3 were eluted in
buffer containing 0.5 mM ATP.
3.3.5 Subunit Interactions of Human RNR in the presence of F2CDP
A similar set of experiments has been carried out with the human RNR. The
Cooperman lab has demonstrated that in contrast with the prokaryotic RNRs, the active
mouse RNR can be c2p2, ca6p2 and a6p6 depending on the concentration of ATP (12).
Recent studies using Gas Phase Electrophoretic Mobility Macromolecule Analysis have
suggested that the active form of human RNR is ca6P2 (13). Biacore studies and kinetic
studies demonstrate that the interactions between a and p in the absence of nucleotides,
as in the prokaryotic case, are weak (Kd = 0.5 M) (18, 24). Anticipated differences in
the aggregation state of active RNR relative to the E. coli RNR caused us to switch to a
Superdex 200 column for molecular weight analysis in the presence and absence of
F2CDP in addition to ATP. The results of incubation of either 0.5 or 1 eq. of [1 '-
3H]
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F2CDP/ATP by SEC with ATP in the elution buffer are shown in Figure 3.7 A and B and
are summarized in Table 3.2. Fractions were collected through the protein peak and
analyzed by scintillation counting and by SDS PAGE (Figure 3.8 B). In the former case
analysis gave 0.8 radiolabels/c2. SDS PAGE revealed the presence of both a and P. The
relative ratio of a:p of 1:1 was established using standard curves made from human or E.
coli a and p (Figure 3.9).
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Figure 3.8. SEC on a Superdex 200 column to detect the complex formation (ann)
in human RNR upon inactivation by F2CDP/ATP.
A. The elution profile monitored by A2 14nm and scintillation counting (m). B. Fractions
through the protein peak in A monitored by SDS PAGE and analysis of the ratio of a:
using standard curves generated from known amounts of a and P.
pM 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
Figure 3.9. Standards on SDS PAGE to determine the ratio of a and p in human
RNR.
a and p human RNR run on 10% SDS-PAGE with designated concentrations were used
to generate standard curves to determine the amounts of a and p in each fraction in Fig.
3.7B.
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Experiments were also carried out to assess the resolution of the SEC method and
to obtain information about the relative molecular weights of the observed protein peaks.
P2 migrates with an apparent molecular weight of 108 KDa (calculated 94.1 KDa, Figure
3.10). a in the absence of nucleotides migrates as the expected monomer, while in the
presence of TTP migrates as a dimer of 189 KDa (Figure 3.10). The retention time of the
protein peak eluted from the RNR inactivated with F2CDP/ATP and with ATP in the
elution buffer, relative to molecular weight standards reveals an apparent molecular
weight of 872 KDa (Figure 3.10). The 1:1 ratio of a:P3, the radiolabeling of the complex,
and the apparent molecular weight in comparison with the expected mass of 834 KDa for
a6p6, 646 KDa for ca6p2, and 278 KDa for c232, suggest that the active form of the
human RNR is a6P6 and that the subunits are tightly interacting. The results, as in the
case of the E. coli RNR, provide an explanation for complete RNR inactivation with sub-
stoichiometric amounts of F2CDP. Inactivation of class I RNRs by F2CDP thus provides
another paradigm for inhibitor design of this protein: increasing the subunit affinity.
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Figure 3.10. SEC on a Superdex 200 column to determine the molecular weight of
the a, a2, P2 and a6p6 in human RNR.
The mobile phase contained 0.5 mM ATP in the 50 mM HEPES, 15 mM MgC12, pH 7.6
running buffer. a was eluted with buffer containing 100 jPM TTP. a and P were eluted in
buffer containing 0.5 mM ATP.
3.3.6 Identification of the covalent labeling site of human RNR inactivated by
F2CDP
To identify the site of covalent modification by the sugar, [1 '-3H] F2CDP, was
incubated with active site mutants of the 5 essential cysteines, C429S/A, E431 Q/D,
C787S/A, C790S/A, C444S/A, C218S/A with P in the presence of DTT. Each mutant
was purified as described for wt-a with similar recoveries. The extent of covalent
labeling measured subsequent to Sephadex G50 chromatograpy in the absence of
denaturant was determined by scintillation counting and compared to the labeling with
wt-RNR. The results are summarized in Table 3.3.
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Table 3.3 Quantitation of the [3H]-label associted of human RNR mutants
inactivated by [1'-3H] F2CDP
labeling/ a2132
Wild type H1 0.8 to 0.9
C444S (C462)a 0.4
C444A (C462) 0.7
C218S (C225) 0.1
C218A (C225) 0.1
C429S (C439) 0.008
C429A (C439) 0.01
E431Q (E441) 0.01
E431D (E441) 0.08
C787S (C754) 0.8
C787A (C754) 0.3
C790S (C759) 0.6
C790A (C759) 0.1
a: In parenthesis are the corresponding residues in E. coli R1.
Comparison of the extent of labeling of mutants to wt hRNR suggests that C218
and E431 result in greatest loss of label and that either could be the site of covalent
modification. However, both E431 and C218 mutants can carry out the first few steps
in the normal reduction process. The E43 1Q however greatly reduces the rate of these
steps and thus lack of a-modification is likely associated with the slow rate of the
reaction. C218 on the other hand allow the first few steps to occur at a rate similar to wt
RNR. Thus at present, and based on recent studies with the E. coli RNR inactivated by
F2CDP, we favor C218 as the site of covalent modification.
To try to identify a peptide alkylated by the sugar, trypsin digest was carried out
on the [1'- 3H]-F 2CDP inactivated human RNR of the protein subsequent to its
alkylation with iodoacetamide. The [1 '-3H] label associated protein was relatively stable
under the conditions required for trypsin digestion, with 15% of the radioactivity being
lost in 24 h. To minimize label loss, the digestion was carried out at 37 'C for 5 h with
137
high levels of digestion into RNR. The peptides were separated by reverse-phase HPLC
in 0-45% CH 3CN, 0.1% TFA over 90 min as shown in Figure 3.11. Twenty % of the
label was lost as it eluted in the void volume of the column. Four broad regions of
radioactivity were identified indicating multiple sites of labeling. Radioactivity in
region I from 65-67 min contain about 14% of total radioactivity, and the region II and
III from 68-70 and 71-73 respectively accounted for 20% and 22% of the total
radioactivity. Region IV from 74-76 min accounted for 10% of the radioactivity.
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Figure 3.11: Trypsin digestion under the conditions of 100 mM NH 4HCO3, 2M
urea, pH 8 for 5 h at 370 C. 4:1 (w/w) protein to trypsin was used. The protein
concentration was 0.5 PM.
Fractions from regions I, II, and III were combined, concentrated and re-injected
onto the Jupiter C 18 peptide column. The peptides were rechromatographed in 10 mM
NH40Ac (pH 6.4) (solvent A), CH 3CN (solvent B) from 0 to 70% in 90 min. An
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additional 25% of the radioactivity was lost during concentration of each sample. The
results from each rechromatography of region I showed 36% recovery (Figure 3.12 A),
Region II showed no co-elution of radioactivity with any peptides in the rechromatograph
(Figure 3.12 B). Region III showed a single peak associated with radiolabel with 30%
recovery in rechromatograph (Figure 3.12 C). Substantial loss of the radiolabel was
observed during the peptide purifications due to the instability of the sugar adduct formed
and rearrangement of the label due to reverse Michael addition.
We collaborated with Prof. Neil Kelleher's lab in University of Illinois, Urbana-
Champaign for mass spectrometry analysis of the purified peptides. Many peptides were
found in each sample even though that they appeared as a single peak on HPLC analysis.
Brad Evans in Kelleher's lab then carried out an in gel digestion on the F2CDP
inactivated human RNR. What he did was to separate a and P on 10% SDS-PAGE, cut
the gel slices containing a and P individually, and treat them with trypsin for digestion
overnight. The peptides were then extracted from gel slices with multiple ammounium
carbonate and acetonitrile washes and separated on a nano C 18 LC column followed by
analyzing on a 12T-FT-ICR-MS with CID fragmentation. Whether the label is stable in
this procedure has not been studied. The coverage of the peptides identified in the MS
analysis is shown in Fig 3.13. Peptides containing the potential labeling site of C218 and
the C-terminal tail Cys were missing. Crosslinking of the C218 with a second peptide
might make the peptide difficult to be identified. All the other catalytic cysteines
including C444 and C429 within their peptides were labeled with iodoacetamide that
possibly rule them out as the site of label, because the protein was treated with
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iodoacetamide after inactivation and cysteines which were not modified by F2CDP would
be labeled with iodoacetamide.
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Figure 3.12: Rechromatography of peptides from human RNR inactivated with [1'-
3H]-F2CDP.
The gradient is 100% 10mM NH40Ac (pH 6.4) for 5 min, increased to 20% CH3CN over
7 min, then increased from 20% to 55% CH3CN from 7 min to 90 min. A2 14 (-), cpm (m)
are shown. Rechromatography of the region I radioactive region (a) yielded a peak with
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(b)
(c)
35.7% recovery, of region II (b) resulted in no radioactivity associated peptides, and of
region III (c) yielded a peak with 63% recovery.
H1 sequence coverage map from 90 kDa band
H2 sequence coverage map from 40 kDa band
Figure 3.13: Mass spectrometry analysis of the in gel trypsin digested peptides
isolated subsequent to alkylation with iodoacetamide.
Those highlighted with red color are peptides identified. All of Cys are highlighted in
yellow. The 1st residue in a is the 2 nd Met on line 1 after His tag. C218 is the 1st C on the
line 4 of a sequence. C429 is the last C on the line 6. C444 is the 1st C on the line 7 of a
sequence. C787 and C790 are the last two C at the end of a sequence. The trypsin digest
site is labeled with ( ).
3.3.7 Time-dependent inactivation in the absence of reductants
Our previous studies on the E. coli RNR have shown that the mode of the
inactivation by F2CDP is reductant-dependent (4). In the presence of reductants, a is
100% inactivated, while in the absence of reductants, the Y* in 0 is completely lost,
accompanied by a formation of a new stable radical, which recently shown to be
nucleotide based (Figure 3.1)
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Figure 3.14: Time-dependent inactivation of human RNR by F2CDP in the absence
of reductant.
Inactivation mixtures contained final concentrations of a, 0, 1.2 tLM; F2CDP, 3 gM; ATP,
3mM. Aliquots were removed at various times and diluted 4 fold for determination of a
(*) and f3 (m) activity in the 7 fold presence of excess of 0 or a. The activity of 0 (H) was
adjusted using results from the control experiment (A) for P activity, which is identical
to the experiment except that F2CDP was omitted.
The assays for inhibition on the human RNR were carried out in the absence of
reductants. Small aliquots of the inactivated RNR complex were removed during a 20
min time course and tested for the activities in the presence of excess of the other subunit.
The experiments revealed that about 50-60% of a activity was lost with 2.5 eq. of F2CDP,
and that 40% of the Y* was lost (Figure 3.14). These results differ from what we
observed with E. coli RNR under similar conditions. In an effort to detect the generation
of the new radical, a sample of 4.9 jM a, 0 (0.8 Y*), 49 gM F2CDP, 3 mM ATP was
incubated at 37 'C for 4.5 min in the absence of reductant before rapidly frozen in liquid
N2 and analyzed by EPR spectrometry at 30 K. As shown in Figure 3.15, no new radical
has been identified besides the Y* after subtracting the spectrum of inactivation mixture
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from the spectrum of the Y*. At t = 4.5 min, 30% of Y* was lost. As limited by the
concentration of a, the intensity of the subtraction spectrum has low signal to noise level.
-50000
g value
Figure 3.15: EPR Spectrum at 9 GHz of human RNR inactivated by F2CDP in the
absence of reductant.
The reaction mixture contained 4.9 [tM a, 13 (0.8 Y*), 49 jM F2CDP, 3 mM ATP,
incubated at 37 'C for 4.5 min (-black, 0.56 Ye remained) before frozen in liquid N2. The
subtraction spectra (-red) was subtracted the intermediate spectra at 4.5 min (-black) from
the spectra of Y* (- blue). Instrument settings for all spectra were as follows: frequency,
9.387 GHz, power 0.201 mW, modulation amplitude 2.00 G, and temperature 30 K.
The products were quantified after the human RNR was inactivated by the [1'-
3H]-F 2CDP or [5- 3H]-F 2CDP in the absence of reductants (Table 3.1). Unlike the 0.8-0.9
eq. of label per a2 with [1'-3H]-F 2CDP in the presence of reductants, only 0.1 eq. of label
was associated per a2. Labeling with [5- 3H]-F 2CDP resulted with 0.1 eq. per a2, showing
the base is also gone after inactivation for 10 min.
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3.4 Discussion
Many 2'-substituted-2'-deoxynucleotides have been shown to be potent
mechanism based inhibitors of RNRs since the initial experiments in 1976 (25). The
detailed studies on 2'-fluoro, 2'-chloro derivatives shown in chapter 1 have provided the
basis for a general mechanism of inhibition by these substrate analogs (26, 27). Most 2'-
substituted deoxynucleotides inhibit class I RNRs by a combination of pathways.
Studies presented in this chapter suggest an additional mechanism by which 2'-
substituted nucleotides may inactivate RNR. F2CDP has two fluorines at C2', both of
which are lost during inactivation (4, 28). [1'- 3H] F2CDP inactivation is accompanied by
0.5 eq. of sugar labeling from F2C/a and loss of cytosine, approximately 40% of tyrosyl
radical loss and 100% loss of RNR activity. The mechanisms by which F2CDP inactivate
the E. coli and human RNRs, thus, must occur by multiple pathways as previously
observed with other 2'-substituted nucleotides. The details of the inactivation mechanism
are complex and are still not understood.
The observation of sub-stoichiometric amounts F2CDP resulting in complete RNR
inactivation is difficult to understand. An explanation for the unusual stoichiometry is
provided by the analysis of the RNR quaternary structure. In the case of the E. coli RNR,
SEC reveals a tight a2P2 complex when it is inactivated by F2CDP (Figure 3.5). A
control in the absence of F2CDP reveals that a2 partially separates from 32 by the same
chromatographic analysis (Fig.3.5). This sub-stoichiometry inactivation is similar to
another mechanism based inhibitor, 2'-azido-2'-deoxynucleotides (N 3NDP) (21-23). With
[5'- 3H] N3NDPs inactivation, >90% of RNR activity is lost in 2 min, 50% of Y* is
reduced and 0.7 eq radiolabel are associated with RNR. However, the radiolabel is not
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stable or it is non-covalently bound because denaturizing protein releases the radiolabel.
In contrast with F2CDP, activity of a with N3UDP is recovered to 50% and complete
inactivation over 30 min is associated with 100% loss of Y*. Thus, while the subunits
must be tightly associated initially to account for > 90% loss of activity with just 50%
loss of Y*, further chemistry associated with nucleotide allows subunit weakening and
dissociation. A similar SEC experiment provides no evidence for an a232 complex.
(Figure 3.6) The unique chemistry associated with the different inhibitors thus can
dramatically effect subunit interactions.
The inactivation of the human RNR shows some differences from that of the E.
coli RNR in the absence of reductant, however, the in the presence of reductant, it mirrors
the observations made with the E. coli RNR. One major difference, however, involves
the quaternary structure of the human RNR. Our SEC studies have provided direct
evidence in support of an active a636 complex based on standard curve made with
globular proteins. This result contrasts with previous proposals of active a232 and with
the recent mass spectrometric studies suggesting that a6P2 is the active form of RNR
(13). Our results support the importance of the a6 form of the large subunit, first
proposed by Cooperman's lab (12). The SEC results also suggest that inactivation is the
result of tight complex formation between the subunits which can occur even in the
presence of sub-stoichiometric amounts of nucleotide. At odds with this interpretation is
the activity assays for each subunit in the presence of an excess of the second subunit. If
a tight complex were present subsequent to inactivation, one would have expected that a
and p would be 100% inactive. While this was the case for a, P2 retains 60% of its
activity. These results are very intriguing and provide us with additional insight about
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subunit interaction. The recovery of P2 activity requires that excess a can form a
transient ternary complex with a66 and liberate P2 which has retained some of its Y*
and is thus active. This proposal is supported by a recent structure of a complex of the
a232 from E. coli where only one of the two Ps interacts with a. Thus one could propose
that binding of a to the unattached P of P2 could facilitate a2 release. In the case of the
inactivated ca*p2 complex assayed with excess a (a* = covalently labeled a), this
mechanism would result in release of aa* and formation of active a2P2. Since there is
only one [3H]-label per a2, one would have expected the unlabeled monomer to be also
active in the presence of excess 3, but this is not the case. Thus this result provides
strong support for asymmetry within the a2 (a6), that is, modification of one a,
precludes activity of the other. The results suggest that if the cell was able to increase the
amount of a, that active RNR could be recovered. Interestingly resistance in a number of
cell lines has identified elevated a levels (29-31). F2CDP is unique with respect to the
well characterized 2' substituted nucleotide mechanism based inhibitors, in that in
addition to labeling a and loss of Ye on 3, inactivation is the result of tight subunit
association.
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Chapter 4
Inactivation studies of Human p53R2 and H1 RNR complex by Gemcitabine
Adapted from Wang J, Lohman GJ, Stubbe J. (2009) Mechanism of Inactivation of
human Ribonucleotide Reductase with p53R2 by Gemcitabine-5'- diphosphate.
Manuscript in preparation.
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4.1 Introduction:
Gemcitabine (2, 2'-dideoxy-difluorocytidine, F2C) is a drug that is used clinically
in the treatment of non-small cell lung carcinomas and advanced pancreatic cancer (1-5).
The mechanism of its cytotoxicity is multifactoral where its metabolites, the mono-, di-
and tri-phosphates (F2CMP, F2CDP and F2CTP) inhibit a variety of steps in nucleic acid
metabolism (3, 6). The essential step in apoptosis of the cells is F2CTP inhibition of DNA
polymerase by its incorporation into the growing polymer chain, resulting in chain
termination (2). Potentiation of the effects of F2CTP results from the inhibition of
ribonucleotide reductase(s) (RNR), the enzymes that make deoxynucleoside 5'-
diphosphates (dNDPs) from nucleoside diphosphates (7-9). RNRs are stoichiometrically
inhibited by F2CDP (7-10). This inhibition leads to a reduction in dNDP pools and
consequently reduction in dNTP pools. Reduced concentrations of dNTPs reduce the
competition for F2CTP to become incorporated into DNA.
Class I RNRs are composed of a (RI) and P (R2) subunits and the human RNRs
(hRNR) have a complex quaternary structure an(P2)m (n = 2, 4, 6 and m = 1, 3) (7, 8). a
houses the active site for nucleotide reduction and the binding sites for ATP/dNTP
allosteric effectors that control the specificity and rate of nucleotide reduction. P3 houses
the essential diferric-tyrosyl radical (Y-) cofactor (9-12). Recently, we have shown that
hRNR involved in DNA replication, is substoichiometrically inactivated by F2CDP (0.5
eq/a) (13). Our studies unexpectedly revealed that the inhibition resulted from tight
association of the two subunits and formation of a quaternary structure determined by
size exclusion chromatography (SEC) where m is 3 and n is 6. Recently a second RNR
small subunit was discovered in humans (14, 15). It was designated p53R2 as its levels
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were induced by p5 3 (14). We will designate p53R2 as P'. In this chapter we report on the
mechanism of inactivation of hRNR, an(P'2)m, by F2CDP and compare the results with
the replicative RNR an(P2)m.
The biology and biochemistry of 13' are actively being investigated. The biological
function of 3' is complex and appears to be different in quiescent cells and cells which
have been subjected to DNA damage. Recent studies of Pontarin et al (16) suggest that 3'
is localized to the cytosol and is not shuttled to the nucleus as previously suggested (14,
17). They proposed that 3' plays a primary role in mitochondrial DNA replication. This
role is supported by identification of children with mutations in 1' that experience severe
mitochondrial DNA depletion (18).
While p53 mediates transcriptional induction of P' and as a consequence led to the
proposal of its involvement in DNA repair, the induction process is not sufficiently rapid
to supply dNTPs given the rate of damage repair (16, 19). Recent observations, however,
have shown that p' interacts with and is phosphorylated by ATM and is found in the
MRE11 complex involved in DNA double strand break repair. P' has also been shown to
interact with ERK1 (ERK2) and to inhibit MEK-ERK signaling and prevent cancer
invasion, demonstrating an important role in genomic stability (19, 20).
p' is composed of 351 amino acids and is 80% homologous to hp (human P). Both
proteins contain an essential diferric-Y* cofactor and are active in nucleotide reduction in
the presence of a. hp' has been reported to have activity 1.4 fold lower than P and a Y*
content of 0.8/P'2, 67% of that of P2 (21). However, the activity of hp reported (21) is
substantially lower (10 fold), than the activity recently reported from our lab (13) for
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reasons unknown. p' has also been proposed to have catalase activity in contrast to hp and
to have a different susceptibility to inactivation by hydroxyurea (22).
As noted above F2CDP is a potent inhibitor of RNRs and its demonstrated
efficacy against a range of solid tumors warrants a detailed investigation of this process.
Studies on the class Ia RNRs from E. coli and human an(2)m, and the class II RNR from
Lactobacillus leichmannii have provided us with the following generalizations about the
mechanism of inactivation. Using [5- 3H] or [1'- 3H] F2CDP (F2CTP) the stoichiometry of
inhibition is 1 F2CDP/a2 for the class I RNRs (13) and 1 F2CTP/a for the class II RNR
(23, 24). The L. leichmannii RNR is a monomeric enzyme that uses adenosylcobalamin
as a cofactor. Despite the stoichiometry, as with all mechanism based inhibitors of RNR,
at least two pathways are responsible for inhibition (25). Covalent modification by a
sugar moiety of F2CDP is responsible for inactivation by one of these pathways.
Destruction of the cofactor (Y- in the class Ia and adenosylcobalamin in the class II
RNRs) (24) is responsible for the remaining inactivation. Subsequent to complete
inactivation, stoichiometric amounts of cytosine are released, as are two fluoride ions.
With the E. coli and L. leichmannii RNRs a new nucleotide radical has been recently
identified 1 (10, 26, 27). This information has been used to formulate mechanisms of
inactivation of the two pathways. Finally, with the class I RNRs we have recently made
the unexpected observation that the basis for complete inactivation by 0.5 F2CDP/ is
that the a and p subunits form a tight complex: c202 for E. coli RNR and a6P6 for
hRNR (13).
PPO C
0
H 1
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The prevalence of gemcitabine as a clinically useful drug and the wealth of
literature evidence suggesting that controlling the levels of P' may increase potency of co-
administered genotoxic therapeutics mandates a better understanding of the enzymology
of 3' to elucidate its function (26). In this chapter we report that F2CDP is an inactivator
of p', although the binding of F2CDP to the a/3' complex appears to be weaker (based on
slower rates of inactivation at stoichiometric amounts) than that observed with the
corresponding complex bearing hp. Studies with [5- 3H] and [1'- 3H] F2CDP reveal the
following: (i) >90% inactivation occurs with 0.5 eq. inhibitor/a; (ii) 0.5 sugars are
attached covalently to a, and (iii) one cytosine is released per inactivation. SDS PAGE
analysis of the inactivated RNR reveals that a has been covalently modified (40% of total
a) migrates as a 120 kDa protein relative to unmodified a which migrates as a 90 kDa
protein. Site directed mutagenesis studies of all of the residues involved in catalysis in a
and studies of the effect of each mutation on the inactivation of RNR (comprising either
hp or 0') suggest that C218 and a cysteine (C790 or C787) from the C-terminus of a are
likely responsible for covalent modification of a and the unusual migratory properties of
a by SDS PAGE analysis. Size exclusion chromatography suggests that subsequent to
inactivation, RNR migrates as a a63'6 complex. 0' thus could also be a target of
gemcitabine and play a role in its cytotoxicity.
4.2 Materials and Methods
4.2.1 Material
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Competent E. coli BL 21 (DE3) -RIL cells were purchased from Stratagene.
Complete EDTA-free protease inhibitor tablets and calf alkaline phosphatase (20 U/[L)
were purchased from Roche Biochemicals. [3H]-CDP (17 Ci /p~mol) is from ViTrax
radiochemicals (CA). p53R2 (27) containing the gene for 1' was a gift from Lars
Thelander (Department of Medical Biosciences, Medical Biochemistry, Umea' University,
SE-901 87 Umed, Sweden). phRRM1 containing the gene for a was from Dr. Yun Yen
(City of Hope National Medical Center, Duarte, CA) (21). Protein concentrations were
determined using extinction coefficients (8280 nm) per monomer [62,000 M1 cm -1 for P',
119,160 M-1 cm ' for a]. E. coli TR (specific activity of 40 U/mg) and TRR (specific
activity of 1320 U/mg) were isolated as previously described (28, 29).
4.2.2 Expression and purification of human P':
1' in pET3a, which does not contain a tag or extra amino acids, was transformed
to BL21 Codon Plus (DE3)-RIL cells (Stratagene), plated on LB agar plates with 100
[tg/mL ampicillin (Amp) and 34 [tg/mL chloramphenicol (CM). A single colony was
added to a culture (20 mL LB in 150 mL flask) and grown to saturation overnight. The
culture was then diluted into 2 L of LB in a 6 L flask containing 100 [ig/mL Amp, 34
Vg/mL CM and grown at 370 C to OD 600nm 0.7. 1,10-Phenanthroline (100 pM) was then
added to the media and the cells were grown for an additional 15min. IPTG (isopropyl-
beta-D-thiogalactopyranoside, 400 jiM) was then added and the cells were grown at 370 C
for an additional 5 h. The cells were harvested and frozen in liquid N2 and typically
yielded 2 g/L.
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For the isolation of the apo p', 16 g cells were suspended (4 vol/g) in 50mM Tris-
HC1, pH 7.6, 1mM PMSF (phenylmethanesulphonylfluoride), 1mM EDTA at 4 oC. The
suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 27, 000 xg for 30 min at 4 OC. Streptomycin sulfate of 10% (w/v) stock
was added to the supernatant over 10 min while stirring at 4 OC, to a final concentration
of 2.5 %. After an additional 10 min of stirring, the pellet was removed by centrifugation
(27, 000 xg for 30 min, 4 'C). Solid ammonium sulfate (0.243 g/mL, 40%) was added to
the supernatant over 10 min at 4 'C. After an additional 30 min of stirring, the protein
pellet was recovered by centrifugation (27, 000 xg for 30 min, 4 °C).
The pellet was dissolved in 4 mL of extraction buffer and loaded directly onto a
Phenyl Sepharose 6 Fast flow column (20 mL, 2.5 x 10 cm) that was pre-equilibrated
with 200 mL, 25 mM Tris pH 7.6, 10% glycerol, 30% w/v (NH4)2S0 4 (buffer A). The
column was washed with buffer A (100 mL) and then 300 mL, 25 mM Tris (pH 7.6),
10% glycerol, 5% w/v (NH4)2 SO 4 (buffer B). Finally, P' was eluted with 50 mM Tris
pH7.6, 5% glycerol, 1 mM EDTA, 1mM PMSF (buffer C). Fractions (2 mL) containing
3' (based on Bradford assay) were collected.
The pooled protein fractions were then loaded onto a Q-Sepharose column (20
mL, 2.5 x 10 cm), which was pre-equilibrated with 100 mL buffer C at 4 OC. The column
was washed with 200 mL buffer C and 150 mM KC1. The protein was eluted with a 70
mL x 70 mL linear gradient of 150 - 400 mM KCl in buffer C. Fractions (2 mL)
containing p' (based on Bradford assay and 10% SDS PAGE analysis) were collected.
The apo P' eluted around 220 mM KC1. A typical yield of 0.4 mg P'/g cells was obtained.
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4.2.3 Construction of Y138F-p', growth, and isolation
The Y138F-p' was generated by site directed mutagenesis using the Quick
Change Kit (Stratagene). The P' gene was amplified by PCR using PfuUltra II
polymerase (Stratagene) with primers for Y138F mutant (Table 4.1). The sequence of the
mutant plasmids was confirmed by sequencing at the MIT biopolymers laboratory.
Y138F-p' was expressed and purified as described for P' with similar yields.
Table 4.1: Primers for mutants of p' and a
Name of Sequence of the primer (from 5'-3')
the
mutant
Y138F-3' GAATGTTCACTCAGAGATGTTCAGTTTGCTGATAGACAC
forward
Y138-P3' GTGTCTATCAGCAAACTGAACATCTCTGAGTGAACATTC
reverse
C218S-a CCGCCCACAACTTTCTAGCTCTTTTCTTCTGAGTATG
forward
C218S-a CATACTCAG AAGAAAAGAG CTAGAAAGTT GTGGGCGG
reverse
C218A-a CCGCCCACAACTTTCTAGCGCTTTTCTTCTGAGTATG
forward
C218A-c CATACTCAG AAGAAAAGCGCTAGAAAGTT GTGGGCGG
reverse
C429S-a GCAGCAACCTGTCCACAGAAATAGTGGAGTACACC
forward
C429S-a GGTGTACTCCACTATTTCTGTGGACAGG TTGCTGC
reverse
C429A-a CCATCAAATGCAGCAACCTGGCCACAGAAATAGTGGAG
forward
C429A-a CTCCACTATTTCTGTGGCCAGGTTGCTGCATTTGATGG
reverse
C444S-a GAGGTTGCTGTTTCTAATTTGGCTTCCCTGGCCC
forward
C444S-a GGGCCAGGGAAGCCAAATTAGAAACAGCAACCTC
reverse
C444A-a GAGGTTGCTGTTGCTAATTTGGCTTCCCTGGCCC
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forward
C444A-ac G GGCCAGGGAAGCCAAATTAGCAACAGCAAC CTC
reverse
C787S-o GGAGAATAGAGATGAATCTCTGATGTGTGGATCCTG
forward
C787S-a CAGGATCC ACACATCAGAGATTCATCTC TATTCTCC
reverse
C787A-a GCTCTTTGGAGAATAGAGATGAAGCTCTGATGTGTGGATCCTG
forward
C787A-c CAGGATCC ACACATCAGAGCTTCATCTCTATTCTCCAA AGAG
reverse
C790S- GGAGAATAGAGATGAATGTCTGATGTCTGGATCCTG
forward
C790S-c CAGGATCCAGACATCAGACATTCATCTCTATTCTCC
reverse
C790A-c GCTCTTTGGAGAATAGAGATGAATGTCTGATGGCTGGATCCTG
forward
C790A-c CAGGATCCAGCCATCAGACATTCATCTC TATTCTCCAAAGAGC
reverse
E43 1Q-a GCAACCTGTGCACACAAATAGTGGAGTACACC
forward
E431Q-a GGTGTACTCCACTATTTGTGTGCACAGG TTGC
reverse
E431D-a GCAACCTGTGCACAGACATAGTGGAGTACACC
forward
E431D-a GGTGTACT CCACTATGTCTGTGCACAGG TTGC
reverse
The mutation sites are highlighted.
4.2.3 Conversion of apo p' to holo p'
P'2 (60 pM) in 500 tL of 50 mM Hepes, 100 mM KC1, 10% glycerol, pH 7.6 and
2.5 mM ascorbate acid was deoxygenated by 6 cycles of evacuation (for 3 x 10 s)
followed by argon flushing (2 min) on a Schlenk line. The deoxygenated P'2 solution was
brought into the glove box (M. Braun, Stratham, NH) and 6 eq. of Fe (II) (deoxygenated
ferrous ammonium sulfate in 50 mM Tris,100 mM KC1, pH 7.6) per P'2 was added. The
resulting mixture was incubated at 4 OC for 30 min. The protein was then removed from
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the glove box and 100 pL of ice cold 02 saturated 50 mM Tris, 100 mM KC1, pH 7.6 was
added. 02 (g) was also blown over the surface of the protein solution for 1 min. Excess
iron was removed by Sephadex G-25 chromatography (40 mL, 2.5 x 30 cm) and the
protein fractions pooled to give 3.5 mg/mL. An activity assay was carried out
immediately and 250 [pL protein solution was placed in an EPR tube and frozen in liquid
N2 for measurement of the Y*. Typically 0.6 Yo/ 3'2 were observed and the specific
activity of this proteins was 420 nmol/min/mg.
4.2.4 Mutants of a: construction of mutant genes, growth, and purification
Mutants of a C218S(A), C429S(A), C444S(A), C787S(A), C790S(A), E431Q(D)
were generated by site directed mutagenesis using the Quick Change Kit (Stratagene).
For each mutant, the gene was amplified by PCR using PfuUltra II polymerase
(Stratagene) with primers (Table 4.1). The sequence of each mutant plasmid was
confirmed by the MIT biopolymers laboratory. The mutants were expressed and purified
as described below for wt a with similar yields.
4.2.5 Purification of a and a mutants by Ni NTA and dATP affinity
chromatography
Cells (15 g) were suspended (5 vol/g) in 50 mM NaH2PO 4, pH 7.0, 0.1% Trition
X-100 and 10 mM 2-mercaptoethanol with the complete protease inhibitor (Roche). The
suspension was passed through the French press at 14,000 psi. The cell lysate was
centrifuged at 20,000 x g for 30 min. Streptomycin sulfate (10%) was added to the
supernatant over 10 min to a final concentration of 1% (w/v) and stirred for additional 10
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min. After the pellet was removed by centrifugation, the supernatant was incubated with
Ni-NTA agarose resin (1 mL/g of cells, Qiagen) at 40C for 1 h and then loaded into a
column (2.5 x 10 cm). The column was washed with 30 column volumes of 50 mM
NaH2PO4, 800 mM NaC1, 50 mM imidazole, pH 7.0, 0.1% Trition X-100 and 10 mM 2-
mercaptoethanol. The protein was eluted with 50 mM NaH2PO 4, 300 mM NaC1, 125 mM
imidazole, pH 7.0. Fractions containing protein were identified using the Bradford assay.
The fractions containing protein were pooled and concentrated to < 10 mL, and then the
imidazole was removed by Sephadex G-25 chromatography (200 mL, 2.5 x 50 cm) using
50 mM Tris, pH 7.6, 5% glycerol, 1 mM DTT as eluent. The pooled protein fractions
were added to dATP affinity resin (30 mL, equilibrated with 50 mM Tris, pH 7.6, 5%
glycerol, 1 mM DTT) (30) and gently mixed for 2 h at 4 OC in a 50 mL falcon tube. The
resin was then loaded into a column (2.5 x 10 cm) and washed with 300 mL 50 mM Tris,
pH 7.6, 5% glycerol, 300 mM KC1, ImM DTT. The protein was eluted with 50 mM Tris,
pH 7.6, 5% glycerol, 100 mM KC1, 5mM DTT, 10 mM ATP. Fractions containing
protein were identified using the Bradford assay. The fractions were pooled and
concentrated to < 0.5 mL, and the ATP was removed by Sephadex G-25 chromatography
(40 mL, 1.5 x 30 cm). a was stored in 50 mM Tris, 100 mM KC1, 15 mM MgC12, 5 mM
DTT, pH 7.6, 5% glycerol with a typical yield of 1 mg/g of cells after the Ni affinity
column, and 0.2 mg/g of cell pellet after dATP affinity chromatography. Only a used in
SEC studies was purified with the dATP chromatography. a in the rest of the
experiments and a mutants were purified by Ni affinity chromatography only.
4.2.6 Activity assays:
160
The reaction mixture contained the following in a final volume of 350 [L: 50 mM
Hepes (pH 7.6), 15 mM MgC12, 1 mM EDTA (assay buffer), 0.3 pM (or 3 gM) ac, 3 pM
(or 0.3 pM) P', 3 mM ATP, 1mM [3H]-CDP (specific activity 5115 cpm /nmol), 100 gM
E.coli TR, 1.0 [pM TR reductase, 2 mM NADPH. The assay mixture was pre-incubated at
37 'C for 2 min and the reaction was initiated by the addition of [3H]-CDP. Aliquots of
30 pL were removed over a 15 min time period and quenched in a boiling water bath for
2 min. dCDP production was analyzed, subsequent to removal of the phosphates with
alkaline phosphatase as previously described (31) and analyzed by the method of Steeper
and Steuart (32).
4.2.7 Time dependent inactivation studies:
The inactivation mixture contained the following in a final volume of 100 tL: 6
IpM a, 6 pM 3', 3 mM ATP, 5 mM DTT, and assay buffer. The reaction was initiated by
addition of 0.5 or 5 eq. of F2CDP (3 [pM, 30 pM) and incubated at 370 C. Three types of
assays were carried out. In assay 1, aliquots (10 pL) from the reaction mixture were
removed at several time points from 30 s to 23 min and diluted 5 fold into 50 gL of assay
buffer. dCDP production was measured as described above. A control experiment under
identical conditions with the omission of F2CDP was always carried out to assess the
stability of P'. In assays 2 and 3, the activity of each subunit was measured. Aliquots (2.5
pL) of the inactivation mixture were diluted into 50 pL of assay buffer containing 3 gM
(10 fold excess) of the second subunit a or P'. dCDP production was measured as
described above.
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4.2.8 Quantitation of covalent labeling of human an(P'2)m with [1'- 3H]-F 2CDP and
[5- 3H]-F 2CDP
A typical reaction mixture contained the following in a final volume of 200 pL:
8.5 [M a, P', with 5 mM DTT, 3 mM ATP in assay buffer. The reaction was initiated
with 10.6 M of [1'- 3H]-F 2CDP (5889 cpm /nmol) or 10.6 pM of [5- 3H]-F 2CDP (6643
cpm /nmol). After 8 min at 370 C, an aliquot of 195 gL was either directly loaded onto a
Sephadex G-50 column (1 cm x 20 cm, 20 mL) that was pre-equilibrated with the assay
buffer, or mixed with guanidine-HCI at a final concentration of 6 M, incubated for 5 min,
and then loaded onto a Sephadex G-50 column with assay buffer containing 2 M
guanidine-HC1. Fractions (1 mL) were collected and assayed for protein by Bradford
assay and 500 tL of each fraction was analyzed by scintillation counting.
4.2.9 Quantitation of cytosine released during the inactivation of human an(P'2)m by
[5- 3H]-F 2CDP
The reaction mixture contained the following in 500 iL with a, 3' each at 1.2 gM
and [5- 3H]-F 2CDP (6643 cpm/nmol) at 1.2 jM (2 eq/a2). The reaction was incubated for
15 min at 37 oC. The mixture was then filtered through an YM-30 Centricon device
(Millipore) at 40 C. F2C (60 nmol) and cytosine (120 nmol) were added as carriers before
filtration. The flow through was treated with 30 U of alkaline phosphatase (Roche) for 3
h at 37 'C and filtered through a second YM-30 Centricon device. The flow through was
analyzed using a Waters 2480 HPLC with an Altech Adsorbosphere Nucleotide
Nucleoside C-18 column (250 mm x 4.6 mm) at a flow rate of lmL/min. The elution
buffer contained: Buffer I, 10 mM NH40Ac, pH 6.8; Buffer II: 100% methanol. A 10
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min isocratic elution was followed by a linear gradient to 40% buffer II over 30 min. A
linear gradient was then run to 100% buffer II over 5 min. Fractions (1 mL) were
collected and 200 gL of each were analyzed by scintillation counting. The recovery of [5-
3H]-cytosine and [5- 3H]-F 2C was calculated based on the UV spectrum (cytosine, k2 67 nm,
8 = 6100 M-l cm -1, F2C, k268 nm, E = 9360 M-l cm-1) and normalized for carrier added. The
radioactivity recovered with [5- 3H]-cytosine and [5- 3H]-F 2C was analyzed by scintillation
counting.
4.2.10 SDS PAGE of Inactivation mixture without boiling
The inactivation mixture contained the following in a final volume of 35 gL: 6
M a or C218S-a, 6 pLM 3', 3 mM ATP, with or without 5 mM DTT, and assay buffer.
The reaction was initiated by addition of 5 eq. of F2CDP (30 gM) and incubated at 370 C
for 5 min. Inactivation mixture (8 [tL) was mixed with 8 [L 2x loading buffer + P-
mercaptoethanol. The samples were either heated at 90 oC for 2 min or not heated before
loading on a 10% SDS-PAGE gel. The proteins were visualized with Coomassie blue
staining. The band intensities were quantified using BioRad Quantity One software.
4.2.11 Incubation of [1'- 3H] F2CDP and C218S/A-, C429S/A-, C444S/A-, C787S/A-,
C790S/A-, E431Q/D-a and p' and analysis for covalent labeling by Sephadex
chromatography
A typical reaction mixture contained in a final volume of 200 ptL: 8.5 iM a
mutant and p', 5 mM DTT, 3 mM ATP in assay buffer. The reaction was initiated with
10.6 [tM of [I'- 3H]-F 2CDP (5889 cpm /nmol). After 8 min at 370 C, an aliquot of 195 ptL
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was loaded onto a Sephadex G-50 column (1 cm x 20 cm, 20 mL) that was pre-
equilibrated with the assay buffer. Fractions (1 mL) were collected and assayed for
protein presence by Bradford assay and 500 pL of each fraction was analyzed by
scintillation counting.
4.2.12 SEC to examine the quaternary structure of an(P'2 )m subsequent to
inactivation by F2CDP:
SEC was performed using a Superdex 200 column (10 x 300 mm, GE healthcare)
attached to a Waters 2480 HPLC. Gel filtration molecular weight standards (GE
healthcare) were ovalbumin, 43 kDa; conalbumin, 75 kDa; aldolase, 158 kDa; catalase
232 KDa; ferritin, 440 kDa; thyroglobulin, 669 kDa; and blue dextran, 2000 kDa. The
elution buffer was 50 mM Hepes (pH 7.6), 15 mM MgC12, 1 mM EDTA and 0.5 mM
ATP. Molecular weight standards were run at the beginning of each experiment. The
reaction mixture (400 pL) contained 15 piM o and P' (or Y138F- 0'), 5 mM DTT, 3 mM
ATP, 37.5 pM F2CDP (2.5 eq) in assay buffer. a was purified using Ni affinity- and
dATP affinity-chromatography and had a specific activity of 232 nmol/min/mg
(measured with 32). 3'2 contained 0.63 Ye (specific activity 413 nmol/min/mg). After 10
min incubation, 390 [pL was injected onto the column using a 500 pL loop. The elution
rate was 0.5 mL/min and 0.5 mL fractions were collected. If [1'- 3H]-F 2CDP was used in
the inactivation mixture, 300 ipL aliquots of each fraction were analyzed by scintillation
counting.
4.2.13 Quantitative analysis of the subunits of an(p'2)m by SDS PAGE
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The fractions collected from the SEC analysis above were analyzed directly (8 ItL
from each fraction) by 10% SDS- PAGE and compared with concentrations of ca and P
from E.coli RNR (0.05 pM to 0.4 jtM) as standards. To analyze the peak of protein that
eluted first from the SEC studies of the Y138F/a and the a/p' with ATP control
experiment, each fraction through the peak was concentrated before loading on the gel.
The proteins were visualized with Coomassie blue staining. The band intensities were
quantified using BioRad Quantity One software. The concentrations of ca and P' in the
complex were determined from standard curves made with E. coli subunits as described
above.
4.3 Results:
4.3.1 Purification and reconstitution of the 1'2
Growth of '2 was carried out in the presence of 1, 10-phenanthroline resulting in
apo protein. This procedure gave higher recovery of Y* and activity than standard growth
conditions with addition of ferrous ammonium sulfate and ascorbate to the crude lysate
prior to purification. 3'2 was purified by addition of Phenyl Sepharose 6 Fast and Q-
Sepharose Fast Flow column chromatographies to the procedure of Thelander (27).
These steps were required to obtain homogeneous protein by SDS PAGE. A variety of
methods to assemble the essential diferric-tyrosyl radical (Y*) cluster of 13'2 were
examined including use of tagged and non-tagged versions of 3'2 and varying the ratio of
Fe 2+/3'. The detailed procedure described in Methods gave 0.63 Y* per 3'2 with activity
of 420 nmol/min/mg. The procedure reported by the Thelander group gave 1 Ye per 3'2
(non-tagged), but the activity was 95 nmol/min/mg (27). A second purification procedure
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reported by Yen and coworkers using a tagged-P'2 gave 0.8 Y/ P3'2 and a specific
activity of 50 nmol/min/mg (21). The low activity and high Y- content reported by these
groups are at odds with activity being directly proportional to Y* (33, 34). The basis for
the discrepancy is not understood. In our hands we have been unable, after many
attempts with identical constructs to those used by Thelander and Yen, to obtain higher
levels of Y*/0'2. However, with our previous purification of hp, our group did obtain the
same amount of radical (1 Y-/02) as these groups but with 7-14 fold higher activity. Our
ability to only obtain 0.6 Y*/P'2 makes the experiments described subsequently to
quantitate products from the F2CDP reaction more complex as there is always present
about 0.4 P'2 and cc that have not reacted. In the quantitations reported below we have
placed numbers normalized to 1Y*/P'2 in parentheses.
4.3.2 Time dependent inactivation studies of a, P'2 by F2CDP/ATP.
Our previous studies with F2CDP on human an(2)m and E. coli a202 showed that
F2CDP is a sub-stoichiometric mechanism based inhibitor resulting in covalent binding of
1 eq. of the sugar moiety from [1'- 3H]-F 2CDP per a2. To determine if 13'2 behaves in a
similar fashion, inactivation studies were carried out with a, P3'(6 j M each) and 0.5 or 5
eq. F2CDP/a in the presence of reductant (either DTT or TR/TRR/NADPH). Three
different assays were carried out. In the first assay (Figure 4.1) the enzyme was diluted 5
fold and assayed for dCDP production. Both concentrations of F2CDP resulted in > 90%
inactivation with the reaction in the presence of 5 fold excess of inhibitor relative to a
being complete in four minutes (A). Even under these conditions it is unlikely that the
enzyme is saturated with F2CDP. As with hp, substoichiometric amounts of inhibitor
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result in >90% inactivation (0), although the inactivation is slow and about 60% of the
activity is lost in the "fast" phase. The control with 3'2 in the absence of inhibitor reveals
that Y* is lost, precluding longer time points (Figure 4.1 ). The half life of Y* loss is
similar to our observations with hp (13).
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Figure 4.1: A Time dependent inactivation assay of human P'2 and a by F2CDP.
Inactivation mixture contained final concentrations of a, p', 6 tM; F2CDP, 30 1IM (A), 3
[tM (0), 0 tM (*); ATP, 3mM; DTT, 5mM. Aliquots were removed at various times
and diluted 5 fold for determination of RNR activity.
Because of the weak interactions between the two subunits in the class I RNRs,
assays of the individual subunits, a (P'), are typically carried out in which a ten fold
excess of the second subunit, p' (a), is present in the assay mixture. The result of a
typical experiment under these conditions is shown in Figure 4.2. Under these conditions
a is 95% inactivated, while P' retained 40% of its activity after correction for P' stability
(*). These results are similar to those for the E. coli RNR and the hRNR with P. The
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results suggest that excess a can facilitate subunit dissociation and liberate the remaining
active p'. The implications of these results will be addressed subsequently.
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Figure 4.2: Time dependent inactivation assay of human P'2 and a by F2CDP in the
presence of an excess of the other subunit.
Inactivation mixtures contained final concentrations of a, 3', 6 pM; F2CDP, 3 jM; ATP,
3mM; DTT, 5mM. Aliquots were removed at various times and diluted 20 fold for
determination of a (A) and p' (U )activity in the presence of 10 fold excess of 0' or a.
The activity of P' (0) was adjusted using results from the control experiment (*) for P'
activity in the absence of inhibitor.
4.3.3 Quantitation of labeled RNR and small molecules generated by inactivation
with [1'- 3H] and [5- 3H]-F 2CDP
With [1 '-3H]-F 2CDP, our previous studies with hp2 containing 1.2 Y-, identified
0.9 eq./l2 of covalently bound sugar. A similar experiment using a and 0' each at 4.2 gM
and 2.5 eq. [1'- 3H] F2CDP was carried out for 8 min at 370C. The reaction mixture was
analyzed by Sephadex G50 column chromatography in the presence or absence of
denaturant (guanidine-HC1). The results are shown in (Table 4.2) and reveal 0.5 eq./a2
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(normalization gives 0.83 eq./a2). When the experiment was repeated with the [5- 3H]-
F2CDP under identical conditions in the absence of denaturant, 0.03 eq./a2 (0.05) was
detected with protein (Table 4.2).
To test if 0.5 eq. sugar/inactivated enzyme is accompanied by 0.5 eq. of cytosine
release, two eq. of [5- 3H] F2CDPs (1.2 jM) were incubated with a2p'2 (0.6 M) for 15
min at 37 'C. Subsequent to inactivation the nucleotides were recovered by ultrafiltration
and analyzed by HPLC. The analysis revealed that 0.65 eq. (1.08) of cytosine were
released and 1.35 eq. of F2C was recovered (Figure 4.3). These results are in agreement
with our previous studies on inactivation of human an( 2 )m and E. coli RNR and reveal
that the extent of reaction correlates with the amount of Y- in 3 or p'.
Table 4.2: Covalent labeling of human an(P'2)m with [1'- 3H]-F 2CDP and
[5- 3H]-F 2CDP analyzed by SEC.
Protein [x-3H]-F 2CDP Conditions [3H] / a2p'2
where x =
human 1' native 0.5
'2, a 1' denaturing 0.5
5 native 0.03
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Figure 4.3: Analysis by HPLC of products generated during inactivation of an(P'2)m
by [5-3H]-F 2CDP.
The inactivation mixture contained final concentrations of a, P', 1.2 [M; [5- 3H]-F 2CDP,
1.2 [IM, 3mM ATP, 5mM DTT. Subsequent to removal of the protein from the small
molecules by YM3 centricon and removal of the phosphates with alkaline phosphatase,
the filtrate was injected into an Altech Adsorbosphere Nucleotide Nucleoside C-18
column at a flow rate of lmL/min. The elution buffer contained: Buffer A, 10 mM
NH40Ac, pH 6.8; Buffer B: 100% methanol. A 10 min isocratic elution was followed by
a linear gradient to 40% B over 30 min. The elution profile monitored by A267nm (-) and
scintillation counting (0). Cytosine (0.65 eq.) was released and 1.35 eq. of F2C was
recovered.
4.3.4 Analysis of the inactivation mixture of wt and C218S-a by SDS PAGE without
boiling
Our recent studies with E. coli RNR and L. leichmannii RNR revealed that when
the enzyme inactivated with the inhibitor was analyzed by an SDS PAGE gel without
boiling, 30 to 50% of a present migrated as a larger species (-1 10 kDa for E. coli and 110
kDa for L. leichmannii) (23, 35). The a with the aberrant migratory properties is likely
associated with the covalently bound sugar moiety from F2CDP. To determine if the
substoichiometric labeling of hRNR, both P' and 0, was accompanied by production of a
modified a, the reaction mixture subsequent to inactivation was analyzed directly without
boiling by SDS PAGE (Figure 4.4). It was observed that 24% (40%) and 33% of the a
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migrated as a larger species (-120 kDa) with P' and hp, respectively. This number in each
case corresponds roughly to the amount of covalently bound sugar. With all RNRs
examined to date, even the monomeric adenosylcobalamin RNR, production of an a with
altered migratory properties that is associated with covalent modification by the sugar
moiety of F2CD(T)P occurs.
The same experiment was repeated with C218S of which protein and the results
are also shown in Figure 4.4 (Lane 8-13). With this mutant no altered conformation of ca
is observed suggesting that this residue may play an important role in its production. A
proposal for these observations is presented subsequently.
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100
100 as
75 75
50
50 37
3377
DTT +++- -- + + - DTT +++- -- + - - -+
P-ME ++-++- + + -++ - -ME ++-++- + + ++ +
Boiling + - - + - - + - - + - - Boiling + - - + - - + - - +
Figure 4.4: SDS-PAGE analysis of the inactivation mixture.
SDS-PAGE analysis of (A) the a/p' (6 pM) and (B) the a/P (6 [M), inactivated by F2CDP
(30 jM) and ATP (3 mM) at 37 'C for 5 min. Each sample was mixed with 2x loading
buffer + 3-ME or boiling for 2 min before loading as indicated. A band at 120 kDa is
observed in Lanes 2, 3 (inactivation in the presence of DTT, without boiling) and Lanes 5,
6 (inactivation in the absence of DTT, without boiling).
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4.3.5 Identification of potential sites of covalent modification of human RNR
inactivated by [1'- 3H] F2CDP using site directed mutants of important residues in a
involved in catalysis
The recent studies in our lab with L. leichmannii RTPR have established that 10%
of the label associated with RNR subsequent to inactivation by [1'- 3H]-F 2CTP is due to
alkylation of the sugar of the nucleotide by both cysteines at the C-terminus of the protein
(23). All efforts to identify the major labeled species failed, due to instability and
rearrangement, even when NaBH4 was used to stabilize the alkyated protein.
Furthermore, studies with the C225S mutant of E. coli RNR, suggested that this residue
plays a key role in covalent modification of the enzyme by F2CDP (35). To identify the
site of covalent modification by the sugar derived from F2CDP, [1 '-3H] F2CDP was
incubated with active site mutants of human c: C429S/A, E431 Q/D, C787S/A, C790S/A,
C444S/A, C218S/A (the equivalent of C225 in E. coli) and with P or P' in the presence of
DTT. Each mutant was purified as described for wt-a with similar recovery. The extent
of covalent labeling measured subsequent to Sephadex G50 chromatograpy (in the
absence of denaturant) was determined by scintillation counting and compared to the
labeling of wt-RNR. The results are summarized in Table 4.3.
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Table 4.3: Quantitation of sugar label covalently attached
incubated with [1'- 3H]-F 2CDP.
a: In parenthesis, the equivalent residues of E.
b: In parenthesis, the values are normalized to
coli RNR are given.
1 Y/ 3'2.
As expected no label was associated with RNR when the radical initiator on a
(C429), essential for removal of the 3'-H for any mechanism based inhibitor, was
changed to S or A. Two other mutants E431Q/D-a and C218S/A-a also showed no
labeling. The E431 mutant is likely not labeled as this glutamate plays an important role
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to human RNR mutants
labeling/ a2 (with P'2) labeling/ a2 (with 02)
wt a 0.5 (0.8)b 0.8-0.9
C429S-a (C439)a 0 0.008
C429A-a (C439) 0 0.01
E431Q-a (E441) 0 0.01
E431D-a (E441) 0 0.08
C787S-a (C754) 0.3 (0.5) 0.8
C787A- (C754) 0.26 (0.4) 0.3
C790S-a (C759) 0.3 (0.5) 0.6
C790A-a (C759) 0 0.1
C444S-a (C462) 0.03 (0.05) 0.4
C444A-a (C462) 0.2 (0.3) 0.7
C218S-a (C225) 0 0.1
C218A-a (C225) 0 0.1
Y138F- P' (Y122) 0
(although not essential role) in the first two steps of the reduction process by removal of
proton from the 3'-OH of F2CDP. Thus the rate of chemistry on any nucleotide is likely to
be greatly reduced when the E is changed to a Q/D. In addition a recent structure of the S.
cerevisiae c soaked with F2CDP (Figure 4.5) showed that E431 is 6.2 A from the 3'- HO
of the sugar and that a water molecule intervenes (36). Thus, it is unlikely that this E is
the site of labeling.
C428
4 E430
N426
Figure 4.5: The yeast
bound.
T" J SI er217
Ser217
C.218 E430 C218
N426
C443 0 C21
C443
RNR active site structures with F2CDP (left) or CDP (right)
C225 on E. coli a, on the other hand has been implicated as playing a key role in
the inactivation pathway involving covalent modification of the E. coli RNR (35). Our
previous studies with the C225S mutant of E. coli have demonstrated that first few steps
in catalysis are not impaired by this mutation (37, 38). Thus lack of labeling with
C218S/A-ha, make this a likely candidate for alkylation. Consistent with this proposal,
the S. cerevisiae structure (Figure 4.5) shows that this is the only nucleophilic residue
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close to the sugar (36). The caveat is however, that the other subunit essential for
catalysis is missing in the structure. Thus our favored model is that C218 is covalently
modified by a sugar moiety derived from F2CDP. In line with this proposal, the SDS
PAGE gel (Figure 4.4), revealed that with the C218S-a mutant and either hp or P', that no
ca with modified migratory properties is observed.
The C-terminal tail mutants of ac, C787S/A and C790S/A retain variable amounts
of label associated with hRNR (with either P or P'). These cysteines are involved in re-
reduction of the active site disulfide generated during the synthesis of dNDP (39). This C
terminus must be able to enter the active site to reduce the disulfide between C218 and
C444 and then must swing out of the active site to react with the protein reductant
thioredoxin. The variability in labeling suggests that one of these cysteines, may be
involved in covalent interaction with the sugar moiety as well. Labeling of the active site
C218 and a C (787 or 790) in the tail might give rise to the observed conformational
change found by SDS PAGE (Figure 4.4).
4.3.6 SEC to examine the quaternary structure of hRNR (with p') inactivated by
F2CDP
Our previous studies have shown that a tight a66 complex was generated when
human RNR was inactivated by F2CDP (a232 in the case of E. coli). The studies
presented herein revealed that modification of the enzyme with 0.5 eq. of F2CDP in the
presence of reductants precluded any subsequent turnovers, and left the enzyme in an
intermediate state with significantly enhanced interaction between the subunits. To
examine the quaternary structure of atn(' 2 )m subsequent to inactivation with [1 '-3H]-
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F2CDP, the inactivated complex was examined by SEC with 0.5 mM ATP in the elution
buffer. The A 280nm revealed protein elution at 18.6 min and at 25.6 min (Figure 4.6).
Comparison of the retention times with a standard curve generated with globular proteins
of known molecular weight (Figure 4.7) suggested that the peak eluting at 18.6 min
exhibits a mass more consistent with a6p'6 than a6p'2 (798 vs 633 kDa). Control
experiments with a (88 kDa), a2 (189 kDa with TTP), 3'2 (116 kDa) (Table 4.4 and
Figure 4.8) suggest that the peak eluting at 25.6 min may be composed of P'2 and a.
Each fraction was examined by SDS-PAGE with the amount of a and P' determined from
a standard curve made with known concentrations of E. coli a and 3 (Figure 4.9).
Analysis of protein in fractions 18, 19 and 20, gave a ratio of a: P' as 1.2, 1.0, 1.0
respectively and respectively 1; an average of 1.06 ± 0.15 (Figure 4.6B, C). This analysis
supports the formation of an a6f' 6 complex in the presence of F2CDP and ATP. Each
fraction was also analyzed for radioactivity and fractions 18 and 19 contained 0.57 and
0.54 labels/a2 respectively.
As discussed above, P'2 contains only 0.6 Ye and thus gives rise to protein that
does not form a complex. The relative amounts of the two peaks support the proposal that
the percentage of active quaternary structure correlates with the amount of the Y-.
Together with the observations of 0.5 eq. sugar/a2 attached, and 0.6 eq. cytosine released
after inactivation, these results support a model where 1 eq. of F2CDP inactivates the two
active sites of a2 by enhancing subunit interactions.
Given the poor resolution of the SEC method, a second control experiment was
carried out under identical conditions to those described above in the absence of F2CDP
(Figure 4.6D). The mixture, analyzed by SEC gave two protein peaks: one with a
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retention time of 20.9 min and an apparent molecular weight of 543 kDa and the second
with a retention time of 26.2 min and an apparent molecular weight of 109 kDa. The
SDS-PAGE analysis of the first peak showed only the presence of a, which correspond to
a6 , and the second peak showed the presence of both a and 0' corresponding to a2 and
P'2 based on the apparent MW (Table 4.4).
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Figure 4.6: SEC on a S200 column to detect complex formation after human p53R2
a is inactivated by [1'-3H] F2CDP.
The inactivation mixture contained final concentrations of a, P', 15 pM; [1'- 3H]-F 2CDP
37.5 pM; ATP, 3mM; DTT, 5mM. The elution buffer contained 0.5 mM ATP. A, the
elution profile monitored by A280nm and scintillation counting (I).The first peak has a
retention time of 18.6 min, with apparent molecular weight of 794 kDa; The second peak
has a retention time of 25.6min with apparent molecular weight of 116 kDa (a, 02'
coelute); B, analysis of the ratio of a:3 (-), using standard curves generated from known
amounts of E. coli a and p; C, SDS PAGE of 8 [L from fractions 18-20 part A
monitored by SDS PAGE; D, A control in the absence of F2CDP. The first protein peak
has a retention time of 20.9 min and an apparent molecular weight of 543 kDa; The
second protein peak has a retention time of 26.2 min with apparent molecular weight of
109 kDa.
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Figure 4.7: Gel filtration molecular weight standards (GE healthcare).
Ovalbumin, 43 kDa; conalbumin, 75 kDa; aldolase, 158 kDa; catalase 232 KDa; ferritin,
440 kDa; thyroglobulin, 669 kDa; and blue dextran, 2000 kDa (* from left to right).
Table 4.4: Molecular weight determination of inactivated hRNR by SEC.
Protein Apparent Retention Expected Oligomeric
(effector) mass (kDa) time (min) mass (kDa) state
3' 116 26 81 3'2
a 88 25.6a 92 a
human a (100gM TTP) 189 24a 184 a2
RNR a, 3' (ATP) 543, 109 20.9,26.2 552, a6, a2, 3'2
184, 81
a, 0' inactivated 794, 18.6, 798 a6'6
by F2CDP 116 25.6 complex b
a, Y138F-P' 389-712, 20-22.5 184, 81 a6p'2, a6
inactivated 88 26.9 a2, 3'2
by F2CDP
a. Superose 12 column was used.
b. Un-reacted a2, 3'2 also present.
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Figure 4.8. SEC of a control with P'2, a and a2 with TTP.
(A) P'2 (81 kDa) migrates at 26 min with an apparent MW 116 kDa. A S200 column (GE
healthcare) was used. (B) c (25 mM DTT). The first peak elutes at 21.7 min is a
contaminant that co-purifies with a, the second protein elutes at 25.6 min, with apparent
MW 88 kD. (C) a2 (100 gM TTP). The protein peak that elutes at 22 min is the
contaminant that co-purifies with a. The second protein elutes at 24 min with an apparent
MW 189 kD. Superose 12 column was used in (B) and (C).
1 2 34 56 7
75kD
50kD
37kD
Figure 4.9. E. coli a and p (0.05- 0.4 pM) standards at different concentrations
analyzed by SDS-PAGE to determine the ratio of a, p' in Figure 4.6B and Figure
4.10.
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4.3.7 An additional control: SEC to examine the quaternary structure of hRNRs
with Y138F-p' in the presence of F2CDP and ATP
To gain further insight into the quaternary structure of hRNR without covalent
modification in the presence of F2CDP, Y138F-P' in which the essential Y- of 3'2 was
replaced with an F, was studied. The reaction mixture was identical to that described
above except that Y138F-P' replaced wt-P'. Analysis of the reaction mixture by SEC
showed that a small portion of protein migrated between 20-22.5 min, with an apparent
MW ranging from 389-712 kDa followed by a second protein peak with a retention time
at 26.9 min and an apparent MW of 88 kDa (Figure 4.10, Table 4.4). No radioactivity
eluted with either peak when [1'- 3H] F2CDP was used. SDS-PAGE analysis revealed that
both a and P' were present in the peak that eluted at 20-22.5 min, but the ratio of a: 3' is
much higher than 1 (within the range 5.8-9.1) by comparison with standards (Figure 4.9).
The results suggest a complex equilibrium between nucleotide analog/ATP and subunits,
consistent with the existence of a6P2, a6 and other species.
(A) (B) Fraction
0.075
a
o 0.035
-0.005, Y1 38F-3'
15 20 25 30
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Figure 4.10. SEC on a S200 column to detect complex formation with human
Y138F- P'/a incubated with [1'-3H] F2CDP.
The inactivation mixture contained final concentrations of a, P', 15 gM; [1'-3H]-F 2CDP
37.5[tM; ATP, 3mM; DTT, 5mM. The elution buffer contains 0.5 mM ATP. A, the
elution profile monitored by A280nm and scintillation counting. The first peak is very
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broad and has a retention time from 20-22.5 min with apparent molecular weights
ranging from 389-712 kDa; The second protein peak has a retention time of 26.9 min,
with apparent molecular weight of 88 kDa. Neither of these peaks contained radioactivity;
B, fractions 20-23 from the first protein peak in A were monitored by 10% SDS PAGE.
4.4 Discussion:
The mechanism of inactivation of RNRs by F2CDP is obviously very complex.
However, despite this complexity, the RNRs from E. coli, L. leichmannii and the two
RNRs from humans share common and mechanistically/structurally informative features.
Stoichiometric amounts of inhibitor are sufficient for complete inactivation (13, 40). In
the case of the class I RNRs, this inhibition prevents the second a/p pair from reaction
because of the tight and unusual subunit interactions (13). In all cases, the protein
becomes covalently modified in a chemically fragile state by a sugar moiety generated
from F2CDP and the cofactor (Y- or adenosylcobalamin) is partially inactivated. In all
cases, if one waits long enough, two fluoride ions and one cytosine are released, requiring
ketone formation at the C3' position of the nucleotide during the inactivation process.
Unexpectedly, the a subunit is observed to have two conformations in about an
approximately 1:1 ratio on SDS PAGE analysis in the absence of heat. Mutagenesis
studies suggest that the second conformation is likely the result of a crosslink between a
cysteine in the C-terminus of a and its active site C218, directly involved in water loss in
the normal reduction process. The key to the function of RNR is understanding the
gymnastics of the structurally floppy, and thus structurally inaccessible, C-termini of f
and C-termini of a.
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From our present observations information about the subunit
architecture/interactions result. The altered a is likely to be formed from an
intramolecular crosslink, rather than a cross-link from the C-terminus of the adjacent a in
the a2 dimer. If the crosslink were intermolecular, a should migrate on the SDS PAGE
gel as a dimer and would likely be sensitive to P-ME treatment. Re-reduction of the
active site disulfide in one a, by the C-terminal tail of the second a in the a2 complex
had previously been suggested by pre-steady state in vitro studies on E. coli RNR by
Ericksson (41) and in vivo studies of S. cerevisiae RNR by Huang and coworkers (42).
Our previous pre-steady state experiments (43) with mutations of the C-terminal
cysteines were not inconsistent with the Ericksson proposal. In the Huang studies, the
kinetics of re-reduction of the active site disulfide are not measured due to the in vivo
nature of the experiments. We have previously shown that the two cysteines in the C-
terminal tail of E. coli RNR can function as a thioredoxin and this observation is also
likely to be applicable to the S. cerevisiae RNR and could account for their in vivo results
(39).
A second observation of interest is that the C-terminus of a, must have access to
the active site of the same a, while P remains bound. If our interpretation of the altered
migratory properties of a is correct, a recent structure of a complex of a class Ib RNR
from Salmonella typhimurium at 4.5 A resolution may be informative in the regard (44).
In this structure, the two subunits are present with a 360 A2 interface. The interface
however, is very informative with respect to the function of the C-termini of each subunit.
One can observe the end of p (residue 285), a gap of 20 amino acids and the last eleven
amino acids of p bound in a hydrophobic patch formed by 3 helices (a 10, cI and aD)
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within a. One can also locate the C-terminus (residue 699 missing the last 15 amino acids)
of a within the structure and its position relative to p. One P is interacting with one a in
a fashion that with tightening could align the radical transfer pathway between the two
subunits in a chemically competent fashion. In this ap the active site cysteines are
oxidized and some electron density exists for the ADP substrate. The second a has no
substrate bound and no contact with the second 3. Examination of the locations of the C-
termini of the subunits suggest that the tails of a and P could be intertwined and that
complete dissociation of the subunits might require a push from an interaction with a
second a2 interacting with the dangling 32. This model would be consistent with the
kinetics of inactivation by F2CDP in all the class I RNRs where a 1:1 complex of
subunits is inactive, while assaying for activity of one subunit in the presence of an
excess of the other subunit leads to some recovery of P2 activity as all the Y* has not
been destroyed. This type of displacement could account for the biphasic nature of the
inactivation process (Figure 1).
Uhlin has suggested that the structure of the class Ib RNR complex is a snapshot
of one of the steps during the RNR mediated reduction: either an initial step in subunit
interaction or a final step after the reduction process. The unusual conformation of a in
the F2CDP inactivated RNR complex suggests that it might be trapping the enzyme in an
asymmetrical configuration as well. The tight interaction between the subunits
subsequent to inactivation by F2CDP suggests that crystallization of the complex may be
possible. Recently we have obtained crystals of the E. coli RNR that diffract to 6 A
resolution (Stock, Drennan, unpublished work). Obviously higher resolution structures
are essential to figure out the key role of the tails of the subunits in the mechanism of
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ribonucleotide reduction. Despite the absence of molecular understanding, our studies
suggest that both human RNRs can be targeted by F2CDP, and that the consequences of
inactivation may differ depending on growth conditions.
4.5 Reference
(1) Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C.,
and Grindey, G. B. (1990) Evaluation of the antitumor-activity of gemcitabine
(2',2'-difluoro-2'-deoxycytidine). Cancer Res. 50, 4417-4422.
(2) Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. (1991)
Action of 2',2'-difluorodeoxycytidine on DNA-synthesis. Cancer res. 51, 6110-
6117.
(3) Plunkett, W., Huang, P., and Gandhi, V. (1997) Gemcitabine: actions and
interactions. Nucleosides & Nucleotides 16, 1261-1270.
(4) Rivera, F., L6pez-Tarruella, S., Vega-Villegas, M. E., and Salcedo, M. (2009)
Treatment of advanced pancreatic cancer: from gemcitabine single agent to
combinations and targeted therapy. Cancer Treat Rev. 35, 335-339.
(5) Danesi, R., Altavilla, G., Giovannetti, E., and Rosell, R. (2009)
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid
tumors. Pharmacogenomics 10, 69-80.
(6) Bergman, A. M., Pinedo, H. M., and Peters, G. J. (2002) Determinants of
resistance to 2 ',2 '-difluorodeoxycytidine (gemcitabine). Drug Resistance
Updates 5, 19-33.
(7) Kashlan, O. B., Cooperman, B. S. (2003) Comprehensive model for allosteric
regulation of mammalian ribonucleotide reductase: refinements and consequences.
Biochemistry 42, 1696-1706.
(8) Rofougaran, R., Vodnala, M., and Hofer, A. (2006) Enzymatically active
mammalian ribonucleotide reductase exists primarily as an alpha(6)beta(2)
octamer. J. Biol. Chem. 281, 27705-27711.
(9) Stubbe, J., van der Donk WA. (1998) Protein radicals in enzyme catalysis. Chem.
Rev. 98, 705-762.
(10) Larsson, A., and Sjoberg, B. M. (1986) Identification of the stable free-radical
tyrosine residue in ribonucleotide reductase. EMBO J. 5, 2037-2040.
(11) Sj6berg, B. M., Reichard, P. (1977) Nature of Free-Radical in Ribonucleotide
Reductase from Escherichia-Coli. J. Biol. Chem. 252, 536-541.
(12) Sjbiberg, B. M., Reichard, P., Griislund, A., Ehrenberg, A. (1978) The tyrosine
free radical in ribonucleotide reductase from Escherichia coli. J. Biol. Chem. 253,
6863-6865.
184
(13) Wang, J., Lohman, G. J., and Stubbe, J. (2007) Enhanced subunit interactions
with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. Proc. Natl.
Acad. Sci. USA. 104, 14324-14329.
(14) Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K.,
Takei, Y. and Nakamura, Y. (2000) A ribonucleotide reductase gene involved in a
p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49.
(15) Nakano, K., Balint, E., Ashcroft, M., and Vousden, K.H. (2000) A ribonucleotide
reductase gene is a transcriptional target of p53 and p73. Oncogene 19, 4283-4289.
(16) Pontarin, G., Fijolek, A., Pizzo, P., Ferraro, P., Rampazzo, C., Pozzan, T.,
Thelander, L., Reichard, P. A., and Bianchi, V. (2008) Ribonucleotide reduction
is a cytosolic process in mammalian cells independently of DNA damage. Proc.
Natl. Acad. Sci. US.A. 105, 17801-17806.
(17) Yamaguchi, T., Matsuda, K., Saqiya, Y., Iwadate, M., Fujino, M. A., Nakamura,
Y., Arakawa, H. (2001) p53R2-dependent pathway for DNA synthesis in a p53-
regulated cell cycle checkpoint. Cancer Res. 61, 8256-8262.
(18) Bourdon, A., Minai, L., Serre, V., Jais, J., Sarzi, E., Aubert, S., Chretien, D.,
Lonlay, P., Paquis-fluckinger, V., Arakawa, H., Nakamura, Y., Munnich, A. and
Rtig, A. (2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide
reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 39,
776-780.
(19) Chang, L., Zhou, B., Hu, S., Guo, R., Liu, X., Jones, SN., and Yen, Y. (2008)
ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase
small subunit p53R2 protein against MDM2 to DNA damage. Proc. Natl. Acad.
Sci. U.S.A. 105, 18519-18524.
(20) Piao, C., Jin, M., Kim, HB., Lee, SM., Amatya, PN., Hyun, JW., Chang, IY., and
You, HJ. (2009) Ribonucleotide reductase small subunit p53R2 suppresses MEK-
EPK activity by binding to ERK kinase 2. Oncogene 28, 2173-2184.
(21) Shao, J. M., Zhou, B. S., Zhu, L. J., Qiu, W. H., Yuan, Y. C., Xi, B. X., and Yen,
Y. (2004) In vitro characterization of enzymatic properties and inhibition of the
p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64, 1-6.
(22) Liu, X., Xue, L., and Yen, Y. (2008) Redox property of ribonucleotide reductase
small subunit M2 and p53R2. Methods Mol Biol. 477, 195-206.
(23) Lohman, G. J. S., Stubbe, J. (2009) manuscript in preparation.
(24) Silva, D. J., Stubbe, J., Samano, V., and Robins, M. J. (1998) Gemcitabine 5 '-
triphosphate is a stoichiometric mechanism-based inhibitor of Lactobacillus
leichmannii ribonucleoside triphosphate reductase: Evidence for thiyl radical-
mediated nucleotide radical formation. Biochemistry 37, 5528-5535.
(25) Stubbe, J., van der Donk WA. (1995) Ribonucleotide reductases: radical enzymes
with suicidal tendencies. Chem. Biol. 12, 793-801.
(26) Wang, X., Zhenchuk, A., Wiman, K. G., and Albertioni, F. (2009) Regulation of
p53R2 and its role as potential target for cancer therapy. Cancer Lett. 276, 1-7.
(27) Guittet, O., HAkansson, P., Voevodskaya, N., Fridd, S., Grislund, A., Arakawa,
H., Nakamura, Y., Thelander, L. (2001) Mammalian p53R2 protein forms an
active ribonucleotide reductase in vitro with the RI protein, which is expressed
both in resting cells in response to DNA damage and in proliferating cells. J. Biol.
Chem. 276, 40647-40651.
185
(28) Lunn, C. A., Kathju, S., Wallace, B. J., Kushner, S. R., Pigiet, V. (1984)
Amplification and purification of plasmid-encoded thioredoxin from Escherichia-
Coli-K12. J Biol. Chem. 259, 469-474.
(29) Russel, M., and Model, P. (1985) Direct Cloning of the Trxb Gene That Encodes
Thioredoxin Reductase. J Bacteriol. 163, 238-242.
(30) Berglund, 0., and Eckstein, F. (1974) ATP- and dATP-substituted agaroses and
the purification of ribonucleotide reductases. Methods Enzymol. 34, 253-261.
(31) Perlstein, D. L., Ge, J., Ortigosa, A. D., Robblee, J. H., Zhang, Z., Huang, M., and
Stubbe, J. (2005) The active form of the Saccharomyces cerevisiae ribonucleotide
reductase small subunit is a heterodimer in vitro and in vivo. Biochemistry 44,
15366-15377.
(32) Steeper, J. R., Steuart, C.C. (1970) A rapid assay for CDP reductase activity in
mammalian cell extracts. Anal. Biochem. 34, 123-130.
(33) Ortigosa, A. D., Hristova, D., Perlstein, D. L., Zhang, Z., Huang, M. X., and
Stubbe, J. (2006) Determination of the in vivo stoichiometry of tyrosyl radical per
beta beta' in Saccharomyces cerevisiae ribonucleotide reductase. Biochemistry 45,
12282-12294.
(34) Hristova, D., Wu, C. H., Jiang, W., Krebs, C., and Stubbe, J. (2008) Importance
of the maintenance pathway in the regulation of the activity of Escherichia coli
ribonucleotide reductase. Biochemistry 47, 3989-3999.
(35) Artin, E., Wang, J., Lohman, G., Yu, G., Griffin, G., Barr, G., and Stubbe, J.
(2009) Insight into the mechanism of inactivation of ribonucleotide reductase by
gemcitabine 5'-diphosphate in the presence and absence of reductant. submitted to
Biochemistry.
(36) Xu H, F., C., Uchiki, T., Racca, J. & Dealwis, C. (2006) Structures of eukaryotic
ribonucleotide reductase I define gemcitabine diphosphate binding and subunit
assembly. Proc. Natl. Acad Sci. U.S.A. 103, 4028-4033.
(37) Mao, S. S., Johnston, M. I., Bollinger, J. M., and Stubbe, J. (1989) Mechanism-
based inhibition of a mutant escherichia-coli ribonucleotide reductase (cysteine-
225-serine) by its substrate CDP. Proc. Natl. Acad. Sci. U.S.A. 86, 1485-1489.
(38) Mao, S. S., Holler, T. P., Bollinger, J. M. Jr, Yu, G. X., Johnston, M. I., and
Stubbe, J. (1992) Interaction of C225SR1 mutant subunit of ribonucleotide
reductase with R2 and nucleoside diphosphates: tales of a suicidal enzyme.
Biochemistry 31, 9744-9751.
(39) Mao, S. S., Holler, T. P., Yu, G. X., Bollinger, J. M., Booker, S., Johnston, M. I.,
and Stubbe, J. (1992) A Model for the role of multiple cysteine residues involved
in ribonucleotide reduction - amazing and still confusing. Biochemistry 31, 9733-
9743.
(40) van der Donk, W. A., Yu, G. X., Perez, L., Sanchez, R. J., Stubbe, J., Samano, V.,
and Robins, M. J. (1998) Detection of a new substrate-derived radical during
inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5 '-
diphosphate. Biochemistry 37, 6419-6426.
(41) Eriksson, H. K. (2001) Kinetics in the pre-steady state of the formation of cystines
in ribonucleoside diphosphate reductase: evidence for an asymmetric complex.
Biochemistry 40, 9631-9637.
186
(42) Zhang, Z., Yang, K., Chen, C., Feser, J., and Huang, M. (2007) Role of the C
terminus of the ribonucleotide reductase large subunit in enzyme regeneration and
its inhibition by Smll. Proc. Natl. Acad. Sci. U.S.A. 104, 2217-2222.
(43) Ge, J., Yu, G. X., Ator, M.A., and Stubbe, J. (2003) Pre-steady-state and steady-
state kinetic analysis of E-coli class I ribonucleotide reductase. Biochemistry 42,
10071-10083.
(44) Uppsten, M., Firnegairdh, M., Domkin, V., and Uhlin, U. (2006) The first
holocomplex structure of ribonucleotide reductase gives new insight into its
mechanism of action. J Mol. Biol. 359, 365-377.
(45) Lawrence, C. C., Bennati, M., Obias, H. V., Bar, G., Griffin, R. G., Stubbe, J.
(1999) High-field EPR detection of a disulfide radical anion in the reduction of
cytidine 5'-diphosphate by the E441Q R1 mutant of Escherichia coli
ribonucleotide reductase. Proc. Natl. Acad. Sci. USA. 96, 8979-8984.
187
Chapter 5
Efforts to Understand Smll Inhibition of S. cerevisiae RNR
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5.1 Introduction:
Smll, a suppressor of MEC1 lethality, was discovered by Rothstein and
coworkers from a genetic screen as an inhibitor of ribonucleotide reductase (RNR) in S.
cerevisiae (1). The deletion of Smll displayed a similar phenotype as over-expression of
the RNR large subunit RNR1 (a), and could restore cell viability in the Mecl and Rad53
deletion strains. RNR catalyzes the reduction of all four ribonucleotides to the
corresponding deoxyribonucleotides and is essential in DNA biosynthesis and DNA
repair in all organisms (2-4). It is tightly regulated in cells to keep balanced dNTP pools
for DNA replication and repair. Yeast two-hybrid assays, co-immunoprecipitation
experiments, and biochemical studies revealed that Smll regulates RNR by binding
directly to a to repress RNR activity, rather than by controlling its transcription (1). The
binding of Smll to a is proposed to block the reduction of the active site disulfide formed
concomitant with dNTP production, leaving a in the oxidized, inactive state (5). In this
study, fluorescent probes were incorporated site-specifically into several positions in
Smll. The resulting Smll mutants were used to investigate the model proposed for
Smll's inhibition of S. cerevisiae RNR.
Smll is a small, dimeric protein composed of 104 amino acids. No crystal
structure of Smll has been solved thus far. The 2D NMR studies however have revealed
that Smll contains a loosely folded structure with two a helices located between residues
4-14 and residues 61-80 (Figure 5.1) (6-8). The N-terminal (residues 8-20) of Smll are
proposed to be responsible for its dimerization (9), while the C-terminal Smll mutants
(R72G/R72A, L73P/L73A, S75P, I76T, S87P, F94S and F104L) were found to disrupt
the interaction of Smll and a (7). All of these mutations are found in the last 33 amino
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acids residing in the C-terminus, suggesting that the C-terminal tail of Smll is a key
region for binding to a (10). The Smll-a interaction has been demonstrated by in vitro
surface plasmon resonance method to have a Kd equal to 0.4 pM (11). A second method
used to examine a-Smll interaction was sucrose gradient centrifugation. Using this
method, a was found to sediment as a2 and a4. SDS-PAGE analysis revealed that Smll
sedimented with a2 but not with a4. Chabes et al further demonstrated that Smll binding
does not affect a binding to pp' (11). The expression level of Smll is regulated by Dunl
phosphorylation via MEC1/RAD53 checkpoint pathway in response to both cell cycle and
DNA damage. Phosphorylation of Smll results in its rapid degradation. Thus the
concentration of Smll is at its lowest level during the S phase of the cell cycle and is
almost undetectable after DNA damage (12, 13). The phosphorylation sites were
determined to be Ser56, Ser58, and Ser60 on the linker region between the two helices by
Mass spectrometry and mutagenesis analysis in vitro (6).
From extensive mutagenesis and two-hybrid assay screens, only one a mutant
(W688G) was identified that could not only bind to wt Smll, but also restore interactions
with Smll mutants which previously failed to bind wt a (10). W688 and E689 of a are
highly conserved from bacteria to human RNR. In vivo studies carried out by Zhang, et al
revealed that a-W688A E689D could increase the affinity of a to Smll and cause Smll-
dependent lethality (5, 10). Moreover, a truncated from 779-888 and including
W688/E689D has demonstrated an enhanced binding with Smll, and reduced interaction
to the tail region of the a C-terminal domain (CTD, residues 765-888).
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Figure 5.1: A molecular model of yeast Smll (6).
The model was constructed based on 2D-NMR analysis. The overall structure of Smll is
unfolded with two a helices at the N- and C-terminus oriented in anti-parallel fashion.
The model shows the proposed phosphorylation sites of Smll are Ser 56, Ser 58 and Ser
60, which are solvent exposed. S61 and M80 are the sites to which and DAN is attached.
NTD CTD
N- CI CX2 C -C
1 778,779 880 888
Scheme 5.1: Substitution and deletions constructs of S. cerevisiae RNRI.
Based on studies of E. coli RNR, the pair of redox active cysteines (C218/C443 of
S. cerevisiae) in the active site of a are oxidized concomitant with substrate reduction
(14). Another pair of cysteines (C883/C886) on the C-terminal tail of a is required to
regenerate the active site cysteines via disulfide exchange (14-16). With yeast, this role of
the C-terminal cysteines has not been demonstrated. Recently, in vivo studies in S.
cerevisiae have revealed that the tail of one a can enter into the active site of its
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neighboring a and re-reduce the active site disulfide (Figure 5.2 a-d) (5). Evidence led to
the model that Smll inactivates a by preventing the C-terminal tail of a to access the
active site (Figure 5.2 e) is supported by the observations that Smll displayed stronger
interaction with the N-terminal domain of a (residues 1-778), than the full length a by
yeast two-hybrid assays. Thus Smll was proposed to behave as an uncompetitive
inhibitor relative to the substrate, that is, it binds to the oxidized form in preference to the
reduced form.
H
S
Riox (inactive)
cxxc
Rlre (active)
Figure 5.2: A model for the role of the a C-terminal tail in regeneration of the
reduced form of a and inhibition by Smll (5).
(a) a is oxidized concomitant with substrate reduction. (b) The C-terminal tail of one a
enters into the active site of the neighboring a and reduces the active site disulfide by
disulfide interchange. (c) A reduced form of a is generated. The active site cysteine pair
is reduced while the CX2C motif at the C-terminus tail forms a disulfide (d) The disulfide
on the tail is reduced by thioredoxin or glutaredoxin (e) Smll competes with the C-
terminal tail of a to prevent regeneration of active cysteines (Adapted from reference(5)).
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In our study, an environmental sensitive fluorescence probe, BADAN was
attached site-specifically to Sml and used to measure and compare the affinities between
Smll to the oxidized and the reduced forms of a. With DAN modification at residue 61,
we obtained a similar Kd value to that determined by Thelander using surface plasmon
resonance method (SPR), and demonstrated that Smll has a stronger interaction with
oxidized a than reduced a. Inhibition studies of CDP reduction by Smll have also been
carried out in an effort to obtain evidence for Smll biding to oxidized and/or reduced a.
The detailed mechanism of inactivation of a and its stoichiometry of interaction
still remain unresolved. Based on 2D NMR studies and the genetic studies, we proposed
that a hydrophobic patch on the C-terminal tail of Smll is the binding site to a. The data
from our inactivation assays and fluorescence measurements with four DAN modified
Smlls agree with our hydrophobic binding model, and support the proposal that the C-
terminal tail of Smll plays a key role in the Smll-a interaction. We have also isolated
W688A-a, E689D-a, and W688A E689D-a mutants, and verified their increased
interaction with Smll. However, activity assays revealed significant loss of activity
associated with the W mutation, suggesting that low activity of a part of the reason for
the Smll-dependent lethality in previous studies.
5.2 Methods
5.2.1 Materials
Competent E. coli BL 21 (DE3) RIL codon plus cells were purchased from
Stratagene. Complete EDTA-free protease inhibitor tablets and calf alkaline phosphatase
(20 U/tL) were purchased from Roche Biochemicals (Indianapolis, IN). 6-Bromoacetyl-
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2-dimethylaminonaphthalene (BADAN) was purchased from Molecular Probes (Eugene,
OR). 5, 5'-Dithio-bis(2-nitrobenzoic acid) (DTNB) was purchased from Sigma (St. Louis,
MO). Isopropyl-1 -thio-p3-D-galactopyranoside (IPTG) and 1, 4-dithiothreitol (DTT) were
from Promega (Madison, WI). Ultrafiltration membranes (YM30) were from Millipore
(Bedford, MA). The dATP-Sepharose resin was synthesized by members of the Stubbe
group (17). Protein concentrations were determined using extinction coefficients (C280 nm)
per monomer [52,800 M' cm -1 for (His)-P, 47,000 M' cm 1 for P', 119,945 M-1 cm -1 for
a] and for pp' heterodimer, 99,800 M 1 cm-1. The plasmid containing W688A E689D
mrnrl double mutant was provided by Prof. M. Huang (University of Colorado Health
Sciences Center). The W688A, E689D mrnrl single mutants were constructed by site
directed mutagenesis using a Quick Change Kit by Stratagene. The plasmid sequences
were confirmed at the MIT Biopolymer lab. E. coli TR (specific activity of 40 U/mg) (18)
and TR reductase (specific activity of 1320 U/mg) (19) were isolated as previously
described.
5.2.2 Expression and purification of wt a, W688A-a, E689D-a single mutants, and
W688A E689D-a double mutants
The plasmids containing the genes for rnrl and mutants were transformed into
BL21 (DE3) CodonPlus RIL cells and plated on LB agar plates with 30 tg/L
chloramphenicol (CM), 75 [g/L kanamycin (Kan). A single colony was selected to
inoculate a 5 mL LB culture with 30 tg /L CM and 75 ig /L Kan. Overnight to saturation.
The culture was grown at 37 'C and then added to 2 L LB in 6 L flasks and grown until
OD 600 reaches 0.6-0.8. The temperature was then cooled to 15 oC, and IPTG (final
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concentration 0.5 mM) was added to induce expression of rnrl and cells were grown for
an additional 16 h. Typically 5 g of cell paste/L culture were obtained.
The purification was carried out at 4 oC. The procedures for a and a mutants were
identical. Ten g of cells were suspended in 50 mL 50 mM Tris-HC1, pH 7.6, 1 mM
EDTA, 5% (v/v) glycerol, 1 mM PMSF, and 1 mM DTT, pH 7.6 (PB buffer). One
complete protease inhibitor tablet per mL of PB buffer was added. Cells were disrupted
by one pass through the French press cell at 14,000 psi. The cell debris was removed by
centrifugation at 20,000 g for 20 min. DNA was precipitated by addition of 10% (w/v)
streptomycin sulfate stock in PB buffer to a final concentration of 1%, and stirred for an
additional 10 min. The precipitated DNA was removed by centrifugation at 20,000 g for
20 min. Solid ammonium sulfate was added to the supernatant (55 mL) over 20 min to a
final concentration of 50% saturation (0.31 g/mL) and the mixture was stirred for
additional 30 min. The protein pellet was collected by centrifugation at 20,000 g for 20
min and re-dissolved in 1 mL PB buffer. The protein was desalted by passage through a
Sephadex G25 column (1.5x30 cm, 40 mL) column. The eluted protein (-30 mL) was
loaded on a dATP-Sepharose column (4.5x6.5 cm, 20 mL) at 4 OC for 1 h. The column
was washed with 800 mL of 50 mM Tris-HC1, pH7.6, 1mM EDTA, 5% (v/v) glycerol, 1
mM PMSF, 1 mM DTT, 50 mM NaC1, and a was eluted with 50 mM Tris-HC1, ImM
EDTA, 5% (v/v) glycerol, 1 mM PMSF, 1 mM DTT, 10 mM ATP, pH 7.6. Fractions
containing a as determined by Bradford assay were combined and concentrated to 0.5 mL
by ultrafiltration using a YM30 membrane. ATP was removed by passage through a
Sephadex G25 chromatography (4x30 cm, 200 mL). The protein containing fractions
were pooled and concentrated by ultrafiltration with a YM30 membrane to 10 mg/mL. a
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was stored in 50 mM Tris-HC1, pH 7.6, 100 mM KC1, 15 mM MgCl 2 , 5 mM DTT, and
5% (w/v) glycerol. A total of 110 mg (specific activity of wt is 350 nmol/min/mg) was
typically obtained from 10 g of cell paste.
5.2.3 Expression and purification of Smll and Smll-E71C, W65C, S61C, M80C
mutants
The Smll cysteine mutants were constructed using a Stratagene Quick Change
site-directed mutagenesis method with primers shown in Table 1. The Smll or Smll
mutant gene in pET-24a was transformed into E. coli BL21-CodonPlus (DE3)-RIL cells
and plated on LB agar plates with 30 gg/L CM, 75 [ig/L Kan. A single colony was used
to inoculate a 5 mL LB which was grown overnight at 370 C with 30 mg/L CM and 75
mg/L Kan. The 5 mL culture was then added to 2 L LB in a 6 L flask and grown at 370 C
until an OD 600 of ~0.8. The culture was then cooled to 300 C, and IPTG (final
concentration 0.5 mM) was added to induce Smll. The cells were grown for an additional
4 h. The cells were harvested at 7,500 rpm with a typical yield of - 3 g/L of culture.
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Smll mutants primers:
C14S C GCT CAA AAT CGC TCC CAA CAA CAA CAA GCC CC
forward
C14S GG GGC TTG TTG TTG TTG GGA GCG ATT TTG AGC G
reverse
S61C GCT TCT GCC TCC GCT TGT TCA TTA GAA ATG TGG G
forward
S61C CCC ACA TTT CTA ATG AAC AAG CGG AGG CAG AAG C
reverse
W65C CCG CTT CTT CAT TAG AAA TGT GCG AAA AGG ATT TGG AGG
forward
W65C CCT CCA AAT CCT TTT CGC ACA TTT CTA ATG AAG AAG CGG
reverse
E71C GTG GGA AAA GGA TTT GGA GTG CAG ACT CAA CTC TAT CGA
forward TCA TG
E71C CAT GAT CGA TAG AGT TGA GTC TGC ACT CCA AAT CCT TTT
reverse CCC AC
M80C CAA CTC TAT CGA TCA TGA CTG CAA CAA CAA CAA ATT TGG
forward TTC TGG CG
M80C CGC CAG AAC CAA ATT TGT TGT TGT TGC AGT CAT GAT CGA
reverse TAG AGT TG
All the purification steps were performed at 40 C. The cell pellet was resuspended
in 50 mM TrisHC1, pH 7.4, 1 mM EDTA and 5 mM DTT (1 g/7-10 mL) containing one
Complete protease inhibitor tablet per 10 mL suspension. The cells were lysed by flash
freezing in a 50 mL falcon tube with liquid nitrogen and then allowing the frozen cells to
thaw at room temperature until the lysate returned to a liquid state. The falcon tube then
was placed at 40C. One freeze-thaw cycle was used. This method was used instead of
the French press, because it decreased the amount of clipped Sml (11). Once the lysate
was thawed, another Complete protease inhibitor tablet per 10 mL suspension was added
and the cells were spun in an ultracentrifuge at 150,000 xg for approximately 1 h and 15
min (Model Beckman L7-55 ultracentrifuge; 45Ti rotor at 36,000 rpm). 10% (w/v)
streptomycin sulfate stock solution was added to the supernatant to a final volume of 1%
197
Table 5.1:
(w/v). After stirring for 10 min at 40 C, the DNA was pelleted at 40,000 xg for 20 min.
(NH4)2SO 4 was then added to 23% saturation (0.136 mg/ml) and stirred at 40 C for 20 min.
The precipitated protein was collected by centrifugation at 40,000 xg for 20 min. The
pellet was dissolved into 50 mM TrisHCl (pH 7.4), 1 mM EDTA, 15 mM MgCl 2, 120
mM NaC1, 5% (w/v) glycerol and 5 mM DTT and the (NH4)2SO 4 was removed using
Sephadex G-25 chromatography (1.5 cm x 25 cm, 20 mL). The protein containing
fractions were pooled and concentrated using a YM-3 membrane. The protein
concentration was determined using 8280 = 8250 M -1 cml (11). Protein purity was
assessed using SDS-PAGE analysis via a 10-20% TRIS-Tricine gradient gel (Invitrogen).
A total of 3 mg was typically obtained from 1 g of cell paste.
5.2.4 Labeling of Smll mutants by BADAN
The Smll-E71C, W65C, S61C, M80C (500 pL, 40 M) mutants were pre-
reduced with 10 mM DTT for 30 min on ice. DTT was then removed by a Sephadex G-
25 column (1.5 cm x 25 cm, 40 mL). The column was equilibrated with 50 mM Tris, pH
7.4, 1 mM EDTA, and 15 mM MgCl2. The Smll mutants were then assayed using DTNB
to determine the amount of free thiol. The background spectrum of both DTNB (250 M)
and Smll (25 gtM) in 50 mM Tris, pH 7.4, 1 mM EDTA, and 15 mM MgCl2 were
individually taken at 410 nm. DTNB was added into the cuvette containing Smll (500 pL,
25 pM) to a final concentration of 250 M. The UV/vis spectrum was recorded every
min until the reaction was complete. The concentration of TNB (2-nitro-5-benzoate) was
determined as follows: [TNB]mM = (A4 10, final - A4 10, Smll background - A4 10, DTNB
background)/13.6 mM' cm -1. The Sml concentration was determined using 8280 = 8250 M-1
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cm'. The percentage of free thiol per molecule was then calculated by [TNB]/[Smll].
The DTNB assay typically resulted in 90-98% of one thiol.
BADAN (final concentration 400 /aM from a 15 mM freshly prepared solution in
DMF) was added slowly to the pre-reduced Smll mutant (500 [IL, 40 /aM final
concentration) and was gently stirred at 4 OC for 3 h. The solution was covered with foil
to protect the reaction from light. The labeling reaction was quenched with 1 L of P-
mercaptoethanol for 30 min at 4 oC. To remove excess DAN-mercaptoethanol, the
solution was centrifuged at 3400 rpm for 10 min. The supernatant then was placed into a
slide-A-lyzer dialysis cassette, MWCO 3500 (Pierce) and dialyzed in 6 x 1 L 50 mM Tris,
pH 7.4, 1 mM EDTA, and 15 mM MgCl 2.
To calculate the extent of labeling, the UV/vis spectrum of each mutant was
recorded. Assuming that extinction coefficient for DAN attached to the protein is the
same as free DAN, its concentration was determined using F390 = 21 mM-1 cm-1 and 6280 =
19.8 mM' cm'1 in H20 (pH 7.6) (Molecular Probes, Invitrogen). The concentration of
Smll was determined as above. The stoichiometry of labeling was calculated by
[DAN]/[Smll]. Each DAN-Smll was also analyzed by Sciex triplequadrupole mass
spectrometer (model API 365) at Biopolymers, MIT to determine the extent of labeling.
5.2.5 Activity assays:
The reaction mixture contained the following in a final volume of 180 pL: 100
mM Hepes, pH 7.6, 15 mM MgCl 2, 0.6 p M a (wt or mutants, specific activity of wt is
319 nmol/min/mg), 3 pM 3p' (0.3 Y*, specific activity of 2410 nmol/min/mg), 3 mM
ATP, 1 mM [3H]-CDP (specific activity of 4290 cpm /nmol), 100 M E.coli TR, 1.0 RM
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TRR, 2 mM NADPH. In the assay of W688A-a, E689D-a, and W688A E689D-a, at 2
pM was mixed with Flag- pp' (7 p~M, 0.3 Y*) and the reaction was carried out for 30 min
at 30'C. For assays with C883S C886S-a, 20 mM DTT replaced TR, TRR, and NADPH.
Each reaction mixture was pre-incubated at 30 oC for 3 min and the reaction was initiated
by addition of a or a mutant. Aliquots of 30 [L were removed over a 20 min period and
the reaction was quenched in a boiling water bath for 2 min. dCDP production was
analyzed by the method of Steeper and Steuart (20).
5.2.6 Inactivation assay of wt a and a-C883S C886S by Smll:
The reaction mixture contained the following in a final volume of 150 PL: 100
mM Hepes, pH 7.6, 15 mM MgCl 2, 1.6 pM a (wt, specific activity of 319 nmol/min/mg
or mutants), 0.8 M 131' (0.3 Y*, specific activity of 2410 nmol/min/mg), Smll (0, 1 jiM,
2 tM, 4 pM), 3 mM ATP, 1 mM [3H]-CDP (specific activity 4290 cpm /nmol), 100 jM
E.coli TR, 1.0 jM TRR, 2 mM NADPH. The C883S C886S-a was assayed with 20 mM
DTT instead of TR, TRR, NADPH. The reaction was initiated by the addition of [3H]-
CDP at 30'C. Aliquots of 30 jiL of were removed at various time points over a 10 min
period and the reaction was quenched in a boiling water bath for 2 min. dCDP production
was analyzed by the method of Steeper and Steuart.
5.2.7 Determination of Kd for DAN-Smll to a:
Fluorescence measurements were performed on a QM-4-SE fluorimeter in from
Photon Technology International (Montreal, Quebec) using FELIX software and 2 nm
excitation and 6 nm emission bandwidth slits. The excitation was at 390 nm, and the
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emission was monitored from 410 nm to 625 nm at 1 nm per sec. The temperature was
controlled at 30 oC. Each sample of 400 [tL was placed in a 500 .L microcuvette that
contained 50 mM HEPES, pH 7.6, 15 mM MgSO 4 and 100 pM TTP, and was scanned
from 410 nm to 625 nm at 1 nm per sec before the start of the titration. The titration was
started by addition of DAN-Smll (1 pL, 19.8 pM) into 400 tL buffer to a final
concentration of 0.04 pM. Titration was carried out with pre-reduced a (156 [M)
incubated with 100 [tM TTP. The pre-reduced a was added in 0.5 [L aliquots with a P2
pipette. The emission spectrum was recorded after 10 min incubation as controls revealed
no further changes occurred subsequent to 10 min. The Kd was calculated using Eq 1:
Kd = [a2]free[DAN-Smll] free /[a2- DAN-Smll] (1)
where [DAN-Smll] free and [a2 ]free are the free concentrations of DAN-Smll and a2. The
above equation for Kd assumes a 1:1 interaction between Dan-Smll and a2 where Smll
is assumed to be a dimer and Eq 1 can be reformulated as
F = [a2]free / (Kd +[a 2 ]free) (2)
where F is the fraction of [DAN-Smll-a2] to the total [DAN-Smll].
For the sigmoidal dose-response model assume cooperative binding,
Kd = [a2]free n [DAN-Smll]/[ (DAN-Smll)-a2n], it can be reformulated as
F = [a2]freen / (Kd +[a2]freen), n is hill coefficient (3)
where F is the fraction of [DAN-Smll-a2 n] to the total [DAN-Smll].
[a2]free = [a2]total - F[DAN-Smll ] total
The fraction of bound a2 for both Eq 2 and 3 was determined using Eq 4 where:
F = (I - lo) / (Imax - lo) (4)
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where I is the emission intensity, and Io is the emission intensity of DAN-Smll before
addition of a2 . Kd was determined by fitting F vs [a2 ]free curve assuming 1:1 binding
model or a sigmoidal dose-response model with non-linear least-squares global analysis
using Origin 6.1 software. The error bars represent the standard deviation of 2-3
independent experiments.
5.2.8 Preparation of oxidized a:
a (156 [M, 500 [L) was pre-reduced with 25 mM DTT on ice for 1 h and DTT
was removed on a Sephadex G-50 column (1 cm x 20 cm, 20 mL) in 50 mM Tris-HC1,
pH 7.4, and 5% (v/v) glycerol at 4 oC. In a final volume of 200 pL, pre-reduced a (80 pM)
was mixed with His-P' (80 [pM, 0.3 Y*), 3 mM ATP, 1 mM CDP, 50 mM Hepes, pH 7.6,
15 mM MgCl 2, and 1 mM EDTA. The oxidation was carried out at 30 oC for 20 min. The
reaction mixture was mixed with 500 pL cobalt resin at 4 oC for 1 h then loaded into a 2
mL spin column. The resin was washed with 5 x 1 mL 50 mM Hepes, pH 7.4, 1mM
EDTA, 100 mM NaC1, and 10% glycerol until A2 80nm < 0.05. Fractions of 500 [L were
collected and each fraction was checked for a purity by 10% SDS-PAGE. The fractions
containing pure oxidized a were combined and concentrated with a YM30 membrane to
about 400 [L. To remove ATP and CDP, the concentrated protein was repeatedly diluted
to 5 mL using 50 mM Hepes, pH 7.4, 1mM EDTA, 100 mM NaC1, and 10% glycerol
buffer, and concentrated to 400 jiL three times. The concentration of oxidized a was
determined by Bradford assay using reduced a as standard. If Pp' was not completely
removed from oxidized a, the concentration of oxidized a was also determined by
comparing the band intensities of a standard curve generated by reduced a (0.5 M to 5
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pM) by 10% SDS-PAGE. The band intensities were quantified using Bio-Rads Quantity
One software.
5.2.9 Surface plasmon resonance by BIAcore to determine Kd for Smll to a:
A Biacore 3000 (GE healthcare) was used to measure the binding of Smll to a.
The binding was characterized following a modification of the procedure of Thelander
(11, 21). Smll (200 M) was diluted in 10 mM sodium acetate, pH 5.2 to 30 pM right
before the immobilization process. Smll was immobilized onto the dextran layer of the
CM5 sensor chip (GE healthcare) using the amine coupling method described by the
manufacturer (22). The amine coupling kit containing EDC (N-ethyl-N-(diaminopropyl)
carbodiimide), NHS (N-hydroxysuccinimide) and ethanolaminehydrochloride, pH 8.5
was obtained from GE healthcare. The matrix of CM5 is carboxymethylated dextran
covalently attached to a gold surface. The carboxylic acid group of the dextran was
activated with 30 tL of 0.2 M EDC and 0.05 M NHS. Smll (35 [L, 20 gM) was flowed
at a rate of 5 iL/min over the channel. Afterward, 30 [tL of 1 M
ethanolaminehydrochloride pH 8.5 was injected to convert the remaining activated esters
to amides. The immobilization level of Smll was 2000 resonance unit (RU), which
corresponds to 2000 pg/mm 2. The RU is proportional to the mass, that is, 1 RU
corresponds to 1 pg/mm2 of the 100 nm thick dextran layer. With a surface of 0.8 mm2,
1600 pg, or 16 fmol of protein is immobilized. The low degree of immobilization avoids
multiple attachment sites for a single Smll molecule. All studies were carried out at 22
'C with a flow rate of 30 [L/min. The ligand (a or P3') was pre-equilibrated with running
buffer (PBS buffer), pH 7.2. The binding of Smll and a was studied by allowing the
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immobilized Sml to interact with the increasing concentrations of a (0.16 pM to 20 yM)
in 100 jM TTP. The surface was regenerated between each a injection with 10 IL of 0.5
M KCl in PBS buffer. The complex formed is detected by a change in RU over time. The
affinity of Smll for a was analyzed using BIAcore Evaluation 3.2 software.
5.2.10 Inhibition on studies with Smll using CDP as the variable substrate:
The reaction mixture contained in a final volume of 135 jiL: 50 mM Hepes (pH
7.6), 15 mM MgC12, 3 mM ATP, 2 mM NADPH, 100 [M TR, 1 pM TRR and 0.3 pM a2
(319 nmol/min/mg), 3 tM His P3' (2400 nmol/min/mg). The concentration of [3H]-CDP
(specific activity is 5860 cpm / nmol) was varied: 0.044 mM, 0.067 mM, 0.1 mM, 0.2
mM, 1 mM. The concentration of Smll varied from 0 jM, 0.25 pM, 0.5 M, 1 M, 1.5
pM, 2 pM. Aliquots of 30 pL were taken out of the reaction mixture at 1 min intervals at
the beginning and 5 min intervals at the end over a 22 min course, and followed up as
described above.
5.3 Results:
5.3.1 Alkylation of Smll, site specifically, with BADAN:
Based on 2D NMR data and biochemical studies (23), Ortigosa in the Stubbe lab
generated a helical wheel for residues 61-80 in Smll known to play a role in the
interaction with a (Figure 5. 3A, B). The model shows an acidic patch (pink, Figure 5.3A)
and hydrophobic patch (orange, Figure 5.3A). Moreover, the residues R72, L73 and 176
which were identified earlier in the mutagenesis studies as key residues for Smll
inhibition and binding to a are close or within the hydrophobic patch (7, 24). To identify
the binding site and measure the affinity of Smll for an, we have attached DAN, an
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environmentally sensitive fluorescence probe, to single cysteines within Smll generated
by site directed mutagenesis. Previous studies of Dealwis and coworkers established that
Smll forms a dimer through intermolecular disulfide bond formation via C14 (7, 24). A
C14S-Smll retains its biological activity and its ability to form a dimer. To simplify the
strategy for attachment of DAN via cysteine alkylation by BADANs (Figure 5.4), we
carried out all of our studies in a C14S-Sml background.
(A)
R72G
Ser R72A
Ile 176T
lie Non-Polar
Leu Polar, Uncharged
E Acidic
Len Basic
(B)
Glu
L 73P
L73A Leu
Met
Leu
Glu Glu
His
Glu
Met
Ser
Leu L73P
L73A Trp Asp
Arg
R72G
R72AGlu - Asp
Figure 5.3: Model for the Smll-Y1 binding.
The alpha helix within the C-terminal tail of Smll is shown. The residues (R72, 176, L73)
which were found essential for c inhibition from previous genetic studies are indicated
in red. A hydrophobic patch (orange m) and an acidic patch (pink m) which are composed
of hydrophobic residues or acidic residues on the C-terminal tail of Sml are proposed as
the binding site to a. The polar residues are shown in green (m), and the basic residues
are shown in blue (m). (A) Helical wheel projection of residues 61-78. (B) Helical wheel
projection of residues 63-80. (Adapted from Dr. Allison Ortigosa's final report)
C-CH2 Br
(CH3 )2 N
Figure 5.4: Structure of BADAN (6-bromoacetyl-2-dimethylamino-naphthalene).
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Four sites for probe attachment were chosen: W65, M80, S61, E71. As shown in
Figure 5.3, W65 resides within the hydrophobic patch, M80 is located at the edge of the
hydrophobic patch and at the C-terminus of the a helix; S61 is at the N-terminus of the a
helix. DAN labeling at S61 or M80 may allow for the detection of changes on the binding
DAN-Smll to a with the minimal perturbation of binding if the model is correct. E71
which is located outside the hydrophobic patch in the helix was chosen as a control.
5.3.2 Labeling Smll mutants with BADAN
Each Smll mutant was alkylated with BADAN. Subsequent to its pre-reduction
with 10 mM DTT, the DTNB assay demonstrated in each case a single thiol/Smll. The
labeling was carried out for 3h at 4 oC and was quenched with ~-mercaptoethanol. The
excess DAN-mecaptoethanol was removed by dialysis and each DAN-Smll was
analyzed by ESI-MS. The results are shown in Table 5.2 with a typical spectrum shown
(Figure 5.5). The unlabeled material appeared to be a small portion of total Smll. In
addition, it should be noted that a little amount of doubly labeled Smll might exist.
Incubation for longer time periods leads to alkylation of histidines and lysines and
complicates the fluorescence titration analysis.
Table 5.2: Determine the amount of DAN labeling with mass spectrometry
Unlabeled Unlabeled Singly Labeled Singly Labeled
(Calculated Mass) (from Mass spec) (Calculated Mass) (from Mass spec)
S61C 11834.1 11833.6 12045.4 12045.5
M80C 11790.0 11787.3 12001.3 12000.2
E71C 11792.1 11789.0 12003.4 12000.6
W65C 11735.0 11732.3 11946.3 11944.1
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12045.51
Mass (mVz)
Figure 5.5 Mass spectrum of DAN-Smll-S61.
The MW of singly labeled Dan-Smll-S61C is 12045, and the MW of unlabeled Smll-
S61C is 11833.55.
5.3.3 Inactivation of RNR activity by mutants and DAN-Smll mutants:
Site directed mutagenesis was carried out to generate S61C, W65C, E71C, M80C.
The expression and purification of the cysteine mutants were successfully carried out
with the wt-Smll protocols. Each cysteine mutant was tested for its ability to inhibit a. a
in the presence of 10 fold excess of 13' (3 1iM) was assayed for dNDP production with
Smll concentrations varying from 1-20 pM. As noted above, the C14S-Smll inhibition is
identical to wt Smll (Figure 5.6, blue). Mutations of either E71 (purple) or S61 (red) had
a minimal effect on the inhibition of RNR, while a mutation at W65 reduced the
inhibition activity of Smll by 80% (Figure 5.6a). These results support the importance of
the hydrophobic face of the a helix of Smll in binding to a. The Dan-Smll-S61C, Dan-
Smll-E71C, Dan-Smll-M80C were also analyzed for their ability to inhibit RNR activity
(Figure 5.6b). Both Dan-E71C and DAN-S61C inhibited a activity with similar potency
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as the non-alkylated Smll mutants. DAN-M80 gained potency subsequent to alkylation
of the cysteine 80.
(a) (b)
100 100
80 80
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40 - 40
20
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Smil (pM)
Figure 5.6: a inactivation by the Smll cysteine mutants.
The cysteine mutants (a) and DAN-labeled cysteine mutants (b) of Smll were tested for
their ability to inhibit RNR activity. The inactivation mixture contained final
concentrations of a, 0.6 pM, His-3', 3.0 [tM. Percent of remaining a activity are shown
at varying concentrations of wt Smll (.), C14S (.), S61C (.), E71C (*), M80C (.), W65F
(-) and W65C (-).
5.3.4 Measurement of the Kd for DAN-Smll relative to a
To study the interaction of Smll-Dan with a, we wished to identify conditions in
which a exists in a homogeneous quaternary state. Although the quaternary structure of
class Ia RNR in E. coli and mouse have been extensively studied, little information is
available about the quaternary structure of S. cerevisiae a. Chabes et al using SEC under
5 mM DTT and 100 tM TTP conditions reported that a is a dimer in equilibrium with a
tetramer (11). Dimerization of a is known to occur in the presence of dNTPs which bind
to the specificity site within the 4 helix bundle at the subunit interface. We examined the
MW of a in the presence of various of dNTPs by SEC (S200), with dNTP in the elution
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buffer (Table 5.3). With dGTP (40 [M), multiple species (a2, a) were detected. With
TTP (100 jM), 80% of a appears as a dimer, while 20% appears as a monomer (Figure
5.7 A). With DTT (25 mM), a is predominantly a monomer (90%). The studies above
suggested that the best conditions for measurement of Smll binding to a was to pre-
reduce a and incubate it with 100 iM TTP. Unlike that reported by Chabes et al, tetramer
was not detected in our experiment with TTP. Instead, in all of our SEC experiments
various amount of high MW aggregates were observed, which complicated our
fluorescence titrations. The aggregation might result from the dATP-Sepharose
chromatography purification.
(a)
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N 0.039
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Figure 5.7: SEC spectra of a in the presence of TTP.
a (44 IAM) was pre-reduced with 30 mM DTT for 30 min and the excess DTT was
removed by Sephadex G25 column. The a was then incubated (a) with 100 pM TTP or (b)
with 40 pM dGTP for 30 min or (c) without nucleotide, and injected onto a S200 column
(GE heathcare). A280nm was monitored. Peak 1 eluted in the void volume (16 min) is
likely aggregate of a. (a) With TTP, the peak 2 eluted at 22.6 min with the apparent MW
of 244 kDa. (b) With dGTP, the peak 2 eluted at 23.1 min with the apparent MW of 212
kDa, Peak 3 (shoulder) eluted at 25.9 min, with the apparent MW of 110 kDa (c) Peak 2
eluted at 25.6 min with the apparent MW of 118 kDa The S200 column was equilibrated
in 100 mM HEPES pH 7.6, 20 mM MgSO 4 at a flow rate of 0.5 mL/min.
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Table 5.3: Molecular Weight Determination of S. cerevisiae a in the presence of
effectors by SEC.
Protein Apparent Expected Oligomeric Retention time
(effector) mass (kDa) mass (kDa) state (min)
a (100 pM TTP) 244 199 a2 22.6
a (40 pM dGTP) 212, 110 199,100 a2, a 23.1, 25.9
a (25 mM DTT) 118 100 a 25.6
Having established a quaternary homogeneous state for an, DAN-Smll-S61C was
placed in a cuvette with 100 M TTP and titrated with increasing concentrations of a2
(100 pM TTP). Two control experiments in which DAN-Smll-E71C, and DAN-Smll-
W65C were used revealed no significant fluorescence intensity changes during titrations;
alkylation of W65 with a bulky group inhibited binding while modification of E71 with
the label failed to reveal Smll- a interactions. Thus, results from the control experiments
further support our model of the putative binding helix.
DAN-Smll-S61C was expected to be most informative probe because it is located
adjacent to the proposed site of binding and showed the most potent inhibition of
nucleotide reduction. The results of a typical titration are shown in Figure 5.8. To
determine the time required for establishing equilibrium subsequent to each addition of
a2, spectra was recorded every min until no further fluorescence change was observed.
Ten min was chosen as the standard time interval between additions. For titration of
DAN-Smll-S61C with a2 in the presence of TTP, the emission intensity increased and
was blue shifted by 20 nm, suggesting a change to a more hydrophobic environment (25),
in agreement with our binding model. The Kd (0.47 pM) for DAN-Smll-S61C and a2
(TTP) at 30 'C was obtained by fitting the fraction bound vs [a2 ]free curve with Eq 2
(Figure 5.8 a, b). In the presence of both CDP and TTP, the binding of DAN-Smll -S61C
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and a2 was significantly increased, given a much lower Kd of 0.17 [M. The emission was
blue shifted by 10 nm, indicating a conformational change of the Sml 1 binding site upon
addition of the substrate. The enhanced binding of Smll to a in the presence of CDP
suggests that Smll binds to the ES form with increased affinity compared to the E form,
which displays a mixed or uncompetitive binding character.
Only the intensity changes were considered in the data analysis, and the dimer
concentrations of both a and Smll were used to compare the Kd values to Thelander's
value. The Kd reported by Thelander using Biacore method was 0.4 PM in the absence of
TTP at 22 'C (11). The running buffer was 10 mM Hepes, pH 7.4, 200 mM potassium
acetate, 1 mM EDTA, 5 mM magnesium acetate, and 0.05% surfactant P20.
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Figure 5.8: Titration of DAN-Smll-S61C with an.
(a) HEPES 50 mM, pH 7.6, 15 mM MgSO4, 100 pM TTP in 400 tL with DAN-Smll-
S61C (0.04 pM, dimer) was titrated with a2 (78 gM) with TTP from 0 to 1.2 pM. Each
emission curve was taken after 10 min incubation at 30 'C. The emission wavelength was
blue shifted by 20 nm during the titration. (b) Kd = 0.47 pM was obtained by fitting with
Eq. 2. (c) The titration condition is identical to (a), except that a2 was incubated with 1
mM CDP, which was also added in the titration buffer. The emission wavelength was
blue shifted by 10 nm. (d) Kd = 0.17 pM was obtained by fitting with Eq. 2.
In an effort to determine if probe placement effects Kd, a second DAN-Smll was
used. Titrations of DAN-Smll-M80C with a were carried out in the presence of TTP ±
CDP. Eq. 3 with sigmoid shape binding model was used to fit the binding data, from
which Kd obtained was 1.1 pM (hill coefficient n=1.3) in the absence of CDP, and 0.46
pM (n=1.4) in the presence of CDP. The emission wavelength blue shifted 20 and 25 nm
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in the absence of CDP and in the presence of CDP respectively (Figure 5.9). DAN-Smll-
M80C shows again that Smll binds the ES form with increased affinity than the E form.
Comparison of these Kd values to the values for S61C to a2, suggest that weaker binding
of M80C to a2 (TTP) might possibly result from a partial impairment of the a-Smll
binding site by substitution at M80 as indicated by the inhibition assays (Figure 5.6).
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Figure 5.9: Titration of DAN- Smll1-M80C by a.
(a) HEPES 50 mM pH 7.6, 15 mM MgSO 4, 100 gM TTP in 400 tL with DAN-Smll-
M80C (0.04 !M, dimer) was titrated with a2 (78 pM) with TTP from 0 to 1.4 VM. Each
emission curve was taken after 10 min incubation at 30 'C. The emission wavelength was
blue shifted by 20 nm during the titration. (b) Kd = 1.1 riM, n= 1.3 was obtained by fitting
with Eq. 3, (c) The titration condition is identical to (a), except that a2 was incubated
with 1 mM CDP, which was also added in the titration buffer. The emission wavelength
was blue shifted by 10 nm. The emission wavelength was blue shifted by 25 nm.(d) Kd
0.46 tM, n=1.4 was obtained by fitting with Eq. 3.
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As a 2nd method, surface plasmon resonance method via BIAcore has been carried
out using the procedure which Thelander (26) applied to measure a/p subunit interaction
in mouse RNR. The wt Smll was immobilized onto a CM5 sensor chip via the amine
coupling method. The ligand (a2 (TTP) or P3') was equilibrated in the running buffer
(PBS buffer, pH 7.2) at 22 'C. Interaction with a (0.156 ptM to 20 pM) 100 tM TTP at
30 [L/min gave rise to a typical chromatograph (Figure 5.10a). The TTP was present to
ensure a was predominantly a dimer. A Kd = 0.6 gM in the presence of TTP was obtained
from our preliminary data by fitting with 1:1 binding model using Eq 2 (Figure 5.10c).
The results of a similar experiment using 5 [M 13' are shown in Figure 5.10b. No
binding to 13' was observed as previously reported by Thelander.
The results from two independent methods are similar with the caveat being that
the quaternary state of a in neither set of experiment is known. A Kd of 0.6 [tM relates to
the physiologically reported concentrations of Smll and a (0.76 ± 0.23 M) (27) and is
thus likely to be interesting.
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Figure 5.10: Determine the Kd of wtSmll with a with surface plasmon resonance
method using a Biacore.
Smll was immobilized on the CM5 sensor chip surface, a2 (5 pM) incubated with 100
jiM TTP was passed though the sensor chip surface to interact with Smll. (a) The plot
showed Smll could bind a2. (b) Smll was immobilized on the CM5 sensor chip surface,
5 pM 33' (0.4 Y*) was passed though the sensor chip surface to interact with Smll. (c)
Smll was immobilized on the surface and titrated with a2 (TTP) at increasing
concentrations.
5.3.5 Purification and activity assays of W688A-a, E689D-a, W688A, E689D-a:
Yeast two-hybrid studies by the Rothstein's group suggested that Smll interacted
strongly with a-W688G. This mutation partially restored interactions between a and
seven Smll mutants (R72, L73, S75, 176, S87, F94, F104) which have significantly
reduced binding affinity to a (10). In addition, Zhang et al performed yeast two hybrid
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assays and showed that W688A, E689D-a could increase the a-Smll affinity. W688 and
E689 in a are highly conserved from bacteria to human. Both mutations are located at an
a helical region on the outside surface of E. coli and yeast a structure (Figure 5.20). The
Huang lab also demostrated that the W688A E689D mutations were lethal to a rnr3A
strain in the presence of Smll. Removal of Sml from the strain restored cell viability (5).
The hypothesis to account for this result was that increased affinity between a and Smll
maintained inhibition of a resulting in insufficient concentrations of dNDPs for cell
viability. To test this proposal, W688A-a, E689D-a, and W688A E689D-a were purified
following the established protocol for a purification, using dATP affinity
chromatography (Figure 5.11).
WA, ED WEAD
& * ' 100 kD
75kD
50kD
37kD
Figure 5.11: SDS-PAGE gel (10%) of purified W688A-a, E689D-a single mutants
(left), and W688A E689D-a double mutants (right).
10 p.M a mutants were loaded. The band at 100 kD is the a mutant, and the lower band
between 37-50 kD is impurities.
The activity of each mutant (1 iM) in the presence of 7 pM Flag-3p' (0.3 Y*), and
[3H]-CDP (specific activity of 5307 cpm/nmol), 3mM ATP, TR, TRR, NADPH was
carried out for 30 min at 30 oC. The activity of wt-a control was 245 nmol/min/mg.
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E689D-a retained 79% of the wt a activity (Table 5.4 and Figure 5.12), while activities
for W688A-a and W688A E689D-a were 1% that of wt. Assays were performed in
triplicate (Table 5.4 and Figure 5.12 a, b). Thus the mutation of W688 is mainly
responsible for the loss of RNR activity.
Previous studies of Huang and coworkers reported that the W688A E689D-a
exhibited a slower growth phenotype relative to the wt a. The results shown above
suggest that the slower growth phenotype could also be associated with the low activity
of the mutant a.
To more quantitatively evaluate the slower growth phenotype, Huang's group
examined the effect of these mutations on wt growth rate in the absence of Smll (Figure
5.13). The data show that W688A or W688G-a, as well as W689A E689D-a display a
prolonged S-phase (30-40 min) relative to wt a and a small portion of mutant cells
showed S-phase arrest. E689D-a has a similar growth rate to wt a. Western blot in Figure
5.14 shows that the level of the mutants are the same as wt a. These results agree well
with our in vitro assays that the W688 mutation affects cell viability by losing RNR
activity, rather than affecting the protein expression.
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Figure 5.12: Activity assay of W688A-a, E689D-a, W688A E689D -a mutants.
The W688A-a (*), E689D-a (A), and W688A, E689D-a (0) (a) were assayed at 1 gM
with 7 eq. of Flag- pp' (7 tM, 0.3 Y*), in the presence of 1mM [3H]-CDP (5307
cpm/nmol), 3mM ATP and TR, TRR, NADPH. The assays were carried out over a 30
min time period at 30 oC. (b) Expansion of the data in (a) for W688A E689D double
mutant (M) and W688A mutant (*) assays (b) are repeated 3 times. Data is shown in
table 5.2 below.
Table 5.4: Summary of W688A, E689D a single mutants and W688A E689D a
double mutant.
Activity Activity %
(nmol/min/mg)
W688A 3.3 ± 0.25 1%
E689D 193 79%
W688A E689D 2.8 ± 0.7 1%
wt a 245 100%
Figure 5.13: FACS analysis by Huang's group.
All strains were of rnrl:: HIS3, rnr3:: Kan, Smll:: Kan background. The mrnrl mutants
were on a TRP1CEN plasmid (1 to 3 copies per cell). All strains were grown in YPD to
early log phase, synchronized in GI phase by alpha factor mediated arrest, and released
back into the cell cycle by washing off the pheromone-containing medium. Cells were
collected at 10 minutes intervals up to 200 min post release and processed for FACS
analyses. For wt, the 1st S phase between 20-30 min, the first G2 phase 50-60 min, and
the second S phase is -110 min. For the WE-to-AD mutant, the first S phase is between
20' and 70' (greatly prolonged by 30 to 40 min), G2 is at 80'-90', and the second S phase
is hard to tell because the cells are out of synchrony. W688A and W688G are similar as
the double mutant, the first S phase is between 20' - 50 min (prolonged by 20 to 30 min),
the second S is around 120 to 150 min. E689D is similar to WT in cell cycle progression.
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Figure 5.14: Western blot showing the protein levels of wt-a, W688A E689D-a,
W688A-a, E689D-a, W688G-a mutants (Left to Right) (From Huang group).
5.3.6 Measurement of the affinity of Smll for W688A, E689D-a
The slow growth phenotype could also be the result of tighter binding of Smll to
the a mutants as originally proposed (28, 29). To test this model, W688A was titrated
with DAN-Smll-S61C. The results of a typical experiment with the W688A E689D-a
double mutant in the absence of CDP are shown in Figure 5.15 a. Analysis of the data
with Eq. 3 gave a Kd=0.004 iM (Figure 5.15 b). Cooperative binding appeared and the
emission wavelength was blue shifted 14 nm. Thus the W688A E689D-a has
significantly higher affinity for Smll as suggested by the two hybrid studies, as well as
significantly lower catalytic activity (5). The mechanism of this tight cooperative binding
needs further analysis.
The binding studies are difficult to interpret for several reasons. First analysis by
SEC of W688A E689D-a in the presence of TTP reveals that it is - 40% aggregation and
60% dimer (Figure 5.16). The effect of the aggregates on the fluorescence titration thus
makes a molecular picture of the interaction between Smll and a impossible to describe.
The aggregate state of W688A E689D-a is double that (40%) of wt (20%). Further
221
analysis could be carried out if aggregation could be separated from wt a2 and can be
shown not to re-equilibrate.
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Figure 5.15: Titration of DAN- Smll1-S61C with W688A E689D- a double mutant.
HEPES 50 mM, pH 7.6, 15 mM MgSO 4 , 100 [M TTP in 400 [tL with DAN-Smll-S61C
(0.04 ptM, dimer) was titrated with (a) W688A E689D-a2 (24 jiM) from 0 to 0.3 ptM with
TTP. The emission wavelength was blue shifted 15 nm. (b) Kd = 0.004 tM, n=6 was
obtained by fitting with Eq. 3.
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Figure 5.16: SEC spectra of W688A E689D-a in the presence of TTP.
W688A E689D-a (24 ptM) was pre-reduced with 30 mM DTT for 30 min, then incubated
with 100 jiM TTP, before injection onto a S200 column (GE heathcare). A280nm was
monitored. Peak 1 eluted at void volume (16 min) is likely an aggregate of a. Peak 2
eluted at 23.7 min, with apparent MW 214 kDa. The calculated a2 is 200 kDa. S200
column was equilibrated in 100 mM HEPES pH 7.6, 20 mM MgSO4, 100 jM TTP at a
flow rate of 0.5 mL/min.
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5.3.7 Purification and activity assays of C883S C886S-a:
The hypothesis for the mechanism of inhibition of RNR a by Smll is that Smll
prevents the C-terminus of a from entering the a active site to re-reduce the active site
disulfide produced concomitant with dNDP production. As a test of this model, mutations
of the C-terminal cysteines (C883S, C886S) postulated to be involved in this re-reduction
were prepared. The hypothesis was that these mutants would still be active with DTT as a
reductant, inactive with TR/TRR, NADPH as reductant, and that by using C883S C886S-
a, DTT would be able to enter directly into the active site in the presence of Smll and re-
reduce the active site disulfide.
The double mutant was generated, expressed and purified following the protocol
for wt-a. Activity assays of C883S, C886S-a with 20 mM DTT gave an activity of 46
nmol/min/mg, 50% of the wt activity. Note that the wt activity, 92 nmol/min/mg with
DTT, is 50% of that obtained when using TR/TRR/NADPH as reductant. When the assay
was carried out on the double mutant using TR/TRR, no activity was detected. Thus the
C-terminal cysteines of eukaryotic RNR appear to play a similar role to that for
prokaryotic systems despite differences in the cysteine motif (CXXC vs CX4C).
The inhibition of RNR activity by Smll using DTT as a reductant was then
examined with the mutant and wt a and the results are shown in Figure 5.17. No
difference in inhibition was observed, suggesting that the hypothesis of Huang is correct
for Smll inhibition, and DTT is unable to access the active site. To test this model further,
a CTD (residues 765-888) shown in yeast two hybrid assays to compete with Smll
binding would need to be constructed and characterized. It could potentially compete
with Smll for binding to a and in fact could potentially re-reduce the active site disulfide.
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Figure 5.17: Inactivation assay of wt-a and C883SC886S-a by Smll.
Inactivation mixture contained final concentrations of 1.6 pM wt a (+) (specific activity
of 319 nmol/min/mg) or 1.6 [tM C883SC886S a mutants (m), in the presence of 0.8 [M
3p' (0.3 Y*, specific activity of 2410 nmol/min/mg), 3 mM ATP, [Smll] = 0, 1, 2, 4 tiM.
The wt a was assayed with TR, TRR, NADPH. And the C883SC886S-a mutant was
assayed with 20 mM DTT. Assays were carried out at 30 OC. The percentage of the
activities remained of wt a (*) and C883SC886S-a (w) at varying concentrations of wt
Smll are shown.
5.3.8 Measurement of the affinity of Smll to oxidized a
The model of Huang et al further suggests that Smll may preferentially bind to
the oxidized form of a rather than the reduced form. Therefore, oxidized a was prepared
by incubating pre-reduced a with excess His-0' (0.3 Y*), in the presence of 3 mM ATP,
1 mM CDP at 30 'C for 20 min. The His-pp' was removed from the resulting oxidized a
by use of cobalt resin. Unfortunately the recovery of oxidized a using this procedure was
20% and the protein appeared to be even less soluble than reduced a. Attempts to
concentrated oxidized a to facilitate fluorescence titrations resulted in its precipitation.
Given these caveats, the Kd of the DAN-Smll-S61C for the oxidized a in the
presence and absence of dCDP were measured (Figure 5.18a, b). The emission
wavelength blue shifted 10 nm (Figure 5.18a) and the binding curve exhibited
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cooperative behavior as shown in Figure 5.18b. The fit to the data using Eq. 3 in the
absence of dCDP is shown, giving a Kd=0.05 gM (n=3). The titration in the presence of
dCDP showed very small changes relative to that in the absence of dCDP. The fit as a
consequence is poor. Furthermore, no blue shift was observed in contrast with all other
titrations. The basis for these observations are unknown, but could be related to
aggregation of a. Our preliminary SEC data has revealed that the quaternary structure of
oxidized a in the absence of dCDP, but in the presence of TTP is predominantly a
monomer, while the reduced a is predominantly a dimer under the same conditions. In
the analysis of the data in Figure 5.18b, dimer concentrations of both Smll and a were
used. The binding of one monomer of the Smll to oxidized a may promote the binding of
the second monomer to an additional oxidized a. Characterizations of oxidized a and the
number of oxidized a interactions with Sml 1 dimer requires further investigation.
(a) (b)
S2 0.7 pM a2 1.00
S0.8
0 pM a2 0.6-
0 0.4u.
S0.2
_ 0.0
0 0.0 0.2 0.4 0.6 0.8
410 460 510 560 610 [free a2]
wavelength (nm)
Figure 5.18: Titration of DAN-S61C-Smll with oxidized a (100 jM TTP).
HEPES 50 mM pH 7.6, 15 mM MgSO4, 100 [M TTP in 400 pL buffer with DAN-Smll-
S61C (0.04 [M, dimer) was titrated with (a) isolated oxidized a in the absence of dCDP,
in the presence of TTP from 0 [M (blue) to 0.7 jM (red). The emission wavelength was
blue shifted 10 nm. (b) Kd = 0.05 jM (n=3.2) was obtained. The titration was carried out
at 30 oC.
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5.3.9 Mechanism of inhibition of Smll relative to CDP:
The model of Huang further suggests that Sml 1 could bind to either the reduced
form of ca (a SH ) in the presence of CDP or the oxidized form (a( S). A simple kinetic
SH S
model is shown in scheme 5.2. Binding to either form could potentially inhibit re-
reduction of the active site disulfide by the C-terminal tail. If Smll bound only to
oxidized a, then its inhibition should be uncompetitive with CDP as it binds to a different
from of the E, than CDP and the forms are irreversible connected. On the other hand, if
Smll binds to both the oxidized and reduced form, then the inhibition would be
noncompetitive.
CDP dCDP
E/SH SH /SSH\SH HSH* CDP E---- e dCDP \ ;
Smll
Smll
E/SH CDP S
SH Sml1 H\
S SH H SH
Scheme 5.2: The kinetic model of Smll binding to different forms of a.
The inhibition kinetic analysis was carried out using the TR/TRR/NADPH
radioactive assay. The concentrations of CDP were varied between 0.044 mM and 1 mM,
while the concentrations of Smll were varied between 0 and 2 pM. The result of the
analysis as a Lineweaver Burk plot is shown in Figure 5.19. The data suggests that the
inhibition pattern changes as [Smll] increases. The data were fit to either equations for
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competitive, v=Vmax[S]/(aKm+[S]); noncompetitive, v=Vmax[S]/[a(Km+  [S])]; or
uncompetitive v=Vmax[S]/(Km+ a'[S]) binding, where a=1+[I]/Ki, a'=1+[I]/Ki'. In the
fitting, Km and Vmax are fixed with the values obtained at [Smll]=0. For [Smll]=0.5, 1,
1.5, 2 [pM, the data fits the best with the uncompetitive model (Table 5.5). For [Smll]=0,
0.5 gM, the uncompetitive inhibition still fits better than the noncompetitive and
competitive inhibition models.
From our studies, Smll binds to the reduced form (Kd = 0.47 gM) and to the
oxidized form (0.05 jM) of a. In the presence of CDP, Sml binds with increased affinity
to the reduced form of a (Kd = 0.17 [M). Smll binding would require CDP to put the
enzyme into the correct state, the oxidized form, which may explain the higher affinity
observed in this case.
Table 5.5: Fitting v vs [CDP] data to distinguish competitive and uncompetitive
inhibition model.
[Smll]( gM) Competitive Uncompetitive Noncompetitive
0.5 R2  0.9 0.98 0.96
Chi2  886 150 386
1 R 0.8 0.99 0.98
Chi2  1047 52 118
1.5 R 0.38 0.99 0.89
Chi2  1462 28 259
2 R -0.18 0.99 0.7
Chi2 1408 8.9 342
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Figure 5.19: CDP vs Smil competition assay.
0.3 pM Y1 (a2, 330 nmol/min/mg) was assayed in the presence of 3 jIM Flag- 3p' (0.3 Y-)
with 3 mM ATP and TR, TRR, NADPH. [Smll] = 0 M (*), 0.5 jM (U), 1 pM (A), 1.5
gIM (x), 2 pIM (x), (from bottom to top), [3H]-CDP = 0 mM, 0.044 mM, 0.067 mM, 0.1
mM, 0.2 mM, 1 mM, with specific activity 5860 cpm/nmol. The assays were carried out
at 30 'C for 20 min. Double-reciprocal plot (1/v vs 1/[CDP]) are displayed. The
equations which used to fit the plots are as follows,
y = 0.0005x + 0.0023, R2 = 0.995, [Smll] = 0 M,
y = 0.0007x + 0.0026, R2 = 0.995, [Smll] = 0.5 jiM,
y = 0.0007x + 0.0042, R2 = 0.997, [Smll] = 1 pM,
y = 0.0008x + 0.0062, R2 = 0.997, [Smll] = 1.5 pM,
y = 0.0008x + 0.009, R2 = 0.996, [Smll]= 2 jM.
5.4 Discussion:
The proposal based on biochemical and yeast two hybrid studies is that Smll
binds to a2 and prevents re-reduction of the active site disulfide generated concomitant
with dNDP production (29). Smll is proposed to interact with a helical surface of a
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including W688 (28, 29) and prevent access of the C-terminal insertion and C-terminal
tail region of a (scheme 5.1).
Several experiments have been described to test the model. While 2D NMR
methods revealed that the structure of Smll is predominantly unfolded, an a-helix within
its C-terminus was identified. The C-terminus of Smll has been demonstrated by deletion
studies to interact with a. Generation of an a helical wheel from this region revealed an
amphipathic helix with both an acidic patch and a hydrophobic patch (Figure 5.3). In
addition, the S. cerevisiae a structure revealed that W688 is located at the entrance of a
tunnel into the active site (Figure 5.20). Interestingly, the structure also shows a
hydrophobic region (cyan circle) and a basic region (pink circle) adjacent to W688,
which can adapt the binding of the hydrophobic patch and acid patch of the helical wheel
of Smll. Unfortunately the C-terminus of yeast a, shown in vivo to be essential for re-
reduction of the disulfide in the active site, is not visible in any structures. Thus based on
this model, cysteine mutants of Smll were generated adjacent to the helix and on
different faces of the helix.
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Figure 5.20: Structure of S. cerevisiae a showing the position of W688
GDP in the actives site, and TTP in the allosteric site are shown in stick. The position of
W688 (green) and the last visible residue Q746 (yellow) in this structure at the C-
terminus are highlighted. The charge on the surface is displayed from positive charge or
basic (blue) to negative charge or acidic (red) and the hydrophobic region is in white
color. A hydrophobic region (cyan) and a basic region (pink) around W688 are identified
which could potentially bind the hydrophobic patch and acid patch of Smll.
Attachment of the fluorescent probe DAN through alkylation generated several
DAN-Smll that were examined for interactions with a. We have found a site (S61 of
Smll) to attach DAN that minimally perturbed binding to a and exhibited a moderate
change in fluorescence binding. The binding partner a, unfortunately is not as well
behaved and complicates analysis of both binding and kinetic studies. Previous studies by
Thelander measured Smll binding to a via SPR (surface plasmon resonance). In their
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studies, Smll was attached to the chip. They reported that the Kd for interaction in the
presence or absence with TTP was 0.4 M. In the same paper, they analyzed a (TTP) by
SEC and sucrose gradient AUC and found that a was a dimer in equilibrium with a
tetramer. No comment was made about the heterogeneity of a and how it could
potentially complicate their data interpretation. We studied the oligomerization state of a
using SEC method with nucleotide in the running buffer, in an attempt to find a set of
conditions with a single complex of a. From previous studies on E. coli and mouse a (30,
31), TTP binds to the specificity site and enhance a dimerization. In our studies on S.
cerevisiae a in the presence of TTP, 20% of a was aggregate and 80% of a was a dimer
(Figure 5.7). This condition was chosen for our binding studies, because of the higher
percentage of homogeneity.
We determined the Kd of Sml1 for a using fluorescence titrations. However, with
our initial titration of a (TTP) with Smll, the data was not well fit to a hyperbolic binding
curve (Figure 5.8). Addition of CDP gave enhanced binding with better fits, and a Kd Of
0.17 M. We additionally reproduced the SPR experiments of Thelander, attaching Sml 1
to the chip and using a (TTP) as elute. The apparent Kd was 0.6 VM, similar to the 0.4
M reported. Thus the Kd of Sml1 to a is 0.4 to 0.6 jM, with CDP increasing Smll
affinity for a.
The Huang model is that Smll prevents re-reduction of the active site disulfide by
the CXXC motif in the C-terminal tail of a. Thus, we conducted experiments using
oxidized a and DAN-Smll-S61C to test this hypothesis. Oxidized a was generated by
incubation with CDP/ATP and pp' in the absence of reductant. The oxidized a was then
separated from tagged fp' by affinity chromatography. However, the oxidized form of a
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is not well behaved and resisted concentration. Preliminary SEC analysis revealed
oxidized a is predominately a monomer. Previous studies by Thelander on E. coli enzyme
suggested that a in its oxidized state is a monomer as well (30). Further study of the
oligomeric state of oxidized a is warranted to shed insight into its nature. A fluorescence
titration of oxidized a with DAN-Smll-S61 was carried out in the presence and absence
of dCDP. In the presence of dCDP, fluorescence changes were very small and not blue
shifted as all other titrations. This data was not analyzed further due to small total
changes. In the absence of dCDP, binding was cooperative with an apparent Kd of 0.05
jM. An understanding of the quaternary structure of oxidized a is required to think about
a molecular model to explain this behavior.
Further analysis of interaction between Smll and a was thus carried out to test the
effect of the W688A (G) mutation in a. By two independent methods, Rothstein and
Huang demonstrated increased affinity of Smll for W688A (G)-a mutants. The single
and double mutants of a at residues W688 and E689 were purified. Surprisingly, given
the location of the mutants (Figure 5.20), the W688-single mutant and the double mutant
had 1% the activity of wt RNR. The mutant at residue 689 had little effect on activity.
This mutant was then analyzed by fluorescence titration with DAN-Smll-S61C and by
SEC chromatography. The binding curve exhibited very steep sigmoidicity with an
apparent Kd of 0.004 jM. The low Kd from fits demonstrates that we actually carry out a
stoichiometric titration. However, SEC revealed 45% of the protein was aggregated.
The activities of the mutant and their apparent tight binding to Smll could
account for their observed biological "slow growth" phenotype and 30 min increase in
progression through the cell cycle relative to wt a. We thought that we might be able to
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get a further handle on the mode of inhibition by Smll using a kinetic analysis with CDP
as the variable substrate. The uncompetitive inhibiton pattern suggests Smll binds to a
different form of a, than CDP, but the complicity of the assay, including potential
competition of Smll and Trx for binding to a, has made interpretation a challenge.
Obviously more studies are essential to understand the nature of Smll inhibiton,
including studies to determine the quaternary structure of a in its reduced and oxidized
states in the presence of nucleotides.
The main conclusion from this work is thus that Smll binds to oxidized and
reduced a and binds more tightly to the W688A-a mutant than the wt a. The
cooperativity in binding is intriguing and likely relates to the effect of Smll on altering
the quaternary structure of a. Finally the results with CXXC to SXXS mutants of the a-C-
terminal tail demonstrate that these residues are involved in active site disulfide re-
reduction. This behavior suggests this mechanistic aspect has been evolutionary
conserved; E. coli RNR also demonstrates this behavior although it has a different C-
terminal motif (CX4C).
Summary:
Smll binds to a, inhibiting dNDP production by a mechanism that involves its C-
terminal helix (likely the hydrophobic face) and a region of a that includes W688. Smll
can bind to multiple states of a, but detailed inhibition mechanism requires further
analysis.
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SUMMARY
The control of dNTP concentrations is critical to the
fidelity of DNA synthesis and repair. One level of regu-
lation is through subcellular localization of ribonucleo-
tide reductase. In Saccharomyces cerevisiae, the
small subunit Rnr2-Rnr4 is nuclear, whereas the large
subunit Rnrl is cytoplasmic. In response to S phase or
DNA damage, Rnr2-Rnr4 enters the cytoplasm to bind
Rnrl, forming an active complex. We previously re-
ported that Wtml anchors Rnr2-Rnr4 in the nucleus.
Here, we identify DIF1, which regulates localization
of Rnr2-Rnr4. Difl binds directly to the Rnr2-Rnr4
complex through a conserved Hug domain to drive nu-
clear import. Difl is both cell-cycle and DNA-damage
regulated, the latter of which occurs via the Mecl -
Dun1 pathway. In response to DNA damage, Dun1
directly phosphorylates Difl, which both inactivates
and degrades Difl and allows Rnr2-Rnr4 to become
cytoplasmic. We propose that Rnr2-Rnr4 nuclear
localization is achieved by a dynamic combination of
Wtml-mediated nuclear retention to limit export and
regulated nuclear import through Difl.
INTRODUCTION
In response to DNA replication blocks, cells activate the DNA-
damage and replication stress-response pathway, the DDR,
which includes the MEC1-RAD53-DUN1-CHK1 kinase cascade
in budding yeast and the rad3-cds -chkl pathway in fission yeast.
The downstream effects include cell-cycle arrest, stabilization of
replication forks, inhibition of late origin firing, and the initiation
of DNA repair (Harper and Elledge, 2007). Part of this process
involves activation of the ribonucleotide reductase (RNR) path-
way-the rate-limiting step in the conversion of rNDPs to dNDPs.
Saccharomyces cerevisiae has a Class la RNR and is composed
of homodimers of Rnrl (a2) and heterodimers of structurally ho-
mologous Rnr2 and Rnr4 (11') (Voegtli et al., 2001). The intimate
relationship between the DDR pathway and RNR function is dem-
onstrated by the fact that the lethality of the meclA or rad53A
mutants can be rescued by the activation of the RNR pathway
70 Molecular Cell 32, 70-80, October 10, 2008 @2008 Elsevier Inc.
(Desany et al., 1998; Vallen and Cross, 1999; Huang et al., 1998;
Zhao et al., 1998).
Adjusting the intracellular concentration of dNTPs to meet
demands under different conditions is critical, as both elevated
or insufficient levels of dNTP can lead to increased mutagenesis
rates (Chabes et al., 2003; Holmberg et al., 2005). Thus, cells have
devised multiple strategies to regulate Rnr (Nordlund and Reich-
ard, 2006). For example, transcriptional induction of the RNR
genes in S. cerevisiae involves Dun1 phosphorylation and inacti-
vation of the Crtl-Ssn6-Tupl repressor complex (Huang et al.,
1998; Zhou and Elledge, 1992). In addition, effectors binding
the large su bunit can alter the rate of catalysis or change the spec-
ificity of the enzyme toward particular ribonucleotide substrates
(Reichard, 2002). Posttranslational regulation in S. cerevisiae
involves the SmIl inhibitor, which can bind to the large subunit
Rnrl through its C-terminal tail (Chabes et al., 1999; Zhao et al.,
2000) and interfere with the regeneration of the catalytic site on
Rnrl (Zhang et al., 2007). Dun1 is required for Smll degradation
in response to DNA damage. Dun1 can phosphorylate Smll
in vitro, but the consequences of this phosphorylation have not
been examined in vivo (Zhao and Rothstein, 2002).
Rnr subcellular localization is an additional layer of control
(Lincker et al., 2004; Liu et al., 2003; Xue et al., 2003; Yao
et al., 2003). The Rnr small subunits of both Schizosaccharomy-
ces pombe and S. cerevisiae are sequestered in the nucleus.
S phase and DNA damage can independently control the trans-
location of nuclear Rnr small subunits out to the cytoplasm,
presumably to form active complexes with cytoplasmic Rnrl.
We previously identified WTM1 as a regulator of Rnr2-Rnr4 local-
ization (Lee and Elledge, 2006; Zhang et al., 2006). Wtml is a
nuclear protein that binds to Rnr2-Rnr4. Their physical associa-
tion is reduced after DNA damage and replication stress, coinci-
dent with the release of Rnr2-Rnr4 from the nucleus. Deletion
of WTM1 causes a significant nuclear-to-cytoplasmic shift of
Rnr2-Rnr4. Forced localization of Wtml to the nucleolus recruits
Rnr2-Rnr4 to the nucleolus, suggesting that Wtml functions as a
nuclear anchor. How DNA damage regulates this association is
unknown. In S. pombe, deletion of the spdl gene causes mis-
localization of the nuclear RNR small subunit Suc22 (SpRnr2).
In vitro experiments have demonstrated that Spdl binds to the
RNR large subunit Cdc22 (SpRnrl), but not to the small subunit
SpRnr2 (Hakansson et al., 2006). Whether and how this binding
between Spdl and the large RNR subunit results in nuclear local-
ization of the small subunit is unknown.
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Here, we describe the discovery of the S. cerevisiae Damage-
regulated Import Facilitator 1 (DIF1), which mediates the localiza-
tion of Rnr small subunits in response to DNA damage. Difl
shares elements of different Rnr regulators and provides a unified
view of Rnr localization regulation.
RESULTS
Difl Has a Conserved Domain Present among
Rnr-lnhibitor Homologs in Yeasts
Wtml binding to Rnr2-Rnr4 is disrupted in response to DNA
damage, resulting in their cytoplasmic localization. We sought
to understand how this regulation was accomplished. As the
upstream regulators are protein kinases, we identified three
phosphorylation sites on Rnr2: S15, S22, and S41. However,
mutation of these sites did not alter the nuclear localization.
Therefore, we initiated a search for additional regulators.
S. cerevisiae Smll and S. pombe Spdl proteins are small in-
hibitors of the RNR pathway that both bind the Rnr large subunit
(Hakansson et al., 2006; Liu et al., 2003; Zhao et al., 1998). How-
ever, Spdl and Smill appear unrelated. Furthermore, whereas
Spdl is essential for the nuclear localization of the Rnr small
subunit Suc22 (Liu et al., 2003), Smll plays no such role in S. cer-
evisiae (Yao et al., 2003). It was thought that there was no Spdl
ortholog in budding yeast. However, using the N-terminal half of
the Spdl sequence as a query, we identified two proteins with se-
quence similarity. One was Hug1, a 7.5 kD protein that is highly in-
duced after DNA damage and is thought to play a role in feedback
inhibition of the RNR pathway through an unknown mechanism
(Basrai et al., 1999). Its genomic sequence is located immediately
5' of SML 1. The second candidate is a novel uncharacterized pro-
tein, YLR437c (hereafter referred to as DIF1). BLAST analysis with
Difl identified similarity to SmIl. Alignment of Difl, Spdl, SmIl,
Hug1, and Aerl22c (a Difl/Smll ortholog in Ashbya gossypii) re-
vealed a conserved domain that we named the Hug domain, which
is present in all homologs except for SmIl (Figures 1A and 1 B). We
also observed a second domain conserved in Difl, Aerl22c, and
Smll, which we call the Smi domain. Aer122c, Smll, and, to
a lesser extent, Spdl share yet a third domain in their C termini
that we call the Rnrl-binding (R1 B) domain because it contains
residues required for Smll binding to Rnrl (Zhao et al., 2000).
The relationship between Difl and Smll suggests evolution
from a common ancestral gene. As S. cerevisiae underwent a ge-
nome duplication during its evolution, we searched for synteny
surrounding HUG1, SML1, and DIF1. As shown in Figure 1C,
Difl and Hug1 -Smll are paralogs derived from an ancestral gene
duplication event that included multiple adjacent genes (Dietrich
et al., 2004; Kellis et al., 2004). We assume that the ancestral
gene is most similar to the ortholog from A. gossypii, as it con-
tains only one gene that shares homology to Difl, Hug1, and
Smll. Duplication and divergence would allow for the splitting
of the ancestral gene into three genes-DIF1 on chromosome
XII, and HUG1 and SML1 on chromosome XIII.
DIFI Dosage Regulates the Viability of meclA Mutants
To test whether Difl is a negative regulator of the RNR pathway,
we overexpressed DIF1 under GAL1 control in meclA smllA
and smllA strains. Difl overexpression slowed growth in smllA
U
cells, but was lethal to the meclA smllA cells (Figure 1D). Difl
overexpression also rendered dun 1 A mutants more hydroxyurea
(HU) sensitive (data not shown). Strains were switched from
glucose to galactose to induce Difl expression and were ana-
lyzed for DNA content by FACS. mecl1 smllA cells overex-
pressing Difl arrested in S phase (Figure 1 E), consistent with a
role in the negative regulation of RNR.
Upregulation of RNR activity can suppress the lethality of the
MEC1 deletion (Desany et al., 1998; Zhao et al., 1998). Whereas
tetrad dissection of a MEC1/meclA diploid always resulted in
only two viable spores, dissection of the MEC1/mec1A::his5 ;
DIF1/difl::TRP1 tetrads yielded many viable three- or four-
spore tetrads. In these, one or two colonies were significantly
smaller and were meclA::his5 diflA::TRP1 (data not shown)
(Figure 1 F).
Dif Is Required for Rnr2-Rnr4 Nuclear Localization
DIF is nonessential, and its deletion has no effect on Rnr protein
levels (data not shown). However, diflA mutants show cytoplas-
mic localization of Rnr2 independent of cell-cycle stage (Fig-
ure 2A). Since Rnr2-Rnr4 is released from the nucleus in
response to DNA damage or replication stress, the cytoplasmic
localization in difl mutants could be indirect. To examine this,
we generated dunlA diflA mutants that still showed cytoplas-
mic Rnr2 (Figure 2B), indicating that Difl does not mislocalize
Rnr2 by mimicking DNA damage.
Whereas Rnr2 mislocalization in diflA mutants is cell-cycle in-
dependent, a factor-arrested diflA mutants showed significant
residual nuclear Rnr2. We have previously shown that the protein
Wtml is required for the nuclear localization of Rnr2-Rnr4
through an anchoring mechanism (Lee and Elledge, 2006; Zhang
et al., 2006). We examined the localization phenotype of wtml1
and diflA mutants. Both mutants showed very similar defects
in Rnr2 nuclear localization with some residual nuclear Rnr2,
especially in G1 (Figure 2C), suggesting that they may work in
the same pathway.
Difl Is the Regulated Component of the Rnr2-Rnr4
Localization Switch
A key question with respect to control of Rnr subcellular localiza-
tion has been the identity of the molecule that imparts cell-cycle
and DNA-damage regulation on the switch. To examine whether
Difl might be that molecule, we generated Difl antibodies. West-
ern blot analysis showed that Difl levels peaked at -70 min after
the release from a factor arrest with an inverse relationship to the
levels of Clb5, an S phase marker (Figure 3A). The low levels of
Difl during S phase coincided with Rnr2-Rnr4 release from the
nucleus. A significant decrease in Difl abundance was also ob-
served when log phase cells were treated with HU or methylme-
thane sulfonate (MMS), also coinciding with Rnr2-Rnr4 release.
This damage-induced reduction in Difl levels is DUN1 dependent
(Figure 3B). To separate the cell-cycle-induced reduction of
Difl from the DNA-damage-induced reduction of Difl, cells
were first arrested in G2/M phase by nocodazole, and then
treated with phleomycin or ionizing radiation (IR) while maintain-
ing G2/M arrest. Under these conditions, phleomycin and IR also
reduced the abundance of Difl in a Dunl-dependent manner
(Figure 3C).
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Figure 1. Difl Is an Inhibitor of S Phase Cell-Cycle Progression and a Paralog of Smil
(A) Sequence alignment between S. cerevisiae (Sc) Difl, Smll, and Hugl; S. pombe (Sp) Spdl; and A. gossypii (Ag) Aer122c. The three conserved domains, the
Hug domain, the Sml domain, and the Rnrl-binding domain, are boxed.
(B) Simplified diagrams showing the three different domains of the orthologs of Difl. The Rnrl-binding domain (R1B), which has been characterized through
mutational analysis, was further divided into an N-terminal (cyan) and a C-terminal (blue) subdomain.
(C) Synteny in the proximity of the HUG1/SML1 loci on chromosome XIII and the DIF1 (YLR437c) locus on chromosome XII in S. cerevisiae.
(D) sm/1A and meclA sml1A strains containing vector alone or a galactose-inducible DIF1 plasmid (pGAL1::DIF1) were serially diluted and spotted on glucose
and galactose media.
(E) Cell-cycle profiles of sm/1A and meclA sm/lA strains overexpressing DIF1. Cells were grown to log phase in glucose before being switched to galactose.
Samples were taken from 0 to 4 hr after the galactose switch for FACS analysis of DNA content.
(F) Tetrad dissection of the MEC1/meclA::his5 + DIF1/dif1A::TRP1 diploid. Arrows mark small colonies, which are HU sensitive and tryptophan and histidine
prototrophic (data not shown).
Difl Is Phosphorylated after Hydroxyurea Treatment
We observed that N-terminal tagging of endogenous Difl with
3Myc led to an increase of the abundance of Difl protein. As
early as 20 min after the release of the smll strain from G1
into HU, 3Myc-Difl was observed to migrate as a doublet (Fig-
ure 3D). However, in the meclA smllA mutant, the shift of
3Myc-Difl from lower to higher mobility was delayed by as
much as 40-60 min and never reached completion even after
2 hr, compared with 40 min for wild-type (WT). HU treatment
does not reduce the 3Myc-Difl levels, indicating that WT
Difl is destroyed in response to HU, but that 3Myc-Difl is
stabilized.
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The mobility shift of 3Myc-Difl in response to DNA damage
suggested possible phosphorylation. Phosphatase (PPase)
treatment of 3Myc-Difl from HU-treated cells confirmed that
the mobility shift was due to phosphorylation (Figure 3E).
The delayed phosphorylation of 3Myc-Difl in the meclA
smIlA mutant is most likely due to the redundant function of
the Tell kinase, as the phosphorylation of Rad53 still occurs,
although with slower kinetics (data not shown). This Difl phos-
phorylation is not observed in dunlA mutants (Figure 3F),
suggesting that Dun1 may directly phosphorylate Difl.
To assess if 3Myc-Difl is inactivated after phosphorylation
independent of degradation, Gl-arrested 3Myc-DIF1 cells
pVector
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meclA pVector
sm/lA IpGAL::DIF1
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Figure 2. Difl Is Required for the Nuclear Localization of Rnr Small
Subunits
(A) difla strains complemented with either vector alone or with a plasmid
containing the wild-type (WT) DIF1 gene were grown to log phase, or arrested
in G1 with a factor, or arrested in G2/M with nocodazole. Cells were processed
for Rnr2 visualization by indirect immunofluorescence.
(B) G1 - or G2/M-arrested WT and dun 1 difl A strains were processed for Rnr2
visualization by indirect immunofluorescence.
(C) Comparison of Rnr2 localization in WT and wtmlA and diflA mutants. Cells
were either grown to log phase, arrested in G1, or arrested in G2/M. Samples
were processed for Rnr2 visualization by indirect immunofluorescence. Exam-
ples of cells with strong nuclear Rnr2 staining are marked with white arrowheads,
and cells with partially nuclear Rnr2 staining are marked with white arrows.
were released into 150 mM HU and examined for Rnr2 localization.
The 3Myc-DIF1 strain showed a degree of nuclear Rnr2 release
that was comparable to WT (Figure 3G), although the phosphory-
lated 3Myc-Difl protein is not efficiently degraded even after 2 hr
of HU treatment (Figures 3D and 3F). Thus, degradation is not ab-
solutely required for Rnr2 regulation and suggests that phosphor-
ylation may be sufficient to inhibit Difl function.
The Sml Domain of Dif Is a Phospho-Degron
To identify potential phosphorylation sites on Difl, a large-scale
immunoprecipitation and mass spectrometry analysis was car-
ried out with lysates from HU-treated 3Myc-DIF1 cells. Phospho-
mapping detected phosphorylation on S103 or T104 of the Sml
domain (Figure 3H).
Smll can be phosphorylated by the Dun1 kinase in vitro, and
its degradation during S phase and after DNA damage requires
U
Dun1 (Uchiki et al., 2004; Zhao and Rothstein, 2002). To link
Difl phosphorylation to its degradation, we mutated several of
the mapped and conserved serine and threonine residues in
the Sml domain to alanine. Difl carrying these single mutations
showed no increase in protein stability after DNA damage or rep-
lication stress (data not shown). Therefore, we made a mutant
Difl (DIF1-4A) consisting of the two residues mapped by mass
spectrometry (S103 and T104) along with two highly conserved
serine residues (S107 and S108) that are conserved in Smll
and were shown to be phosphorylated by Dun1 in vitro (Uchiki
et al., 2004). Difl-4A was not degraded when G2/M-arrested
cells were treated with phleomycin (Figure 4A) or when G1 cells
were released into the cell cycle in the presence of HU (Fig-
ure 4B), and Difl-4A mutants were significantly impaired with
regard to the release of Rnr2-Rnr4 in both circumstances
(Figures 4C-4E).
Since the degree of conservation is high throughout the Sml
domain in addition to the serines and threonines mutated in
Difl -4A, we reasoned that a larger part of this domain may be re-
quired for the degron function. Therefore, we changed the most
conserved residues, PPMLINQRT, in this domain to alanines
while preserving the four phosphoserine/threonine residues
and tested this mutant protein (Difl-sml) for its stability during
DNA-damage response. As shown in Figures 4F and 4G, the
Difl-sml mutant protein failed to display a comparable mobility
shift or reduction in protein level after HU or phleomycin treat-
ment compared to WT Difl, but maintained the ability to localize
Rnr2-Rnr4 inside the nucleus (Figure 4H). Therefore, the Sml
domain is required for the phosphorylation and degradation of
Difl after DNA damage or replication stress.
Difl Is Directly Phosphorylated by the Duni Kinase
To determine whether Dun1 can directly phosphorylate Difl,
we purified GST-Dunl from Baculovirus-infected SF9 insect cells
and incubated it with different mutant Difl proteins in the presence
of [y-3 2 P]ATP. As shown in Figure 41, incubation of GST-Dunl with
WT Difl (Difl -WT) and a Difl mutant altered in the Hug domain
(Difl-hug, see Figure 7 for details), but not phospho mutant Difl
(Difl-4A), results in incorporation of 32p. This, together with
the phosphomapping data by mass spectrometry (Figure 3H),
indicates that the Dun1 kinase can directly phosphorylate Difl
on residues, which leads to its inactivation and degradation.
Dif Is Much Less Abundant than Rnr2
One model for the role of Difl in Rnr2-Rnr4 localization is as an
adaptor that enhances the association of Rnr2-Rnr4 with
Wtml. If this model is correct, Difl and Rnr2-Rnr4 should be
present in roughly equal amounts. Thus, we carefully determined
the absolute abundance of Rnrl, Rnr2, Rnr4, and Difl. Rnrl and
Rnr2-Rnr4 were purified as previously described (Ge et al., 2001;
Nguyen et al., 1999), and Difl was purified from E. coli as a His 6-
tagged protein. We estimated the concentration of purified Rnrl,
Rnr2, Rnr4, and Difl proteins with Coomassie staining by using
known BSA standards (Figures 5A-5D, left panels). Serial dilu-
tions of these protein samples were loaded alongside cell lysates
from asynchronous cultures of WT cells in log phase or cell lysates
from samples after release from a G1 block (Figures 5A-5D, right
panels). Clb5 serves as a marker of cell-cycle progression
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Figure 3. Difl Is Regulated during the
Cell-Cycle and DNA-Damage Responses
(A) Cell-cycle analysis of Difl abundance. Cells
arrested in G1 by a factor were released into
the cell cycle. Samples were collected at
10 min intervals for western blotting of Difl.
Clb5 was used to monitor cell-cycle progression.
Ponceau staining served as a loading control. A
log phase sample from an asynchronous (AS)
population of cells was loaded in the first lane
for comparison.
(B) Western blot analysis of Difl from log phase
wild-type (WT) and dunlA cells treated with HU
(150 mM, 1.5 hr) or MMS (0.1%, 1.5 hr). Tubulin
(Tubl) serves as a loading control.
(C) Western blot analysis of Difl from WT
and dunlA cells treated with phleomycin (Ph,
50 ng/ml, 1 hr) or ionizing radiation (IR, 20 kRad,
1 hr) while maintained in G2/M arrest.
(D) Mecl-dependent posttranslational modifica-
tion of 3Myc-Difl in smIlA and meclA smllA
cells. Cells with a single copy of 3Myc-DIF1 inte-
grated at the endogenous locus were arrested
in G1 by a factor, and then released into the
cell cycle in the presence of HU (150 mM).
Samples were collected at 20 min intervals for
western analysis of 3Myc-Difl mobility and abun-
dance. Clb5 was used to monitor cell-cycle
progression.
(E) Phosphatase (PPase) treatment of 3Myc-Difl.
Log phase yeast cells carrying integrated 3Myc-
DIF1 were treated with HU (150 mM, 1.5 hr).
3Myc-Difl was immunoprecipitated from the
lysate and subjected to PPase treatment, with
or without PPase inhibitors.
(F) Dunl-dependent Difl phosphorylation after
HU treatment. WT and dunlA strains with
integrated 3Myc-DIF1 were arrested in G1 by a factor, and then released into HU media (150 mM). Samples were collected at 20 min intervals for western
analysis of 3Myc-Difl mobility and abundance.
(G) Rnr2 visualization by indirect immunofluorescence of WT or a 3Myc-DIF1-integrated strain arrested in G1 phase with a factor, and then released into HU
media (150 mM) for 1 and 2 hr.
(H) Phosphomapping of 3Myc-Difl. Log phase cells with integrated 3Myc-DIF1 were treated with HU (150 mM, 1.5 hr). 3Myc-Difl was immunoprecipitated
with anti-Myc antibodies, resolved and silver stained on SDS-PAGE, and excised for phosphomapping by mass spectrometry. The "#" signs indicate two
potential sites for phosphorylation.
(Figure 5E). We estimate that during log phase, the number of mol-
ecules per cell for Difl, Rnrl, Rnr2, and Rnr4 is 1,300, 16,000,
190,000, and 130,000, respectively. The molecular ratio of
Difl:Rnrl is -1:12, and that of Difl:Rnr2 is -1:140. At 80 min after
G1 release, when cells are in G2 and the abundance of Difl is max-
imal, the ratio of Difl:Rnrl is 1:8.3, whereas that of Difl:Rnr2 is
1:110. Thus, the number of Rnr2 molecules greatly exceeds that
of the Difl molecules. This indicates that Difl cannot act as a stoi-
chiometric adaptor that facilitates binding to Wtml, and instead
suggests that Difl functions catalytically to maintain nuclear
Rnr2-Rnr4.
DIFI and WTM1 Regulate Rnr2-Rnr4 Localization
through Mechanistically Distinct Pathways
The elimination of the Wtml adaptor role for Difl opened up the
possibility that it might work in a separate pathway from Wtml
even though their null phenotypes are very similar (Figure 2C).
Thus, we examined Rnr2 localization in the difl wtm l mutants
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compared to the single mutants. Whereas each mutant displayed
residual nuclear accumulation, difl A wtm 1 double mutants lost
this residual nuclear Rnr2 staining and often displayed significant
Rnr2 nuclear exclusion (Figure 6A, black arrows). The above-
mentioned observation suggests that Wtml and Difl can func-
tion through separate mechanisms and may be involved in differ-
ent pathways.
If Difl functions through a mechanism independent of Wtml,
hyperactivation of either the Difl or Wtml pathway might sup-
press the defective Rnr2-Rnr4 anchoring phenotype of the other
mutants. Thus, we overproduced Difl in the wtml A background,
or Wtml in the diflA background. Difl overproduction signifi-
cantly rescued the Rnr2 localization defect in wtml mutants
(Figure 6B), whereas overproduction of Wtml in diflA mutants
had no effect (data not shown). Together, the enhanced defect
of the double mutants and the suppression of wtml mutants
by DIF1 overproduction suggest that Wtml and Difl operate in
two independent branches of the Rnr2 localization pathway.
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(I) Dun1 in vitro kinase assay. Polyclonal anti-Difl antibodies were used to immunoprecipitate Difl from difl A yeast strain complemented by plasmid alone (A), wild-
type (WT), phospho mutant (4A), and hug-domain mutant (hug) Difl, and then incubated with or without recombinant GST-Dunl purified from insect cells in the
presence of [y32 -P]ATP. The bottom panel shows a western blot with anti-Difl antibodies. The predominant Difl bands are marked with single asterisks. The dif-
ference in their size is dueto site-directed mutagenesis. The top panel shows an autoradiograph; the expected position of each Difl from the western blot is marked
by arrows. The nonspecific bands present even in the diflA sample are marked by double asterisks.
DIFI Is Required for the Nuclear Import of Rnr2-Rnr4
The inability of diflA mutants to localize Rnr2-Rnr4 could be due
either to a defective import or to a problem in retaining Rnr2-Rnr4
inside the nucleus once imported (i.e., enhanced export or failed
anchoring). If this is a nuclear retention defect, blocking nuclear
export should accumulate Rnr2-Rnr4 inside the nucleus. Alter-
natively, if the defect occurs prior to nuclear import, blocking
the nuclear export would have a minimal effect on nuclear accu-
mulation. Therefore, we used leptomycin B (LMB) to inhibit the
Crml exportin pathway (Kudo et al., 1998), which is essential
for the release of nuclear Rnr after DNA damage in S. pombe
(Liu et al., 2003). We confirmed that release of Rnr2 from the
nucleus after HU treatment is inhibited by LMB, by using a strain
carrying the LMB-sensitive CRM1-T439C allele (Neville and
Rosbash, 1999) (data not shown).
We first examined the effects of blocking nuclear export in the
wtmlA mutant. A GAL I::GFP-RNR4 reporter plasmid was intro-
duced into different strains, induced for 3 hr, then repressed by
the addition of glucose to prevent further synthesis of the
reporter during the analysis (Figure 6C). LMB was then added
for an additional hour prior to visualization. LMB treatment led
to the nuclear accumulation of GFP-Rnr4 in the wtmlA, LMB-
sensitive background (Figures 6D and 6E), consistent with
a role for Wtml in nuclear retention rather than import. In con-
trast, LMB treatment of the difl A or difl A wtm 1A double mutants
did not cause nuclear accumulation of the GFP-Rnr4 reporter
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Figure 4. The Smi and Hug Domains Have
Distinct Roles in Difl Regulation
(A) Western blot analysis of wild-type (WT) and
phospho mutant Difl after phleomycin treatment.
diflA strains containing a WT DIF1 plasmid
(pDIF1-WT) orthe phospho mutant plasmid (pDIF1-
4A) were treated with phleomycin (50 ng/ml) for the
indicated times during G2/M arrest by nocodazole.
Tubulin (Tubl) served as a loading control.
(B) Western blot analysis of WT and phospho
mutant Difl from cells arrested in G1 by a factor,
and then released into HU media (150 mM) for
the indicated times.
(C) G2/M-arrested WT and phospho mutant Difl
strains were treated with phleomycin for 2 hr and
processed for Rnr2 visualization by indirect immu-
nofluorescence.
(D) WT or phospho mutant Difl cells were arrested
in G1 by a factor (crF) or released from G1 into HU
(150 mM) for 1 hr and processed for Rnr2 visualiza-
tion by indirect immunofluorescence. Examples of
cells with Rnr2 staining that is predominately
nuclear (white arrowhead), predominately cyto-
plasmic (black arrow), or equal in distribution (white
arrow) are indicted.
(E) Quantification of (D). For each treatment, more
than 160 cells were counted (range: 161-200 cells).
(F) Western blot analysis of WT, hug-domain
mutant, or sml-domain mutant Difl after phleomy-
cin treatment. diflA strains complemented by
plasmids containing WT (pDIF1-WT), hug-domain
mutant (pDIF1-hug), or sml-domain mutant
(pDIFl-sml) versions of DIF1 were treated with
phleomycin (50 ng/ml) for the indicated times while
maintained in G2/M. Tubulin (Tubl) served as the
loading control.
(G) Western blot analysis of Difl, Difl-hug, and
Difl-sml mutants after HU treatment. diflA strains
complemented by plasmids containing WT
(pDIF1-WT), hug-domain mutant (pDIFl-hug), or
sml-domain mutant (pDIFl-sml) versions of DIF1
were arrested in G1 by a factor, and then released
into HU media (150 mM) for the indicated times.
(H) Rnr2 visualization by indirect immunofluores-
cence from log phase cultures of diflA strains
carrying pDIF1-WTor pDIFl-sml plasmids.
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(Figures 6D and 6E), indicating that the defect of the diflA mutant
occurs prior to nuclear import. To rule out potential cell-cycle arti-
facts, a factor was used to arrest cells in G1 before LMB treatment
and provided similar results (Figure 6F). These results indicate that
Difl is a regulator of nuclear import of Rnr2-Rnr4.
Difl Directly Binds to Rnr2-Rnr4 Complexes
Difl may affect nuclear import of Rnr2-Rnr4 directly or indirectly.
However, a strong prediction of the direct importer model is that
Difl will directly bind Rnr2-Rnr4 complexes. Consistent with that
possibility, during the course of our investigation we found that
purified recombinant Difl had a mild but reproducible inhibitory
effect on RNR enzymatic activity in vitro (data not shown). We
therefore examined binding between purified Difl and RNR sub-
units by using surface plasmon resonance. Rnr2-Rnr4 immobi-
lized on the surface of the sensor chip could bind to Difl in
a dose-dependent manner (Figure 7A). We calculated the KD of
this binding to be 0.6 gM. Conversely, Difl immobilized on the
surface of the sensor chip also bound to Rnr2-Rnr4 heterodimers
(data not shown). No detectable binding to the Rnrl homodimer
was observed (data not shown). To examine what portion of Difl
might mediate this interaction, we generated mutations in the
conserved Hug domain (Difl-hug) (Figure 7B). The binding of
Difl to Rnr2-Rnr4 required an intact Hug domain (Figure 7A). Im-
portantly, the Difl-hug mutant was also defective for the proper
nuclear localization of Rnr2-Rnr4 (Figure 7C), even though it
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Figure 5. Difl Is Much Less Abundant than the Rnr2-Rnr4
Heterodimer
(A) Left panel: known standards of bovine serum albumin (BSA) were
resolved on SDS-PAGE alongside of five-fold serial dilutions of puri-
fied recombinant His 6-Difl to estimate the concentration of the origi-
nal Difl sample in nanograms. Difl serial dilutions that are beyond the
range of the BSA standard were not used for estimation of protein con-
centration and were marked by asterisks (*). Right panel: known quan-
tities of His6-Difl were resolved on SDS-PAGE alongside of lysates
from asynchronous (AS) and synchronized WT cells released from
a G1 block and taken at 20 min intervals. The membrane was probed
with anti-Difl antibodies.
(B) As in (A), except measuring Rnrl. Right panel: estimated Rnrl:Difl
ratios are indicated below the western blot for the asynchronous,
0 min, and 80 min time points.
(C) As in (A), except measuring Rnr2.
(D) As in (A), except measuring Rnr4.
(E) Clb5 western blot to show progression of S phase in the synchro-
nized culture.
(F) Tubulin western blot serves as a loading control.
maintained similar kinetics of phosphorylation and degra-
40 dation as Difl-WT (Figures 4F and 4G). We have consis-
tently observed higher levels of endogenous Difl-hug
compare to WT Difl for unknown reasons. These data
suggest that Difl facilitates the nuclear import of Rnr2-
Rnr4 via direct binding through its Hug domain.
o DISCUSSION
The precise control of intracellular dNTP pools is critical to
the maintenance of genomic integrity. Therefore, organ-
isms have evolved multilayered controls to regulate the RNR
pathway. In yeast, RNR is regulated by the cell-cycle and
DNA-damage response pathways through gene expression, in-
hibitor destruction, and subcellular localization-the focus of
this study. Our previous studies demonstrated that the nuclear
protein Wtml secures Rnr2-Rnr4 inside the nucleus through an
anchoring mechanism. However, how localization responded to
DNA damage was not understood. Our current study identifies
a DNA-damage-regulated protein, Difl, that controls the nuclear
localization of Rnr2-Rnr4 by regulated nuclear import.
Dif and Wtml Form Distinct Branches of the RNR
Nuclear Localization Pathway
Initially, the similarities in the phenotypes of diflA and wtm 1 mu-
tants suggested that they might function in the same pathway,
possibly by forming a complex with Wtml and Rnr2-Rnr4. How-
ever, careful analysis of the relative abundance of Difl and the Rnr
proteins showed that Difl was much less abundant than Rnr2 and
Rnr4, eliminating the co-tether model. Instead, we find that DIF1
and WTM1 function in different branches of the Rnr localization
pathway based on several pieces of data. First, diflA wtmlA
double mutants display enhanced cytoplasmic localization of
Rnr2-Rnr4 relative to the single mutants. Second, overexpres-
sion of Difl suppresses the defect in Rnr2-Rnr4 nuclear localiza-
tion in wtmlA mutants. Finally, blocking nuclear export by
using LMB in wtmlA mutants caused accumulation of nuclear
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Rnr2-Rnr4, and this accumulation was prevented in the wtmlA
diflA double mutants. This observation is consistent with the
role of Wtml as a nuclear anchor to limit nuclear export, whereas
Difl facilitates the nuclear import of Rnr2-Rnr4 and leads to the
model shown in Figure 7D. In this model, Wtm1 acts to limit the nu-
cleoplasmic levels of Rnr2-Rnr4 complexes that are available for
nuclear export. This reduces the rate of flux out of the nucleus and
makes the system more responsive to the rate of nuclear import.
Regulation of this localization switch is accomplished largely
through modulation of the rate of nuclear import through Difl.
Difl is controlled at three levels. First it is cell-cycle regulated,
with its abundance peaking at the end of S phase, when Rnr2-
Rnr4 returns to the nucleus. There are likely to be additional
aspects to this regulation induced by a factor, as Difl levels are
lower in a factor-arrested cells, yet they are sufficient to localize
Rnr2-Rnr4 into the nucleus. The rates of nuclear export could be
regulated by a factor. Consistent with this, wtm 1 mutants show
more nuclear localization in a factor-arrested cells. Second, Difl
is regulated by proteolysis through direct phosphorylation by the
Dun1 kinase on the Sml domain, which constitutes a phosphode-
gron. The four serine and threonine residues near the end of the
Sml domain are essential for the phosphorylation, inhibition, and
destruction of Difl in response to DNA damage. Mutation of
the phosphorylation sites results in stabilization of Difl and
defective release of nuclear Rnr2-Rnr4 in response to DNA dam-
age. Finally, phosphorylation of the Smi domain is sufficient
to abolish the function of Difl prior to its degradation. This, to our
knowledge, is the first example of a phosphorylation event that
both inactivates a protein and separately targets it for degradation.
Although regulatory information flows through the Difl branch
of the pathway, there are additional regulatory inputs into the
system, because the residual nuclear localization seen in difl
mutants can be relieved by treatment with HU to generate a
nuclear halo or empty nucleus phenotype seen in wtmlA diflA
double mutants. Whether this works through regulation of
Wtml -Rnr2-Rnr4 affinity, the rate of nuclear export via regulation
on the exportin Crml, or the residual DIF1-independent Rnr2-
Rnr4 nuclear import pathway remains to be determined.
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Figure 6. Difl Controls the Nuclear Import
of Rnr2-Rnr4
(A) The nuclear localization of Rnr2 in the diflA
wtmlA double mutant was compared to wild-
type (WT), wtmlA, and diflA single mutants.
Log phase and G1-arrested cells were processed
for visualization of Rnr2 by indirect immuno-
fluorescence. Cells with strong nuclear Rnr2 stain-
ing (white arrowhead), residual nuclear Rnr2 stain-
ing (white arrow), and Rnr2 nuclear exclusion
staining (black arrow) are indicated.
(B) wtmlA strains containing vector alone or a
galactose-inducible DIF1 plasmid (pGAL::DIF1)
were grown to log phase in glucose media. Cells
were then switched to galactose media for 3 hr,
while either being kept in log phase or arrested
in G1 or G2/M. Samples were processed for Rnr2
visualization by indirect immunofluorescence.
(C) A schematic of the experiment used to exam-
ine nuclear import of Rnr2-Rnr4. Cells were
grown to log phase in raffinose-glucose media,
then switched to raffinose-galactose media for
3 hr to turn on the transcription of the GAL1-
GFP-RNR4 reporter. The promoter was shut off
by switching back to glucose media for 3 hr, be-
fore leptomycin B was added for an additional
hour (LMB, 200 ng/ml). For the analysis of G1-
arrested cells, the last two steps (4 hr) were car-
ried out in the presence of a factor. Cells were
photographed for GFP-Rnr4 localization.
(D) GFP-Rnr4 localization in WT, wtmlA, diflA,
and wtmlA diflA mutants in the LMB-sensitive
(Crml-T539C) background were treated with or
without LMB during log phase.
(E) Quantification of GFP-Rnr4 localization in (D).
(F) Quantification of GFP-Rnr4 localization in
Gi-arrested cells, treated with or without LMB.
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Figure 7. Difl Directly Interacts with Rnr2-Rnr4
(A) Binding between Difl and Rnr2-Rnr4 was detected with BIAcore. Purified Rnr2-Rnr4 was immobilized on the sensor surface. Recombinant wild-type (WT) Difl
protein (Dif 1 -WT) flowed over the immobilized Rnr2-Rnr4 at the indicated concentrations. Recombinant Difl-hug (Dif -hug) protein flowed over the same sensor
surface at a concentration of 5.0 gM (turquoise line). Binding between Rnr2-Rnr4 and Difl was measured in response units (RU).
(B) Diagram of the amino acid changes in the Difl-hug mutant.
(C) Rnr2 visualization by indirect immunofluorescence from log phase cultures of diflA strains carrying pDIF1-WT or pDIFl-hug plasmids.
(D) Model demonstrating nuclear import and retention of Rnr2-Rnr4 in response to DNA damage. (Left) Difl facilitates the nuclear import of Rnr2-Rnr4,
whereas Wtml functions as a nuclear anchor for Rnr2-Rnr4. In the absence of DNA damage, the net contribution of these two pathways leads to a net ac-
cumulation of Rnr2-Rnr4 inside the nucleus. (Right) Activation of the DNA-damage response (DDR) leads to the phosphorylation, inactivation, and degradation
of Difl, reducing the nuclear import of Rnr2-Rnr4. DNA damage also releases the pool of nuclear Rnr2-Rnr4, either by decreasing the affinity between the
Wtml-Rnr2-Rnr4 interactions, or through an increased rate of Crml-mediated Rnr2-Rnr4 nuclear export.
The key mechanistic insight into Difl function comes from the
direct binding of Difl with Rnr2-Rnr4 through the Hug domain.
Difl-hug mutants retain the ability to be phosphorylated and de-
graded in response to DNA damage, but fail to properly localize
Rnr2-Rnr4. Given the inability of the diflA mutant to import
Rnr2-Rnr4, the simplest model is that Difl binds the Rnr2-Rnr4
complex through its Hug domain and activates import by serving
as an adaptor or by activating a latent nuclear localization signal
on the Rnr2-Rnr4 complex. In unpublished work, we have iden-
tified candidate importins/karyopherins with defective Rnr2-
Rnr4 nuclear localization. The mechanism of how Difl influences
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the interaction between Rnr2-Rnr4 and its importin(s) remains an
important area to be elucidated.
A Unifying Theory for Functions of the Spdl, Dif1,
and Smll Families of Rnr Regulators
The DIF1 and the HUG1/SML1 loci are syntenic and arose from
a genome duplication in an ancestor of S. cerevisiae (Dietrich
et al., 2004; Kellis et al., 2004) that further diverged into three
separate genes. The likely structure of the original protein is
best illustrated by their ortholog, Aer122c, in Ashbya gossypii,
a species closely related to S. cerevisiae but which did not
i i L I ! I
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undergo the genome duplication. Aer122c is also related to
S. pombe Spdl, the first demonstrated regulator of Rnr small sub-
unit localization. Spdl has been shown to maintain spRnr2
(Suc22) of S. pombe in the nucleus (Liu et al., 2003). However,
recent experiments have suggested that it acts as an inhibitor
of RNR activity by binding to S. pombe spRnrl (Cdc22), the large
RNR subunit, casting doubt on the suggested spRnr2 nuclear re-
tention mechanism. Our work proposes an explanation for these
seeming discrepancies. We propose that Spdl, Difl, Smll, and
Hug1 all evolved from a common ancestral gene related to
Aer122c that had three basic domains. The first domain, which
we call the Hug domain, is required for the physical binding
and nuclear import of Rnr2 family members. The second domain,
the SmI domain, is a degron/phosphodegron that confers DNA-
damage and cell-cycle regulation on the activities of the pro-
teins. The third domain is the R1B domain that binds the Rnrl
subunit to act as an RNR enzymatic inhibitor. Thus, this ancestral
gene employed two different mechanisms through which to
negatively regulate RNR function and a regulatory region that
allowed those functions to be modulated. We propose that
Spdl is closely related to this ancestral gene and retains all three
functions, although its degradation is likely regulated at the level
of ubiqutin ligase activation rather than through phosphorylation
of the degron (Liu et al., 2005). This explains what had on the sur-
face appeared to be an inconsistency with the ability of Spdl to
bind spRnrl but at the same time localize spRnr2. In budding
yeast, these functions have been split between Difl and Smll.
Both proteins retain a phosphodegron that confers cell-cycle
and DNA-damage regulation through an as yet unknown ubiqui-
tin ligase. However, Difl lacks the C-terminal Rnrl-interacting
domain, whereas Smll lacks the Rnr2-binding Hug domain.
The biochemical role of the damage-inducible Hug1 protein re-
mains to be elucidated, although our model would predict that
it should be able to bind Rnr2-Rnr4, and possibly compete
with or negatively regulate Difl activity.
Our discovery of Difl has illuminated part of the mechanism
cells use to regulate localization of RNR small subunits. To our
knowledge, the combination of a nuclear anchor limiting nuclear
export and a regulated importer to coordinate subcellular localiza-
tion appears to be unique. This is yet another example of a dynamic
switch in which two antagonistic processes, here export and im-
port, are coordinately regulated to produce an outcome, much
like Cdkl phosphorylation and dephosphorylation (Harper and El-
ledge, 2007) and Cdc20 ubiquitination and deubiquitination (Steg-
meieret al., 2007). This is likely to be a strategy that will be found to
regulate the localization of many other proteins in the future.
EXPERIMENTAL PROCEDURES
Media and Growth Conditions
a factor and nocodazole arrest were carried out as previously described
(Desany et al., 1998). DNA-damage agents were used at the following concen-
trations: phleomycin, 25-100 ng/ml; MMS, 0.1%; HU, 150 mM; and ionizing
radiation, 20 kRad. Leptomycin B (LC laboratories) was used at 100-200 ng/ml.
Polyclonal Antibody for Difl
Recombinant full-length GST-Difl was purified from E. coli and was used to
generate a rabbit antibodies (Bethyl Laboratories). For western blot analysis,
a 1:1000 dilution was used.
U
Protein Sample Preparation and Phosphatase Treatment
TCA precipitation was performed as previously described (Longhese et al.,
1997). Phosphatase treatment of protein sample was carried out as described
(Vialard et al., 1998), except that calf intestinal phosphatase (New England
Biolab) was used as the phosphatase, and 10 mM Na3VO4 and 50 mM
EDTA were used as the phosphatase inhibitors.
Indirect Immunofluorescence and Visualization of GFP
Indirect immunofluorescence was performed as previously described (Lee and
Elledge, 2006). Both anti-Rnr2 and anti-Rnr4 antibodies were used at 1:10,000
(Yao et al., 2003).
Phosphomapping of Dif and Rnr2
Strains carrying 3HA-Rnr2 and 3Myc-Difl were HU treated. 3HA-Rnr2 and
3Myc-Difl were immunoprecipitated and resolved by SDS-PAGE. The gel
with the 3HA-Rnr2 sample was Coomassie stained, whereas that with
3Myc-Difl was silver stained by SilverQuest (Invitrogen). The bands were
excised for phosphomapping analysis.
In Vitro Duni Kinase Assay
Wild-type, phosphoserine/threonine-mutated, or Hug-domain-mutated Difl
strains were used for immunoprecipitation by anti-Difl polyclonal antibodies.
The Difl proteins were left on 15 pl protein A beads and washed twice with
kinase buffer (50 mM Tris-HCI [pH 7.5], 10 mM MgCl2, 1 mM DTT, 0.1 mM
NaVO4). GST-Dunl purified from Baculovirus-infected SF9 insect cells was
incubated with the protein A beads containing Difl in 100 tl kinase buffer,
with 2 gM cold ATP, and 5 [iCi [y-32P]ATP at 30'C for 45 min.
Protein Expression and Purification
Rnrl and Rnr2-Rnr4 were purified from yeast as described (Ge et al., 2001;
Nguyen et al., 1999). His 6-tagged DIF1 plasmid (based on the pET15b vector)
in BL21(DE3) pLysS cells were grown to an OD600 of 0.6 and were induced
overnight with IPTG (0.2 mM) at 18°C. Cells were washed, resuspended in
binding buffer (30 mM Tris [pH 7.5], 150 mM NaCI, 1 mM DTT, 0.1% Triton,
1 mM PMSF, Roche Complete Protease Inhibitor Cocktail), and sonicated to
disrupt the cells. The crude lysate was spun at 10,000 x g for 15 min. Difl pro-
tein in the supernatant was purified by using Ni-NTA beads according to the
Qiaexpressionist manual (QIAGEN), with 5 mM imidazole added to the binding
and washing steps to increase the stringency of purification. Hise-Difl was
eluted by 200 mM imidazole and dialyzed into the appropriate buffers.
Quantification of Protein Abundance
Coomassie-stained SDS-PAGE or exposed films from western blots were
scanned digitally, and the intensity of protein bands was quantified by using
the gel analysis function of ImageJ software (NIH). For the western blot quan-
tification of Difl, Rnrl, Rnr2, and Rnr4, each lane was loaded with 170, 17, 3.4,
and 3.4 ng protein from cell lysate, respectively. The total number of cells used
for protein extraction was determined by colony plating and optical density
(ODeoo) and is used for the calculation of molecules per cell.
BIAcore Analysis
Purified Rnr2-Rnr4 was immobilized on a CM5 chip by amine coupling at a level
of 9945 response units (RU). All analytes were dialyzed in PBS buffer, which
also serves as the running buffer. The binding assay was carried out at 251C
with a flow rate of 30 l/min on a Biacore 3000. Data were analyzed by using
BIAevalution 3.2 software, and reference was subtracted and corrected for
the bulk effect. Binding affinity was calculated by steady-state fit by using
a 1:1 binding model.
Strains and Plasmids
For a complete list of yeast strains and plasmids used for this work, see Table
S1 (available online).
SUPPLEMENTAL DATA
The Supplemental Data include a table listing the strains and plasmids used and
are available at http://www.molecule.org/cgVcontent/fulv32/1/70/DC1/.
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Ribonucleotide reductases (RNRs) catalyze the conversion of nu-
cleotides to deoxynucleotides in all organisms. The class I RNRs are
composed of two subunits, a and j3, with proposed quaternary
structures of a2P32, a6P32, or a6136, depending on the organism. The
a subunits bind the nucleoside diphosphate substrates and the
dNTP/ATP allosteric effectors that govern specificity and turnover.
The 32 subunit houses the diferric Y* (1 radical per 32) cofactor that
is required to initiate nucleotide reduction. 2',2'-Difluoro-2'-
deoxycytidine (F2C) is presently used clinically in a variety of cancer
treatments and the 5'-diphosphorylated F2C (F2CDP) is a potent
inhibitor of RNRs. The studies with [1'- 3H]-F2CDP and [5-3 H]-F 2CDP
have established that F2CDP is a substoichiometric mechanism
based inhibitor (0.5 eq F2CDP/a) of both the Escherichia coliand the
human RNRs in the presence of reductant. Inactivation is caused by
covalent labeling of RNR by the sugar of F2CDP (0.5 eq/a) and is
accompanied by release of 0.5 eq cytosine/a. Inactivation also
results in loss of 40% of 32 activity. Studies using size exclusion
chromatography reveal that in the E. coli RNR, an a232 tight
complex is generated subsequent to enzyme inactivation by F2CDP,
whereas in the human RNR, an a6136 tight complex is generated.
Isolation of these complexes establishes that the weak interactions
of the subunits in the absence of nucleotides are substantially
increased in the presence of F2CDP and ATP. This information and
the proposed asymmetry between the interactions of anPn pro-
vide an explanation for complete inactivation of RNR with subs-
toichiometric amounts of F2CDP.
G emcitabine, or 2',2'-difluoro-2'-deoxycytidine (F2C), is a drug
that is used clinically in the treatment of advanced pancreatic
cancer and non-small cell lung carcinomas (1-3). In humans, F2C
enters the cell via CNT-type or ENT-type transporters (4-6) and
must be phosphorylated to exhibit its cytotoxicity. The monophos-
phate of F 2C (F2CMP) is generated by deoxycytidine kinase (7) and
is rapidly phosphorylated to the di- and triphosphates (F2CDP and
F 2CTP) (8, 9). Diphosphorylated F2C (F2CDP) is an irreversible
inhibitor of ribonucleotide reductase (RNR) (10-13), and F2CTP
functions as a chain terminator in the DNA polymerase reaction
(14, 15). Differentially phosphorylated states of gemzar can also
interfere with other enzymes involved in nucleotide metabolism.
The mechanisms of cytotoxicity of F2C depend on the phosphor-
ylated state of the inhibitor and are likely to be cell specific and
multifactoral. Our recent synthesis of [1'- 3H]-F 2CDP has provided
the required tool to investigate the mechanism by which this
molecule inactivates RNRs. Studies reported herein provide a
previously unrecognized approach for RNR inhibition, one in
which the mechanism based inhibitor (F2CDP) enhances the in-
teractions between the two subunits of RNR preventing nucleotide
reduction despite substoichiometric labeling.
RNRs catalyze the conversion on nucleoside di(tri)phosphates to
deoxynucleoside di(tri)phosphates in all organisms and are the
predominant control point for abundance and ratios of dNTPs
pools required for the initiation and elongation processes catalyzed
by DNA polymerases (16, 17). The class I RNRs are composed of
two types of subunits, a and p. The quaternary structure of a is
nucleotide- and organism-dependent. It can be a monomer, dimer,
tetramer, or hexamer (16, 18). P is a homodimer that houses the
diferric-tyrosyl radical (Y') required for initiating nucleotide re-
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duction on a. Current evidence suggests that there is one Y' and
2 di-iron clusters/P2 (19, 20). The interactions between a and P are
weak (Kd of 0.2 rCM) in the absence of nucleotide (21). In prokary-
otic systems a and 3 are both homodimers. The active Escherichia
coli RNR is thought to be an a202 complex (22, 23). The a
oligomeric state of the mouse RNR has been the best characterized
eukaryotic RNR to date. In the absence of nucleotides, a is a
monomer. It dimerizes in the presence of allosteric effectors
(dATP, TTP, dGTP, and ATP) (18). In addition, the millimolar
levels of ATP found intracellularly cause a to oligomerize to a
hexamer (a6). P is a homodimer (P2). The quaternary structure of
eukaryotic RNRs is still being actively investigated. The complex
responsible for RNR activity has been proposed by Cooperman and
coworkers (18) to be a2p2, a6p2, or a6P6 on the basis of a variety
of physical biochemical and kinetic studies. Recent gas-phase
electrophoretic-mobility macromolecule analysis studies have sug-
gested that the mouse quaternary structure is a6P2 (24). Studying
subunit interactions has been difficult by conventional methods
because of a's nucleotide-dependent aggregation state and the
weak binding of a and 0, which is also nucleotide-dependent (21).
Determination of apparent molecular masses of the active RNR
complexes requires nucleotides in the analysis buffer, and thus
protein detection by UV spectroscopy is obscured (18, 23).
A number of years ago, we reported on the inactivation of E. coli
RNR by F2CDP (11, 12). We showed that 1 eq of F2CDP per E. coli
RNR, presumably a 232, in the presence of reductants, thioredoxin
(TR) and TR reductase or DTT, is sufficient for enzyme inactiva-
tion and that the inactivation is accompanied by release of 2
fluoride ions and one cytosine (12). We also demonstrated that the
mode of inhibition changed in the absence of reductants. Thus, as
with all nucleotide mechanism based inhibitors of RNRs studied in
detail, multiple modes of inactivation are involved in the inhibition
process (Scheme 1). The details of the inhibition by F2CDP have
remained largely unexplored because of the unavailability of sugar
and base radiolabeled F2CDP. We have recently developed a
method to synthesize [1'- 3H]-F 2CDP and [5- 3H]-F2CDP (9). These
compounds have allowed us to reinvestigate the mechanism of
inhibition of the E. coli RNR and to report for the first time on the
details of the inhibition of the human RNR. The present commu-
nication shows that incubation of human and E. coli RNRs with
[1'- 3H] or [5- 3H] F2CDP results in 1 eq of sugar covalently bound
per a2, which is sufficient for RNR inactivation. Size exclusion
chromatography (SEC) of the inactivated RNRs reveals that this
modification of a dramatically alters an/3n subunit interactions,
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forming a tight complex, which is ultimately responsible for com-
plete RNR inhibition.
Results
Synthesis of [1 '-3H]-F 2CDP and [5-3H]-F 2CDP. Synthesis of [1'- 3H]-F2C
involved modification of previously published procedures (25, 26).
The 2-deoxy-3,5-di-O-benzoyl-3,3-difluororibonolactone was re-
duced with [3H]-disiamylborane made from NaB3H4 and 2-methyl-
2-butene. The lactol formed was converted without purification to
2-deoxy-3,5-di-O-benzoyl-3,3-difluoro-1-O-methanesulfonyl-D-
ribofuranoside which was then coupled with bis(trimethylsilyl)-
cytosine to give, subsequent to deblocking, an a,p mixture (60:40)
of [1'- 3H]-F2 C. Phosphorylation to the monophosphate (F2CMP)
was effected by using human deoxycytidine kinase (7). Because only
the p isomer of the nucleoside is a substrate, this step allowed
removal of a F 2C. F2CMP was then phosphorylated to the diphos-
phate with human UMP/CMP kinase (8). The details of this
syntheses will be reported elsewhere (9).
Purification of the a and P Subunits of Human RNR. The clones for
a and p were obtained from the Y. Yen laboratory (City of Hope
National Medical Center, Duarte, CA). Mutations in the genes
were corrected to the sequence reported in the National Center
for Biotechnology Information (NCBI) database (27, 28), and
the N terminus of each protein was reengineered to maintain the
(His)6 tag and to reduce the length of the intervening linker
before the start of the gene to 10 aa. The proteins were purified
to -90% homogeneity based on SDS/PAGE, using Ni affinity
chromatography.
32 as isolated is a dimer in the apo form and was reconstituted
by following the protocol we have developed for reconstitution of
the E. coli P2 (29). The resulting protein had 0.8 tyrosyl radicals/P32
and a specific activity of 1,089 nmol/min/mg in the presence of a
7-fold excess of a. a was difficult to work with because of its low
solubility. However, its specific activity in the presence of a 7-fold
excess of 0 was 462 nmol/min/mg. These results contrast with
previous reports in the literature of 75 nmol/min/mg and 158
nmol/min/mg for P and 6.8 nmol/min/mg for a (30, 31). The basis
for the activity differences are not understood, but are likely related
to the complexity of the assay as we articulated in detail in ref. 32.
Table 1. Covalent labeling of E. coli and human RNR with
[1'-3H]-F 2CDP and [5-3H]-F2CDP analyzed by SEC
Protein [3H]-F2CDP Conditions [3H]/a2
E. coli RNR 1' Native 0.9
1' Denaturing 1.11
5 Native 0.19
5 Denaturing 0.08
Human RNR 1' Native 0.85
1' Denaturing 0.8
5 Native 0.1
A
0 a
Fe/0 Fe
Time-Dependent Inactivation of Human and E. coil RNRs. Our previous
studies of the mechanism of F2CDP inactivation of RNR were
carried out on the E. coli enzyme, by using unlabeled inhibitor. Our
results were provocative in that 1 mol of F2CDP inactivated 1 mol
of a2P2, which has two active sites. The experiments have been
repeated by using [1'- 3H]-F 2CDP and [5- 3H]-F 2CDP. Incubation of
15 AxM a2 and 15 [kM 02 with 15 or 30 gM of [1'- 3H]-F 2CDP
resulted in recovery of 0.9 (1.1) mol of radiolabel/RNR (a2p2) from
analysis of the reaction mixture that was passed through a Sephadex
G50 column in the absence or presence of denaturant (Table 1).
With the [5- 3H]-F2CDP, 0.19 and 0.08 eq were detected in the
absence or presence of denaturant, respectively. These results
establish that there is 1 eq of the sugar from F2CDP covalently
bound to the enzyme and that most of the cytosine has been
released. In addition, under these conditions, 40% of the tyrosyl
radical is lost similar to our previous studies (12). These results, in
conjunction with the time-dependent inactivation studies, establish
that substoichiometric amounts of F2CDP completely inactivate the
E. coli RNR.
A similar set of experiments has been carried out on the human
RNR. Time-dependent inactivation studies in which the inactiva-
tion mixture contained 0.5, 1.0, or 5.0 eq of F2CDP/a reveal that 0.5
eq of F2CDP/a results in complete loss of RNR activity (Fig. 1). The
instability of the /32 radical requires that a control in the absence of
F2CDP be carried out and used to correct the data observed in its
presence. The weak interaction between a and /3 of RNR allow
assays of the subunit activity individually (21, 32). Thus, the
inactivation mixture was assayed for activity of a (0) in the presence
of a 7-fold excess of /3 (a). Under these conditions, a is 100%
inactive. In contrast to expectations, / retained 60-70% of its
activity [supporting information (SI) Fig. 4], suggesting that the
excess a is capable of facilitating subunit dissociation. The results of
these experiments have interesting implications in recovering RNR
activity in vivo subsequent to its inactivation by F2CDP and will be
discussed subsequently.
Studies using [1'- 3H]-F2CDP and [5-3H]-F 2CDP were carried out
100
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Fig. 1. Time-dependent inactivation of human RNR by F2CDP. Inactivation
mixture contained final concentrations of a, p, 1.2 /,M; F2CDP, 0.6 M (0), and
6 /M (A); ATP, 3 mM; and DTT, 5 mM. Aliquots were removed at varioustimes
and diluted 4-fold for determination of RNR activity. Control experiment (*)
is identical to the experiment except that F2CDP was omitted.
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to determine whether the label was attached covalently. Incubation
of [1'-3H] or [5- 3H]-F 2CDP with human RNR followed by Seph-
adex G50 chromatography under native and denaturing conditions
gave the results summarized in Table 1. With the [1'- 3H] F2CDP
0.8-0.85 labels were bound per a2, whereas with the [5-3H] only 0.1
labels were covalently bound. The results are very similar to those
observed with the E. coli RNR, with the unusual stoichiometry of
1 F2CDP per a2 observed.
Cytosine Release by Human RNR. The inactivation studies suggested
that covalent modification is accompanied by cytosine release. To
test this hypothesis, 2 eq of [5-3H] F2CDPs were incubated with
a202. Subsequent to inactivation the nucleotides were recovered by
ultrafiltration and analyzed by HPLC. The analysis revealed 1 eq of
cytosine and 1 eq of F2CDP. These results parallel those reported
for inactivation of E. coli RNR (12) and support the model that
inactivation can be achieved with substoichiometric amounts of
F2CDP.
Subunit Interactions of E. coliRNR in the Presence of F2CDP. The active
form of E. coli RNR is thought to be a 1:1 mixture of a2 and p2,
although there is only one Y' per p2, suggesting the active RNR
complex is asymmetric. One way to achieve complete inactivation
of a202 with 1 F 2CDP is that once chemistry has occurred in the
active site of the first a, it precludes chemistry from occurring in the
active site of the second a. This chemistry further leads to a tight
complex between the two subunits preventing recycling of the
unmodified a. To test this model, the inactivation mixture and a
number of controls (including one with a mixture of a, P, and ATP)
were examined by using SEC on a Superose 12 FPLC column. All
elution buffers contained either 0.5 mM ATP or 100 gM TTP
previously shown to enhance a2 formation and more recently to
enhance a2P2 interactions.
The results of SEC analysis of RNR inactivated with F2CDP/
ATP, with ATP in the elution buffer, are summarized in Fig. 2A-C
and Table 2. Fig. 2A reveals a single protein peak. Fractions
collected through the protein peak were analyzed by scintillation
counting and by SDS/PAGE. The former revealed 0.9 labels per
a2P2 (Fig. 2A). The SDS/PAGE analysis (Fig. 2B) revealed the
presence of a and p. Their relative ratios were determined in each
fraction by comparison with standard curves made with known
concentrations of a and p (Fig. 2B, standard curves not shown) and
found to be -1:1 (Fig. 2C).
A control SEC analysis in the absence of F2CDP, with ATP in the
elution buffer reveals separation of a2 and P2 (Fig. 2 D and E).
Analysis of the ratio of a:p supports this conclusion (Fig. 2F). The
analysis in Fig. 2 suggests that a tight complex between subunits is
unique to the presence of F2CDP.
Further experiments were carried out to assess the resolution of
the SEC method and to obtain information about the relative
molecular masses of the observed protein peaks. The behavior of
the individual subunits and complex were examined. In the absence
of nucleotides, a migrates as a mixture of monomer and dimer with
apparent molecular masses of 105 and 143 kDa (Table 2), respec-
tively. The apparent molecular masses are obtained by comparison
of the retention times of the eluting proteins with retention times
of known molecular mass standards (SI Fig. 5). With ATP or TTP
in the running buffer, a now migrates as a dimer (a2) of 174 kDa
(Table 2 and SI Fig. 5). When RNR is inactivated by [1'- 3H]
F 2CDP/ATP and chromatographed with ATP in the running
buffer, the protein has an apparent molecular mass of 277 kDa (Fig.
2A and SI Fig. 5). The SEC analysis presented in Fig. 2 A-C, the
stability of the complex during the inactivation reaction and the
subsequent 25 min chromatogratography, and the apparent mo-
lecular mass suggests that the active form of RNR is a2P2 and that
the interaction between the subunits has dramatically increased
relative to the non-nucleotide bound forms (Table 2).
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Fig. 2. SEC on a Superose 12 column to detect complex formation (a2f2) in E.
coli RNR incubated with ATP in the presence or absence of [1'-3H] F2CDP. Elution
buffer contains 0.5 mM ATP. (A-C) Presence of F2CDP. (A) Elution profile moni-
tored by A280 nm and scintillation counting (*). (B) Fractions through the protein
peak in A monitored by SDS/PAGE. Note the slower migrating band (5% of the
protein) is an altered conformation of a. (C) Analysis of the ratio of a:P (-), using
standard curves generated from known amounts of a and P. (D-F) Absence of
F2CDP. (D) Elution profile. (E) Fractions through the protein peak in D monitored
by SDS/PAGE. (F) Analysis of the ratio of a:P, using standard curves generated
from known amounts of a and p.
Subunit Interactions of Human RNR in the Presence of F2CDP. A similar
set of experiments has been carried out with the human RNR. The
Cooperman laboratory has demonstrated that in contrast with the
prokaryotic RNRs, the active mouse RNR can be a2f32, a6)32, and
a6P6 depending on the concentration of ATP (18). Recent studies
using gas phase electrophoretic mobility macromolecule analysis
have suggested that the active form of hRNR is a6P2 (24). Biacore
studies and kinetic studies demonstrate that the interactions be-
tween a and p in the absence of nucleotides, as in the prokaryotic
case, are weak (Kd = 0.2 gM) (21). Anticipated differences in the
aggregation state of active RNR relative to the E. coli RNR caused
us to switch to a Superdex 200 column for molecular mass analysis
in the presence and absence of F2CDP in addition to ATP. The
results of incubation of either 0.5 or 1 eq of [1'- 3H] F2CDP/ATP by
SEC with ATP in the elution buffer are shown in Fig. 3A and B and
are summarized in Table 2. Fractions were collected through the
protein peak and analyzed by scintillation counting and by SDS/
PAGE (Fig. 3B). In the former case, analysis gave 0.8 radiolabels/
a2. SDS/PAGE revealed the presence of both a and /3. The relative
ratio of a:p of 1:1 was established by using standard curves made
from a and p (SI Fig. 6).
Experiments were also carried out to assess the resolution of the
SEC method and to obtain information about the relative molec-
ular masses of the observed protein peaks. 32 migrates with an
apparent molecular mass of 108 kDa (calculated 94.1 kDa; SI Fig.
7). a in the absence of nucleotides migrates as the expected
monomer, whereas in the presence of TTP, it migrates as a dimer
of 189 kDa (SI Fig. 7). The retention time of the protein peak eluted
from the RNR inactivated with F2CDP/ATP and with ATP in the
elution buffer, relative to molecular mass standards reveals an
apparent molecular mass of 872 kDa (SI Fig. 7). The 1:1 ratio of a: P,
the radiolabeling of the complex, and the apparent molecular mass
in comparison with the expected mass of 834 kDa for a636, 646 kDa
for a602, and 278 kDa for a2/32, suggest that the active form of the
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Table 2. Molecular mass determination of E. coli and human RNR and their subunits by SEC
Protein Protein (effector) Apparent mass, kDa Expected mass, kDa Oligomeric state
E. coli RNR P 96 87 32
a* 143, 105 172,86 a2,a
a (100 iM TTP) 174 172 a2
a (0.5 mM ATP) 174 172 a2
a, /3* 156, 108 172, 87 a2, /32
a, P (ATP)t 167, 109 172, 87 a2, /32
a, p inactivated by F2CDPt 277 259 a2p32 complex
Human RNR p 108 94 /32
a 88 92 a
a (100 gM TTP) 189 184 a2
a, p (ATP) 589, 94 553, 94 a6, p2
a, p inactivated by F2CDP
t $ 872 834 a6/6 complex
*The HPLC trace indicates multiple species. Gaussian fits to the peak shape, using Origin software, Version 6.1, gave the peak retention
times.
tElution buffer contains 0.5 mM ATP. Fractions were collected through the protein peak and were analyzed by 10% SDS/PAGE as
summarized in Fig. 2 A-F and Fig. 3.
*Peak I, apparent mass 872 kDa (a6/6, 834 kDa) based on standard curve (SI Fig. 6); Peak II: ArnA, apparent mass 484 kDa (hexamer of
ArnA is 446 kDa); Peak III, subunit molecular mass 65 kDa based on SDS/PAGE.
human RNR is a6P6 and that the subunits are tightly interacting.
The results, as in the case of the E. coli RNR, provide an
explanation for complete RNR inactivation with substoichiometric
amounts of F2CDP. Inactivation of class I RNRs by F2CDP thus
provides another paradigm for inhibitor design of this protein:
increasing the subunit affinity.
A number of additional features in the chromatogram in Fig. 3A,
peaks II and III, require comment. Two proteins copurify with a
and can be seen on SDS/PAGE with subunit molecular masses of
74 kDa and 65 kDa. The protein from peak II was isolated,
sequenced and identified as an E. coli protein Arna, which exists as
a hexamer in its native state (33). The identity of peak III has not
been determined, but SDS/PAGE analysis reveals it is not associ-
ated with RNR. Efforts to further purify a via peptide and dATP
affinity chromatography and several different anion exchange
methods failed, because a is not very soluble and is prone to
aggregation. Recovery of a and radiolabel from the column was
82%. The difference in the intensity of proteins in peak II and III
(Fig. 3A) relative to SDS/PAGE is not understood.
Discussion
Many 2'-substituted-2'-deoxynucleotides have been shown to be
potent mechanism based inhibitors of RNRs because the initial
experiments in 1976 (34). Detailed studies on 2'-fluoro, 2'-chloro
and 2'-azido derivatives have provided the basis for a general
mechanism of inhibition by these substrate analogs (Scheme 1) (35,
36). The Y' in P is reduced and generates a transient thiyl radical
Ao.151 1500
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Fig. 3. SEC on a Superdex 200 column to detect the complex formation
(anpn) in human RNR upon inactivation by F2CDP/ATP. (A) The elution profile
monitored by A214 and scintillation counting (u). (B) Fractions through the
protein peak inA monitored by SDS/PAGE and analysis of the ratio of a:3 using
standard curves generated from known amounts of a and p/. Peak I contains
a and /3; Peak II contains Arna; and Peak III contains no a or /3, but an
unidentified protein of monomer molecular mass 65 kDa. We have repeated
this experiment with homogeneous a (provided by the C. G. Dealwis labora-
tory, University of Tennessee, Knoxville, TN). The results are identical, but look
cleaner, because the E. coli contaminating protein has been removed.
in a that initiates nucleotide reduction by 3'-hydrogen atom ab-
straction. Loss of the 2' substituent (HO-, F-, Cl-, N3-, or their
conjugate acids) results in formation of intermediate A, which then
partitions into two pathways depending on whether the 2'-radical is
reduced by the top face thiol or a bottom face thiol. In the former
case, the inactivation is caused by formation of a 3'-ketodeoxynucle-
otide which dissociates from the active site and decomposes to
generate the nucleic acid base, pyrophosphate, and a furanone. The
furanone then alkylates a resulting in its inactivation. In the case of
bottom face reduction, in addition to generating the 3'-
ketodeoxynucleotide that eventually inactivates a from solution
through the furanone, the Y' in p remains reduced, thus P also
becomes inactivated. Most 2'-substituted deoxynucleotides inhibit
class I RNRs by a combination of these pathways.
Studies presented herein suggest an additional mechanism by
which 2'-substituted nucleotides may inactivate RNR. Gemzar has
two fluorines at C2'. Both are lost during inactivation, at least in the
case of the E. coli and Lactobacillus leichmannii RNRs, which have
thus far been examined (12, 13). In addition, with [1'-3H] F2CDP
inactivation is accompanied by 0.5 eq of sugar labeling from F2C/a,
-20-40% of tyrosyl radical loss and 100% loss of RNR activity.
The mechanisms by which F2CDP inactivate the E. coli and human
RNRs, thus, must occur by multiple pathways as previously ob-
served with other 2'-substituted nucleotides. Furthermore, all
pathways result in covalent labeling with the sugar of F2CDP and
loss of cytosine. The details of the inactivation mechanism are
complex and are not yet understood.
The observation of substoichiometric amounts of nucleotide
resulting in complete RNR inactivation, at face value, seems
difficult to understand. An explanation for the unusual stoichiom-
etry is provided by the analysis of the RNR quaternary structure.
In the case of the E. coli RNR, SEC reveals a tight a2P2 complex
(Fig. 2 A--C) when it is inactivated by F2CDP. A control in the
absence of F2CDP reveals that a2 separates from 32 by the same
chromatographic analysis (Fig. 2 D-F). In retrospect, we have
previously seen this type of behavior with another substoichiomet-
ric mechanism based inhibitor: 2'-azido-2'-deoxynucleotides,
N3NDP (19, 37, 38). During a 2-min incubation of RNR with
[5'- 3H] N3NDPs, >90% of RNR activity is lost, 50% of Y' is lost,
and 0.7 eq radiolabel are associated with RNR. Protein denatur-
ation, however, resulted in radiolabel release suggesting it is non-
covalently bound or covalently bound in an unstable structure. In
contrast with F2CDP, activity of a with N3UDP is recovered to 50%
and complete inactivation over 30 min is associated with 100% loss
of Y'. Thus, although the subunits must be tightly associated
initially to account for >90% loss of activity with just 50% loss of
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Y', further chemistry associated with nucleotide allows subunit
weakening and dissociation. An SEC experiment similar to the one
described in Fig. 2 provides no evidence for an a2P2 complex (SI
Fig. 8). The unique chemistry associated with the different inhib-
itors thus can dramatically effect subunit interactions.
Inactivation of the human RNR, at least in the presence of
reductant, mirrors the observations made with the E. coli RNR.
One major difference, however, involves the quaternary structure
of the human RNR. Our SEC studies have provided direct evidence
in support of an active a6P6 complex. This result contrasts with
previous proposals of active a202 and with the recent mass
spectrometric studies suggesting that a6P2 is the active form of
RNR (24). Our results support the importance of the a6 form of the
large subunit, first proposed by Cooperman's laboratory (18). The
SEC results also suggest that inactivation is the result of tight
complex formation between the subunits that can occur even in the
presence of substoichiometric amounts of nucleotide. At odds with
this interpretation are the activity assays for each subunit in the
presence of an excess of the second subunit. If a tight complex were
present subsequent to inactivation, one would have expected that a
and p would be 100% inactive. Although this was the case for a (SI
Fig. 4), 32 retains 60% of its activity. These results are very
intriguing and provide us with additional insight about subunit
interaction. The recovery of P32 activity requires that excess a can
form a transient ternary complex with a636 and liberate 32, which
has retained some of its Y' and is thus active. This proposal is
supported by a recent structure of a complex of the a2P2 from E.
coli where only one of the two ps interacts with a (39). Thus, one
could propose that binding of a to the unattached P of P2 could
facilitate a2 release. In the case of the inactivated aa*P2 complex
assayed with excess a (a* = covalently labeled a), this mechanism
would result in release of aa* and formation of active a202.
Because there is only one [3H]-label per a2, one would have
expected the unlabeled monomer to be also active in the presence
of excess 0, but this is not the case. Thus, this result provides strong
support for asymmetry within the a2 (a6); that is, modification of
one a precludes activity of the other. The results suggest that if the
cell was able to increase the amount of a, then active RNR could
be recovered. Interestingly resistance in a number of cell lines has
identified elevated a levels (40-42). F2CDP is unique with respect
to the well characterized 2'-substituted nucleotide mechanism
based inhibitors, in that in addition to labeling a and loss of Y' on
p, inactivation is the result of tight subunit association.
Summary. RNR is inactivated by 0.5 eq of F 2CDP/a, as a conse-
quence of altering the affinity of its two subunits and generating an
asymmetric interaction within this complex. Recent studies using a
and p substituted site specifically with unnatural amino acids have
also been interpreted to suggest an asymmetry within the active
RNR complex (19, 20). Our results suggest that the paradigm of a
1:1 symmetrical complex between the two subunits of RNR must
be re-evaluated. They further suggest a novel mode of inactivation
of RNR.
Materials and Methods
[5- 3H] F2C and 2-deoxy-3,5-di-O-benzoyl-3,3-difluororibonolac-
tone were kind gifts of Eli Lilly (Indianapolis, IN). Competent E.
coli BL 21 (DE3) cells were purchased from Stratagene (La Jolla,
CA). Complete EDTA-free protease inhibitor tablets and calf
alkaline phosphatase (20 units/gl) were purchased from Roche
Biochemicals (Indianapolis, IN). Plasmids containing the genes for
a (formerly called H1) and P (formerly called H2), phRRM1, and
phRRM2, were generous gifts from Y. Yen (City of Hope National
Medical Center). Protein concentrations were determined by using
extinction coefficients (s280 nm) per monomer [45,900 M- 1 cm -1 for
(His)6-P and 119,160 M- 1 cm -1 for a]. E. coli TR (specific activity
of 40 units/mg) and TR reductase (specific activity of 1,320 units/
mg) were isolated as described in refs. 43 and 44.
Expression Plasmids for Human a and 3 in E. coli. Sequencing of the
a and 3 genes in phRRM1 and phRRM2, respectively, revealed a
number of mutations relative to the sequences reported in the
NCBI database (27, 28). In the a gene, nucleotide C521 was
mutated to a T, resulting in a Val to Ala substitution. At residue
1763, C was changed to T, resulting in an Ile to Thr substitution. In
the gene for 0, A650 was changed to G, resulting in the conversion
of a Lys to Arg. These mutations were corrected by site-directed
mutagenesis, using the QuikChange Kit by Stratagene. In addi-
tion the N-terminal tags of each protein were reengineered to
minimize the number of additional residues. The NdeI digestion site
in a was silenced. Both a and P genes were digested with NdeI and
NotI and ligated into the NdeI-NotI sites of pET-28a (Novagen) to
produce (His)6-a and (His) 6-3 containing a MGSSHHHHHHS-
SGLVPRGSH-N terminus. All constructs were verified by se-
quencing at the MIT biopolymers laboratory.
Expression and Purification of Human a and p. phRRM1 and
phRRM2 were transformed into E. coli BL21 (DE3) (Stratagene)
and plated on LB agar plates with 50 .tg/ml kanamycin, and a single
colony was chosen for growth. For isolation of 3, an overnight
culture (40 ml) grown to saturation was diluted into 2 liters of LB
containing 50 tg/ml kanamycin and grown at 37°C to an OD 600 Of
0.7-0.9. Isopropyl-l-thio-P-D-galactopyranoside (1 mM) was then
added, and the cells were grown for an additional 6 h at 300C. For
growth of a, an overnight culture (40 ml) was grown from a single
colony at 37°C and transferred to 2 liters of LB and grown at 370C.
Isopropyl-l-thio-P-D-galactopyranoside (1 mM) was added at an
OD 600 of 0.7-0.9, and the cells were grown overnight at 25°C. The
isolation of P2 and a were carried out by the following general
procedure: The cells were harvested and typically yielded 4 g/liter.
The cell pellets were suspended (5 vol/g) in 50 mM NaH 2PO4, pH
7.0, 0.1% Triton X-100, and 10 mM 2-mercaptoethanol. The
suspension was passed through the French press at 14,000 psi. The
cell lysate was centrifuged at 20,000 x g for 30 min. The supernatant
was treated with streptomycin sulfate to a final concentration of 1%
(wt/vol), and the pellet was removed by centrifugation. The super-
natant was incubated with Ni-NTA agarose resin (1 ml/g of cells;
Qiagen, Valencia, CA) at 40C for 1 h and then loaded into a column
(2.5 x 10 cm). The column was subsequently washed with 40
column vol of 50 mM NaH 2PO4/800 mM NaCl/50 mM imidazole,
pH 7.0/0.1% Triton X-100/10 mM 2-mercaptoethanol. The protein
was eluted with 50 mM NaH 2PO4/300 mM NaCl/125 mM imida-
zole, pH 7.0. Fractions containing protein were identified by using
the Bradford assay. The fractions were pooled and concentrated to
<10 ml, and then the imidazole was removed by Sephadex G-25
chromatography (200 ml, 2.5 x 50 cm). 32 was stored in 50 mM
Tris, 100 mM KC1, pH 7.6, 5% glycerol. a was stored in 50 mM Tris,
100 mM KCI, 15 mM MgC12, 5 mM DTT, pH 7.6, 5% glycerol.
Protein yields of a and P were -2 mg and 15 mg/liter culture,
respectively. The purity of a and P were analyzed on 10% SDS/
PAGE. Two more rapidly migrating bands detected by SDS/PAGE
copurified with a. One of these impurities, identified by sequencing,
is Arna, a hexameric E. coli protein with a subunit molecular mass
of 74 kDa. The second impurity has not been identified.
Conversion of Human apo 32 to Holo 32. Stock solutions of (His)6-32
(2 ml, 2.5 mg/ml) were deoxygenated by 6 cycles of evacuation (for
3 x 10 s) followed by argon flushing (2 min) on a Schlenk line. The
deoxygenated P2 solution was brought into the glovebox (MBraun,
Stratham, NH) and 5 eq of Fe(II) per 32 was added from a
FeNH 4SO 4 solution in buffer A (50 mM Tris/100 mM KC1, pH
7.6/5% glycerol). The resulting mixture was incubated at 4°C for 15
min. The protein was then removed from the glovebox, and 1 ml of
02 saturated buffer A (50 mM Tris/100 mM KC1, pH 7.6, 5%) was
added. Excess iron was removed by Sephadex G-25 chromatogra-
phy (40 ml, 2.5 x 20 cm).
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Activity Assays. A reaction mixture contained, in a final volume of
350 Ml, 50 mM Hepes (pH 7.6), 15 mM MgCl 2, 1 mM EDTA, 0.3
MM (or 2.1 MM) a, 2.1 MM (or 0.3 MM) P, 3 mM ATP, 1 mM
[3H]-CDP (specific activity 3,400 cpm/nmol), 100 AME. coli TR, 1.0
MM TR reductase, and 2 mM NADPH. The assay mixture was
preincubated at 370C for 3 min, and the reaction was initiated by the
addition of CDP. Aliquots (50 Al) were removed over a 15-min time
period and quenched in a boiling water bath. dCDP production was
analyzed by the method of Steeper and Steuart (45).
Time-Dependent Inactivation Studies. The inactivation mixture con-
tained in a final volume of 100 Al: 1.2 MM a/1.2 MM P/3 mM ATP/1
mM [3H]-CDP (specific activity 3,400 cpm/nmol)/5 mM DTT/50
mM Hepes (pH 7.6)/15 mM MgC12/1 mM EDTA. The reaction was
initiated by addition of F2CDP (0.6 MM, 1.2 MM and 6 MM, final
concentrations) and incubated at 370C. Aliquots (12.5 pl) were
removed from 30 s to 17 min and assayed for dCDP production as
described above. Control experiments were carried out in which the
F2CDP was omitted.
Quantitation of Covalent Labeling of E. coli RNR and Human RNR with
[1 '-3H]-F 2CDP and [5- 3H]-F 2CDP. A typical reaction mixture (5.5 MM a,
p in 300 Ml) was identical to that described above, except that
F2CDP was replaced by either [1'- 3H]-F 2CDP (5,889 cpm/nmol) or
[5- 3H]-F 2CDP (6,643 cpm/nmol). After 10 min at 370C, a 270-gl
aliquot was loaded onto a Sephadex G-50 column (1 x 20 cm, 20
ml) that was preequilibrated with the assay buffer (50 mM Hepes/15
mM MgC12/1 mM EDTA, pH7.6) or made 6 M in guanidine-HCI
and loaded onto a Sephadex G-50 column with assay buffer
containing 2 M guanidine-HC1. Fractions (1 ml) were collected and
assayed forA 280 and A260, and 500 Ml of each fraction was analyzed
by scintillation counting.
Quantification of Cytosine Released During the Inactivation of E. coli
and Human RNR by [5- 3H]-F 2CDP. The reaction mixture was as
described in Time-Dependent Inactivation Studies (1.2 MM human
RNR a, 3 in 500 Al). The reaction was initiated by addition of 1.2
M [5-3H]-F 2CDP (6643 cpm/nmol). After 20 min, the inactivation
mixture was filtered through an YM-30 Centricon device (Milli-
pore, Billerica, MA) at 4'C. F 2C (120 nmol) and cytosine (120
nmol) were added as carriers before filtration. The flow-through
was treated with 30 units of alkaline phosphatase (Roche) for 3 h
at 370C and filtered through a second YM-30 Centricon device. The
flow through was analyzed by using a Waters (Milford, MA) 2480
HPLC with an Altech Adsorbosphere Nucleotide Nucleoside C-18
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column (250 mm x 4.6 mm) at a flow rate of 1 ml/min. The elution
buffer contained buffer A (10 mM NH4OAc, pH 6.8) and buffer B
(100% methanol). A 10-min isocratic elution was followed by a
linear gradient to 40% B over 30 min. A linear gradient was then
run to 100% B over 5 min. Fractions (1 ml) were collected, and 200
Al of each were analyzed by scintillation counting. Standards were
as follows: retention times are: cytosine, 5.7 min; cytidine, 12.6 min;
ara-C, 17.4 min; dC, 19.0 min and F2C, 23.2 min. The recovery of
cytosine and F 2C was calculated based on the UV spectrum
(cytosine, A267, E = 6100 M - 1 cm - 1, F2C, X268, e = 9360 M - 1 cm-1).
The radioactivity recovered with cytosine and F2C was analyzed by
scintillation counting.
SEC to Examine the Quaternary Structure of RNRs Subsequent to
Inactivation by F2CDP. SEC was performed by using a Superose 12
column (10 x 300 mm, GE Healthcare, Little Chalfont, U.K.) for
E. coli RNR or a Superdex 200 column (10 x 300 mm, GE
Healthcare) for human RNR attached to a Waters 2480 HPLC. Gel
filtration molecular mass standards (GE Healthcare) were ovalbu-
min, 43 kDa; conalbumin, 75 kDa; aldolase, 158 kDa; pyruvate
kinase, 232 kDa or catalase 232 kDa; ferritin, 440 kDa; thyroglob-
ulin, 669 kDa; and blue dextran, 2,000 kDa. The elution buffer was
50 mM Hepes (pH 7.6)/15 mM MgC12/0.5 mM ATP, with or
without 150 mM KCI. Molecular mass standards were run at the
beginning of each experiment. The reaction mixture was prepared
as described above (15 1AM a, 3 in 300 .l or 30 MM a, P in 150 Al).
After 10 min of incubation, 150 M1 or 300 M1 was injected onto the
column. The elution rate was 0.5 ml/min and 0.5 ml fractions were
collected. If [1'- 3H]-F2CDP was used in the inactivation, 100-Ml
aliquots of each fraction was analyzed by scintillation counting.
Quantitative Analysis of the Subunits of E. coli and Human RNRs by
SDSIPAGE. The fractions collected from the SEC analysis were
analyzed by 10% SDS/PAGE and compared with concentrations of
a and p from E.coli RNR (0.4 MM to 3.2 MM) or human RNR (0.2
MM to 1.6 MM) as standards. The proteins were visualized with
Coomassie blue staining. The band intensities were quantified by
using Quantity One software (Bio-Rad, Hercules, CA). The con-
centrations of a and p in the complex were determined from the
standard curves.
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